Page last updated: 2024-11-04

bisoprolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2405
CHEMBL ID645
CHEBI ID3127
SCHEMBL ID20960
MeSH IDM0026256

Synonyms (105)

Synonym
AC-18540
bisoprololum
CHEBI:3127 ,
1-{4-[(2-isopropoxyethoxy)methyl]phenoxy}-3-(isopropylamino)propan-2-ol
BB 0262613
1-(propan-2-ylamino)-3-(4-{[2-(propan-2-yloxy)ethoxy]methyl}phenoxy)propan-2-ol
STL355996
AB00514681-08
emd-33512
cl-297939
1-[(1-methylethyl)amino]-3-({4-[({2-[(1-methylethyl)oxy]ethyl}oxy)methyl]phenyl}oxy)propan-2-ol
bisoprolol hemifumarate
bisoprolol fumarate
concor
zebeta
2-propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)-, (+-)-
bisoprololum [latin]
BSPBIO_000339
PRESTWICK3_000330
BPBIO1_000373
PRESTWICK2_000330
[2-hydroxy-3-(4-{[2-(propan-2-yloxy)ethoxy]methyl}phenoxy)propyl](propan-2-yl)amine
bdbm25751
AB00514681
66722-44-9
C06852
bisoprolol
(rs)-1-(4-(2-isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol
(+-)-1-((alpha-(2-isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol
NCGC00024868-03
DB00612
D02342
104344-23-2
bisoprolol (jan/usan/inn)
NCGC00024868-02
PRESTWICK1_000330
SPBIO_002260
PRESTWICK0_000330
NCGC00024868-04
NCGC00024868-05
cl 297939
CHEMBL645
emd 33 512
L000133
AKOS005110983
1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol
NCGC00024868-06
BCP9000418
bisoprolol fumerate
bisoprolol [usan:inn:ban]
hsdb 8316
unii-y41js2nl6u
bisocor
y41js2nl6u ,
BCPP000332
bisoprolol hemifumarate salt
NCGC00024868-08
S5942
gtpl7129
2-propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)-, (+/-)-
bisoprolol [who-dd]
bisoprolol [vandf]
bisoprolol [usan]
bisoprolol [inn]
bisoprolol [jan]
bisoprolol [mi]
(+/-)-1-((.alpha.-(2-isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol
SCHEMBL20960
(.+/-.)-1-[[.alpha.-(2-isopropoxyethoxy)-p-tolyl]oxy]-3-(isopropylamino)-2-propanol
2-propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-, (.+/-.)-
1-(4-[(2-isopropoxyethoxy)methyl]phenoxy)-3-(isopropylamino)-2-propanol #
bisoprolol - from tablet donated by watson -
Q-200728
1-(4-((2-isopropoxyethoxy)methyl)phenoxy)-3-(isopropylamino)propan-2-ol
AB00514681_09
AB00514681_10
2-propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-
(+/-)-bisoprolol (hemifumarate)
DTXSID6022682 ,
mfcd00865795
SR-01000597980-1
sr-01000597980
1-[4-[2-(1-methylethoxy)ethoxymethyl]phenoxy]-3-(1-methylethylamino)propan-2-ol
bisoprolol, analytical standard
HY-129029
CS-0103208
SBI-0206894.P001
Q412515
1-[isopropylamino]-3-[isopropoxyethoxymethylphenoxy]-2-propanol
AS-35262
BCP02461
BRD-A89175223-051-05-6
SDCCGSBI-0206894.P002
NCGC00024868-21
1-{4-{[2-(1-methylethoxy)ethoxy]methyl}phenoxy}-3-[(1-methylethyl)amino]-2-propanol
1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan- 2-ol
1-[(propan-2-yl)amino]-3-(4-{[2-(propan-2-yloxy)ethoxy]methyl}phenoxy)propan-2-ol
EN300-18386635
EX-A5544
(2rs)-1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)propan-2-ol
(+/-)-1-((alpha-(2-isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol
c07ab07
bisoprololo
bisoprololum (latin)
dtxcid602682

Research Excerpts

Overview

Bisoprolol is an attractive candidate for use in LQT because of its cardioselective properties and favorable side-effect profile. It is often used in the settings of percutaneous coronary intervention or acute coronary syndrome in patients on dual antiplatelet therapy.

ExcerptReferenceRelevance
"Bisoprolol is a selective beta adrenergic antagonist commonly used in treatment of coronary artery disease (CAD). "( Population Pharmacokinetic Analysis of Bisoprolol in Patients with Stable Coronary Artery Disease.
Deljanin-Ilic, M; Jankovic, SM; Jevtovic-Stoimenov, T; Milovanovic, JR; Nikolic, ML; Nikolic, VN; Stojanovic, SS; Stokanovic, D; Zivanovic, S, 2018
)
2.19
"Bisoprolol (BIS) is a selective antagonist of β₁ adrenergic receptors. "( Bisoprolol, Known to Be a Selective β₁-Receptor Antagonist, Differentially but Directly Suppresses I
Foo, NP; Ko, SY; So, EC; Wu, SN, 2019
)
3.4
"Bisoprolol is a drug belonging to beta blockers drugs used primarily for the treatment of cardiovascular diseases."( Validation of a spectrophotometric assay method for bisoprolol using picric acid.
Apostu, M; Bibire, N; Panainte, AD; Tântaru, G; Vieriu, M,
)
1.82
"Bisoprolol is an attractive candidate for use in LQT because of its cardioselective properties and favorable side-effect profile."( Experience with bisoprolol in long-QT1 and long-QT2 syndrome.
Adler, A; Al-Sabeq, B; Andrade, JG; Bennett, MT; Chakrabarti, S; Deyell, MW; Green, M; Kerr, CR; Klein, GJ; Krahn, AD; Laksman, ZW; Padfield, GJ; Steinberg, C; Yee, R; Yeung-Lai-Wah, JA, 2016
)
1.5
"Bisoprolol is a highly selective adrenoceptor-blocker, which is often used in the settings of percutaneous coronary intervention or acute coronary syndrome in patients on dual antiplatelet therapy."( The influence of bisoprolol dose on ADP-induced platelet aggregability in patients on dual antiplatelet therapy.
Andjelkovic, A; Cokanovic, V; Grdinic, A; Ignjatovic, S; Ignjatovic, VS; Miloradovic, V; Nikolic, S; Paramentic, D; Petrovic, I; Petrovic, N; Simic, I, 2010
)
1.42
"Bisoprolol is a highly selective beta(1)-adrenoceptor antagonist. "( Bisoprolol: a review of its use in chronic heart failure.
Keating, GM; McGavin, JK, 2002
)
3.2
"Bisoprolol fumarate is a highly selective beta-1 receptor blocker. "( Bisoprolol in the treatment of chronic heart failure.
de Groote, P; Ennezat, PV; Mouquet, F, 2007
)
3.23
"Bisoprolol is an effective and well-tolerated first-line beta-blocker for patients with systolic heart failure. "( Bisoprolol for congestive heart failure.
Gustafsson, F; Rosenberg, J, 2008
)
3.23
"Bisoprolol is a new beta-adrenoceptor antagonist which has shown beta-adrenoceptor selectivity in studies in isolated tissues. "( Assessment of beta-adrenoceptor selectivity of a new beta-adrenoceptor antagonist, bisoprolol, in man.
Bacon, RJ; Cragg, DJ; Tattersfield, AE, 1984
)
1.94
"Bisoprolol is a selective beta 1-adrenoceptor antagonist devoid of partial agonist activity that can be used for treatment of chronic and acute myocardial ischemia. "( Relationships between acute and chronic beta-blocking effects of bisoprolol in healthy volunteers: a practical approach to predict intensity of beta-blockade.
Funck-Brentano, C; Jaillon, P; Jamin, P; LeCoz, F; Poirier, JM, 1994
)
1.97
"Bisoprolol is an effective and safe antihypertensive agent."( [The antihypertensive effect of the new cardioselective prolonged-action beta-adrenoblocker bisoprolol compared with propranolol, metoprolol and placebo].
Buchner-Moll, D; Chel'dieva, EIa; Deev, AD; Duda, SG; Filatova, NP; Gorbunov, VM; Metelitsa, VI; Shastun, RS; Simonov, DV; Vygodin, VA,
)
1.07
"Bisoprolol is an effective antihypertensive drug which reduces significantly the systolic, and diastolic blood pressure, the pulse rate in a recumbent, sitting and standing position. "( [Bisoprolol in the treatment of hypertension].
Spinar, J; Vítovec, J; Zicha, J, 1993
)
2.64
"Bisoprolol is a new beta1-selective beta-blocker with a clear 24-h duration of action regarding symptoms and improvement of exercise capacity in patients with stable exercise-induced angina pectoris."( Safety and efficacy of beta-blockers in the treatment of stable angina pectoris.
de Muinck, ED; Lie, KI, 1990
)
1
"Bisoprolol appears to be a very potent beta-blocker that is well tolerated at an intravenous dose of 10 mg."( Study of the electrophysiological properties of intravenous bisoprolol in patients with and without coronary artery disease by programmed stimulation.
Bricaud, H; Clémenty, J; Coste, P; Samoyeau, R, 1990
)
1.24
"Bisoprolol is a highly beta1-selective beta-blocker, without intrinsic sympathomimetic activity (ISA), and with a plasma elimination half-life of 10-12 h, permitting treatment with one daily dose."( Bisoprolol pilot studies in myocardial infarction.
de Muinck, ED; Lie, KI; Reck, R; Verkenne, P; von Mengden, HJ, 1990
)
2.44
"Bisoprolol is an effective antihypertensive drug with no detrimental effects on sexuality in newly diagnosed men with hypertension. "( Bisoprolol and hypertension: effects on sexual functioning in men.
Broekman, CP; Haensel, SM; Slob, AK; Van de Ven, LL, 1992
)
3.17
"Bisoprolol is an effective antihypertensive agent with no sexual side effects."( Bisoprolol and hypertension: effects on sexual functioning in men.
Broekman, CP; Haensel, SM; Slob, AK; Van de Ven, LL, 1992
)
3.17
"Bisoprolol (Detensiel) is a high beta 1-selective beta-adrenoceptor blocking agent without intrinsic sympathomimetric activity and local anaesthetic activity."( [Treatment of acute phase of myocardial infarction with injectable bisoprolol with oral versus].
Grollier, G; Potier, JC; Samoyeau, R,
)
1.09
"Bisoprolol is a new cardioselective beta1 adrenergic blocking agent without intrinsic sympathomimetic activity but with minimal effects on myocardial contractility. "( Hemodynamic evaluation of bisoprolol after coronary artery surgery in patients with altered left ventricular function.
d'Hollander, A; Goldstein, M; Kahn, RJ; Le Clerc, JL; Melot, C; Vincent, JL, 1991
)
2.02
"Bisoprolol is a new beta 1-selective beta-blocking agent with a plasma half-life of 10-12 h and without intrinsic sympathomimetic activity (ISA)."( Dose-effect relationship and long-term effects of bisoprolol in mild to moderate hypertension.
Frithz, G; Weiner, L, 1986
)
1.25
"Bisoprolol is a new cardioselective beta-blocker with a long half-life. "( Efficacy of once daily bisoprolol in stable angina pectoris: an objective comparison with atenolol and long term follow-up.
Hughes, LO; Kardash, MM; Khurmi, NS; Kohli, RS; Lahiri, A; Raftery, EB, 1985
)
2.02
"Bisoprolol is a new beta 1-selective beta-blocking agent with a plasma half-time of 10-12 h and without partial agonist properties. "( Antihypertensive effects of bisoprolol during once daily administration in patients with essential hypertension. A dose-ranging study with parallel groups.
Frithz, G; Weiner, L, 1986
)
2.01
"Bisoprolol was found to be an effective beta-adrenoceptor antagonist, the pA2 values determined against isoprenaline in guinea pig atria and tracheal muscle being 7.45 and 6.41, respectively."( Pharmacodynamic profile of the selective beta 1-adrenoceptor antagonist bisoprolol.
Becker, KH; Bergmann, R; Bourgois, R; Enenkel, HJ; Fuchs, A; Harting, J; Jonas, R; Lettenbaur, H; Minck, KO; Schelling, P, 1986
)
1.22
"Bisoprolol is a potent new cardioselective beta-adrenoceptor antagonist with a competitive action at beta 1-adrenoceptors."( Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist.
Bühring, KU; Leopold, G; Pabst, J; Simane, Z; Ungethüm, W; Wiemann, H, 1986
)
1.29
"Bisoprolol is a new highly beta 1-selective beta-adrenoceptor blocking drug; it is devoid of intrinsic sympathomimetic effects. "( Bisoprolol: a new beta-adrenoceptor blocking drug.
Prichard, BN, 1987
)
3.16
"Bisoprolol is a beta 1-adrenoceptor antagonist with no partial agonist (intrinsic sympathomimetic) activity or membrane stabilising (local anaesthetic) activity. "( Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.
Lancaster, SG; Sorkin, EM, 1988
)
3.16
"Bisoprolol is a new highly beta 1-selective adrenoceptor blocker with moderate lipophilia and without intrinsic sympathomimetic activity (ISA)."( [Comparative study of the central nervous system effect of the beta receptor blockaders pindolol and bisoprolol].
Görtelmeyer, R; Klingmann, I, 1985
)
1.21

Effects

Bisoprolol has been extensively studied in three large mortality trials in stable chronic heart failure (CHF) patients. The drug has anti-arrhythmic effects, but its direct effect on I(Na) in cardiac cells remains unclear. Bisoprollol has minimal effects on glucose tolerance and plasma lipid profiles.

ExcerptReferenceRelevance
"Bisoprolol has a favourable side-effect profile."( Bisoprolol: a new beta-adrenoceptor blocking drug.
Prichard, BN, 1987
)
2.44
"Bisoprolol has decreased MPAP from 23.8 +/- 0.8 mmHg to 21.9 +/- 1.0 mmHg, by 8%, p < 0.05; frequency of anginal attacks, heart rate from 82.2 +/- 1.4 to 73.2 +/- 1.5 b/min; number of episodes of ST segment depression from 2.35 +/- 0.43 to 0.95 +/- 0.22, p < 0.01; total duration of ST segment depression from 10.1 +/- 2.54 to 2.89 +/- 0.76 min, p < 0.01; number of supraventricular and ventricular extrasystoles for 24 hours from 194.5 +/- 74.4 to 96.2 +/- 27.4 and from 239.1 +/- 124.9 to 111.3 +/- 44.1, respectively. "( [Efficacy of a cardioselective beta1-adrenoblocker bisoprolol in patients with chronic obstructive pulmonary disease in combination with ischemic heart disease].
Tsvetkova, OA; Veselovskaia, MV, 2007
)
2.03
"Bisoprolol has anti-arrhythmic effects, but its direct effect on I(Na) in cardiac cells remains unclear."( Bisoprolol inhibits sodium current in ventricular myocytes of rats with diastolic heart failure.
Deng, CY; Kuang, SJ; Tang, HF; Wu, SL; Zhang, WC, 2007
)
2.5
"Bisoprolol has been extensively studied in three large mortality trials in stable chronic heart failure (CHF) patients."( Bisoprolol in the treatment of chronic heart failure.
de Groote, P; Ennezat, PV; Mouquet, F, 2007
)
2.5
"Bisoprolol has minimal effects on glucose tolerance and plasma lipid profiles."( Bisoprolol: is this just another beta-blocker for hypertension or angina?
Johns, TE; Lopez, LM, 1995
)
2.46
"Bisoprolol has been shown to exhibit a greater beta 1-selectivity than atenolol."( The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics.
Chatterjee, SS, 1986
)
1.25
"Bisoprolol has similar solubility in water and organic solvents and predictably therefore about half is excreted by the kidneys unchanged, half metabolized by the liver."( Bisoprolol: a new beta-adrenoceptor blocking drug.
Prichard, BN, 1987
)
2.44
"Bisoprolol have been confirmed to have strictly beta-blocking properties."( Electrophysiological effects of bisoprolol.
Feruglio, GA; Gradnik, R; Proclemer, A; Savonitto, S, 1987
)
1.28
"Bisoprolol has been well tolerated in most patients."( Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.
Lancaster, SG; Sorkin, EM, 1988
)
2.44

Actions

Bisoprolol was found to increase PEP and QS2c (total electromechanical systole) in patients with benign prostatic hyperplasia.

ExcerptReferenceRelevance
"Bisoprolol deteriorated lower urinary tract symptoms in patient with benign prostatic hyperplasia."( Repeated intensification of lower urinary tract symptoms in the patient with benign prostatic hyperplasia during bisoprolol treatment.
Chodorowski, Z; Hajduk, A; Sein Anand, J, 2005
)
1.26
"With bisoprolol an increase of PEP and QS2c (total electromechanical systole) was observed, indicative of a negative inotropic effect."( Comparative cardiac haemodynamics of bisoprolol, celiprolol, carvedilol and nebivolol in normal volunteers.
De Cree, J; Geukens, H; Van Nueten, L; Verhaegen, H, 1992
)
1.01

Treatment

Bisoprolol treatment ameliorated HF-related adverse cardiac remodelling and reduced plasma catecholamine levels, compared with HF/C rats. In bisoproll-treated animals, systolic blood pressure did not change and was significantly higher than in controls.

ExcerptReferenceRelevance
"Bisoprolol treatment results in QTc shortening in gene-positive LQT1 and LQT2 patients and is well tolerated during long-term administration. "( Experience with bisoprolol in long-QT1 and long-QT2 syndrome.
Adler, A; Al-Sabeq, B; Andrade, JG; Bennett, MT; Chakrabarti, S; Deyell, MW; Green, M; Kerr, CR; Klein, GJ; Krahn, AD; Laksman, ZW; Padfield, GJ; Steinberg, C; Yee, R; Yeung-Lai-Wah, JA, 2016
)
2.22
"Bisoprolol treatment ameliorated HF-related adverse cardiac remodelling and reduced plasma catecholamine levels, compared with HF/C rats. "( Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2) -adrenoceptor-catecholamine production axis in heart failure.
Cannavo, A; de Lucia, C; Femminella, G; Ferrara, N; Gargiulo, P; Koch, W; Leosco, D; Liccardo, D; Lymperopoulos, A; Pagano, G; Perrone Filardi, P; Rengo, G; Zincarelli, C, 2012
)
1.82
"Bisoprolol treatment for 4 months resulted in a significant improvement of RVEF, which paralleled the improvement of LVEF."( Effect of bisoprolol on right ventricular function and brain natriuretic peptide in patients with heart failure.
Beck-da-Silva, L; Chow, B; Davies, R; de Bold, A; Fraser, M; Haddad, H; Ruddy, T; Struthers, C,
)
1.26
"Bisoprolol treatment in patients with chronic heart failure was effectively and safely carried out by primary care physicians."( Effects of bisoprolol treatment for chronic heart failure initiated and followed up by primary care physicians.
Schuchert, A, 2005
)
2.16
"Bisoprolol-first treatment was noninferior to enalapril-first treatment if the upper limit of the 95% confidence interval (CI) for the absolute between-group difference was <5%, corresponding to a hazard ratio (HR) of 1.17."( Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III.
Erdmann, E; Follath, F; Krum, H; Lechat, P; Ponikowski, P; Silke, B; Skene, A; van de Ven, L; van Veldhuisen, DJ; Verkenne, P; Willenheimer, R, 2005
)
1.27
"In bisoprolol-treated animals, systolic blood pressure did not change and was even significantly higher than in controls."( Life survival and cardiovascular structures following selective beta-blockade in spontaneously hypertensive rats.
Benetos, A; Levy, BI; Poitevin, P; Prost, PL; Safar, ME, 1994
)
0.8
"Late bisoprolol treatment improved stroke volume index, and early bisoprolol treatment reduced diastolic wall stress, in rats with a large myocardial infarct."( Long-term effects of beta-adrenergic blocking agent treatment on hemodynamic function and left ventricular remodeling in rats with experimental myocardial infarction: importance of timing of treatment and infarct size.
Ertl, G; Gaudron, P; Hu, K, 1998
)
0.76
"Bisoprolol and warfarin treatments were well tolerated, and there was no effect on prothrombin times of either starting or stopping bisoprolol treatment."( Bisoprolol: studies of potential interactions with theophylline and warfarin in healthy volunteers.
Johnston, A; Lewis, Y; Murphy, M; Warrington, SJ, 1990
)
2.44
"Bisoprolol treatment (both 10 and 20 mg) resulted in a decrease in blood pressure in the supine position from 154/100 to 138/89 mm Hg; and atenolol treatment resulted in decreases from 161/102 to 145/90 mm Hg (50 mg/d) and 146/91 mm Hg (100 mg/d)."( A comparison of the effects of bisoprolol and atenolol on lipoprotein concentrations and blood pressure.
Lithell, H; Selinus, I; Vessby, B; Weiner, L, 1986
)
1.28
"Treatment with bisoprolol was well-tolerated and effective in relieving obstruction and improving symptoms in a significant proportion of patients with symptomatic obstructive HCM."( Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study.
Caiazza, M; Calabrò, P; Cirillo, A; Dongiglio, F; Franco, F; Fusco, A; Limongelli, G; Lioncino, M; Mazzella, M; Monda, E; Moscarella, E; Pacileo, G; Palmiero, G; Rubino, M; Sepe, J; Verrillo, F, 2022
)
2.52
"Treatment with bisoprolol reversed, to varying degrees, the expression of 10 of the 46 miRNAs whose expression was differentially expressed in the heart failure model."( Regulation by bisoprolol for cardiac microRNA expression in a rat volume-overload heart failure model.
Chen, C; Geng, T; Jin, T; Li, S; Li, X; Ma, A; Sun, C; Wang, T; Yan, H; Zhang, J; Zhang, X, 2013
)
1.09
"Treatment with bisoprolol slowed the heart rate, and treatment with losartan lowered mean arterial pressure, confirming adequate dosing, but none of the treatments improved RV function or arrested the progression of RV hypertrophy and failure compared with vehicle."( Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart.
Andersen, A; Andersen, S; Bogaard, HJ; de Man, FS; Holmboe, S; Nielsen, JM; Nielsen-Kudsk, JE; Ringgaard, S; Schultz, JG; Vildbrad, MD; Vonk-Noordegraaf, A, 2014
)
1.13
"Treatment with bisoprolol could reverse both the SAN function and the Nav1.1, Nav1.6, and HCN4 mRNA expression partially."( β1-Adrenergic blocker bisoprolol reverses down-regulated ion channels in sinoatrial node of heart failure rats.
Du, Y; Han, K; Huang, X; Ma, A; Wang, T; Wu, G; Xi, Y; Zhang, J, 2016
)
1.09
"Treatment with bisoprolol resulted in a trend to lower ventricular response rate in AF cases."( Postoperative oral amiodarone versus oral bisoprolol as prophylaxis against atrial fibrillation after coronary artery bypass graft surgery: a prospective randomized trial.
Ashoush, R; El Rassi, I; Haddad, F; Hayeck, G; Jebara, V; Madi-Jebara, S; Sleilaty, G; Yazigi, A, 2009
)
0.96
"Treatment with bisoprolol was initiated according to current guidelines (starting dose 1.25 mg/day, with weekly increments to 5 mg/day, and then increments every four weeks to a targeted dosis of 10 mg/day)."( [Use of bisoprolol in heart failure. The BISOCOR observational study].
Alegría Ezquerra, E; Anguita Sánchez, M; Espinosa Caliani, JS; García Saavedra, V; González-Juanatey, JR; Pérez Ojeda, G; Ruiz Ros, JA, 2003
)
1.09
"Treatment with bisoprolol prevented the progression of cardiac dysfunction in TO-2 hamsters."( Attenuation of oxidative stress and cardiac dysfunction by bisoprolol in an animal model of dilated cardiomyopathy.
Hashimoto, K; Ichihara, G; Ichihara, S; Iwase, M; Kanazawa, H; Kato, Y; Matsushita, A; Oikawa, S; Yamada, Y; Yokota, M, 2006
)
0.92
"Treatment with bisoprolol was helpful in maintaining an acceptable functional status and in preventing multiple shocks until transplantation became mandatory."( Familial dilated cardiomyopathy and spontaneous ventricular arrhythmias.
Caes, F; de Pauw, M; Jordaens, L, 1996
)
0.63
"Treatment with bisoprolol 5 mg resulted in a significant reduction in the frequency of migraine attacks (39% vs 22%) compared to placebo treatment (p < 0.05)."( Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study.
Franke, CL; Koehler, PJ; van de Ven, LL, 1997
)
0.9
"Treatment with bisoprolol or captopril largely prevented all of these changes in infarcted hearts."( Effects of ACE inhibition and beta-receptor blockade on energy metabolism in rats postmyocardial infarction.
de Groot, M; Dienesch, C; Ertl, G; Horn, M; Hu, K; Hügel, S; Neubauer, S; Remkes, H, 1999
)
0.64
"Treatment with bisoprolol failed to reduce myeloperoxidase activity in the ischemic myocardial tissue."( Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model.
Chen, J; Christopher, TA; Gao, F; Gu, J; Lopez, BL; Lysko, P; Ma, XL; Ohlstein, EH; Ruffolo, RR; Yue, TL, 2000
)
1.01
"Treatment with bisoprolol is recommended in symptomatic children and also improved symptoms in our patient."( Bisoprolol treatment for cyanotic spells--a 69-year-old female with uncorrected pentalogy of Fallot.
Anders, HJ; Fuchshuber, S, 2001
)
2.09

Toxicity

Bisoprolol is effective, well-tolerated and safe in the treatment of hypertension. No severe adverse effects occurred in the intervention group related to the treatment with lisinopril and bisoproll. Overall adverse events for bisoprool and amlodipine were 39% and 40%, respectively.

ExcerptReferenceRelevance
" There were no significant differences regarding nature and incidence of adverse events between the groups."( Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise-induced angina pectoris: a Multicenter International Randomized Study of Angina Pectoris (MIRSA).
Buchner-Moell, D; de Muinck, ED; Lie, KI; van de Ven, LL, 1992
)
0.55
" Bisoprolol is effective, well-tolerated and safe in the treatment of hypertension."( Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension: a double-blind, parallel group international multicentre study.
Frithz, G; Hosie, J; Lithell, H; Selinus, I; Weiner, L, 1987
)
1.49
" Nor have previous studies compared commonly used quality of life instruments for consistency, or investigated whether improvement or worsening of quality of life correlates with adverse events or blood pressure reduction."( Antihypertensive therapy and quality of life. Influence of blood pressure reduction, adverse events, and prior antihypertensive therapy.
Adegbile, IA; Alemayehu, D; Lefkowitz, MP; Papademetriou, V; Prisant, LM; Weber, MA; Weir, MR, 1996
)
0.29
" Overall adverse events for bisoprolol and amlodipine were 39% and 40%, respectively."( Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension.
Benetos, A; Consoli, S; Dubanchet, A; Safar, M; Safavian, A, 2000
)
0.85
"Beta-blockers substantially improve survival in patients with chronic heart failure (HF) with left ventricular systolic dysfunction, but concerns about cardiovascular adverse effects may deter physicians from prescribing this therapy."( Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials.
Coffey, CS; Curtis, JP; Foody, JM; Hebert, PR; Ko, DT; Krumholz, HM; Sedrakyan, A, 2004
)
0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" We also assessed the relations between dose levels and baseline variables or adverse events."( Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial.
Follath, F; Funck-Brentano, C; Goulder, M; van de Ven, LL; van Veldhuisen, DJ; Willenheimer, R, 2011
)
0.64
" For both study drugs, the dose level reached was associated with baseline characteristics and adverse events."( Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial.
Follath, F; Funck-Brentano, C; Goulder, M; van de Ven, LL; van Veldhuisen, DJ; Willenheimer, R, 2011
)
0.64
" We aimed to evaluate the relation between SRH and adverse events during titration of beta-blockers in elderly patients with heart failure."( Self-rated health predicts adverse events during β-blocker treatment: the CIBIS-ELD randomised trial analysis.
Anker, SD; Apostolovic, S; Düngen, HD; Farkas, J; Gelbrich, G; Haverkamp, W; Herrmann-Lingen, C; Inkrot, S; Lainscak, M; Neskovic, AN; Rau, T; Tahirovic, E; Töpper, A, 2013
)
0.39
" Adverse events were experienced by 64% patients and 38% experienced > 1 adverse event or serious adverse event, with higher prevalence in lower SRH categories."( Self-rated health predicts adverse events during β-blocker treatment: the CIBIS-ELD randomised trial analysis.
Anker, SD; Apostolovic, S; Düngen, HD; Farkas, J; Gelbrich, G; Haverkamp, W; Herrmann-Lingen, C; Inkrot, S; Lainscak, M; Neskovic, AN; Rau, T; Tahirovic, E; Töpper, A, 2013
)
0.39
"SRH is an independent predictor of adverse events during titration of beta-blockers and correlates with the proportion and number of adverse events per patient."( Self-rated health predicts adverse events during β-blocker treatment: the CIBIS-ELD randomised trial analysis.
Anker, SD; Apostolovic, S; Düngen, HD; Farkas, J; Gelbrich, G; Haverkamp, W; Herrmann-Lingen, C; Inkrot, S; Lainscak, M; Neskovic, AN; Rau, T; Tahirovic, E; Töpper, A, 2013
)
0.39
" However, its most common adverse effects, dizziness and hypotension, often discourage continuation or dosage increase."( Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension.
Asano, Y; Ichibori, Y; Kanzaki, M; Komuro, I; Minamiguchi, H; Mizote, I; Ohtani, T; Sakata, Y; Taniguchi, T, 2013
)
0.68
"All 13 patients with dizziness (100%) and 9 of 16 with hypotension (56%) were relieved of adverse symptoms or signs."( Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension.
Asano, Y; Ichibori, Y; Kanzaki, M; Komuro, I; Minamiguchi, H; Mizote, I; Ohtani, T; Sakata, Y; Taniguchi, T, 2013
)
0.68
"Switching from carvedilol to bisoprolol may help with continuation of β-blocker treatment as well as dosage increase in HF patients with adverse symptoms or signs, allowing them to reach the target dose."( Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension.
Asano, Y; Ichibori, Y; Kanzaki, M; Komuro, I; Minamiguchi, H; Mizote, I; Ohtani, T; Sakata, Y; Taniguchi, T, 2013
)
0.97
" We aimed to review the published and ongoing researches on cardioprevention strategies and to present the SAFE trial (CT registry ID: NCT2236806; EudraCT number: 2015-000914-23)."( SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab.
Airoldi, M; Allegrini, G; Amoroso, D; Barletta, G; Barni, S; Becherini, C; Bengala, C; Curigliano, G; Desideri, I; Galanti, G; Guarneri, V; Livi, L; Marchetti, P; Martella, F; Meattini, I; Piovano, P; Tarquini, R; Terziani, F; Vannini, A, 2017
)
0.46
"Clinical efficacy and adverse effects of the β-blocking agents, carvedilol, bisoprolol, and metoprolol were analyzed theoretically, and then compared quantitatively, for the purpose of determining their proper use for chronic heart failure."( Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure.
Fujito, K; Kimura, K; Takayanagi, R; Yamada, Y, 2017
)
0.68
"Heart substructures of 16 left-sided breast cancer patients included in the SAFE protocol were delineated by five operators."( Assessment of a guideline-based heart substructures delineation in left-sided breast cancer patients undergoing adjuvant radiotherapy : Quality assessment within a randomized phase III trial testing a cardioprotective treatment strategy (SAFE-2014).
Becherini, C; Bonomo, P; Calusi, S; Casati, M; Delli Paoli, C; Desideri, I; Francolini, G; Greto, D; Livi, L; Loi, M; Meattini, I; Olmetto, E; Pallotta, S; Pezzulla, D; Terziani, F, 2019
)
0.51
" The incidence of adverse events did not differ between the groups."( Comparison of heart rate reduction effect and safety between bisoprolol transdermal patch and bisoprolol fumarate oral formulation in Japanese patients with persistent/permanent atrial fibrillation (BISONO-AF study).
Akita, Y; Ikeda, T; Yamashita, T, 2019
)
0.76
" Results obtained for SOT and RAN showed that acute adverse effects are not expected to occur on aquatic organisms at the concentrations at which these pharmaceuticals are usually found in fresh surface waters."( Assessment of the ecotoxicity of the pharmaceuticals bisoprolol, sotalol, and ranitidine using standard and behavioral endpoints.
Assano, PK; de Almeida Vergara Hidalgo, V; de Carvalho, LB; de Jesus Azevedo, CC; Domingues, I; Godoy, AA; Kummrow, F; Mori, V; Nogueira, AJA; Oliveira, ÁC; Taparo, JM, 2020
)
0.81
" No severe adverse effects occurred in the intervention group related to the treatment with lisinopril and bisoprolol."( The Role of Lisinopril and Bisoprolol to Prevent Anthracycline Induced Cardiotoxicity in Locally Advanced Breast Cancer Patients.
Abdurahman, M; Azhar, Y; Hidayat, S; Wihandono, A, 2021
)
1.13
" No significant adverse effects occurred."( Bisoprolol versus celiprolol on dynamic hyperinflation, cardiopulmonary exercise and domiciliary safety in COPD: a single-centre, randomised, crossover study.
Anderson, W; Lipworth, BJ; Ross, R; Short, P, 2023
)
2.35

Pharmacokinetics

The aim of the study was to develop a population pharmacokinetic (PK) model for clearance of bisoprolol in patients with congestive heart failure (CHF) The method was successfully applied to studies of amlodipine and bisoprollol in Sprague-Dawley (SD) rats.

ExcerptReferenceRelevance
" On the other hand, none of the pharmacokinetic parameters, including nonrenal clearance, of rac-bisoprolol was changed during febrile infectious disease, indicating specificity in the effects of acute febrile disease on oxidative drug metabolism."( Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol.
Breimer, DD; Grib, C; Kirch, W; Soons, PA, 1992
)
0.71
" In obese subjects the pharmacokinetic data calculated for sotalol (total clearance (CL), volume of distribution (V beta), half-life of elimination (t1/2), were comparable with those measured in the controls."( [Comparison of beta-blocking agents pharmacokinetics in obese and non-obese subjects].
Cheymol, G, 1990
)
0.28
" Pharmacokinetic data were derived from measurements of plasma bisoprolol concentrations after the first dose and at steady state after 7 days treatment."( Pharmacokinetics of bisoprolol and influence on serum thyroid hormones in hyperthyroid patients.
Adam, W; Baew-Christow, T; Bux, B; Cordes, M; Disselhoff, G; Pabst, J; Panitz, N; Pfannenstiel, P; Rummeny, E, 1986
)
0.83
" A long plasma-elimination half-life (10-11h) allows a once-a-day dose regimen."( Balanced pharmacokinetics and metabolism of bisoprolol.
Leopold, G, 1986
)
0.53
" The high beta 1-selectivity of bisoprolol is linked with extremely favourable pharmacokinetic properties."( High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol.
Becker, KH; Bergmann, R; Enenkel, HJ; Haeusler, G; Klockow, M; Minck, KO; Schelling, P; Schliep, HJ; Schmitges, CJ; Schulze, E, 1986
)
0.78
"The pharmacokinetic properties of bisoprolol-14C were studied in Wistar rats, beagle dogs, and Cynomolgus monkeys."( Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans.
Bühring, KU; Faro, HP; Garbe, A; Leopold, G; Pabst, J; Sailer, H, 1986
)
0.83
"The technique of population pharmacokinetic analysis was employed to study the variability in the dose concentration relationship of bisoprolol during its clinical development."( Population pharmacokinetic analysis of bisoprolol.
Grevel, J; Thomas, P; Whiting, B, 1989
)
0.75
"The pharmacodynamic activity of (+/-)-1-[4-(2-isopropoxyethoxymethyl)-phenoxy]-3-isopropylamino-2- propranol- hemifumarate (bisoprolol, EMD 33 512) has been investigated under in vitro and in vivo conditions."( Pharmacodynamic profile of the selective beta 1-adrenoceptor antagonist bisoprolol.
Becker, KH; Bergmann, R; Bourgois, R; Enenkel, HJ; Fuchs, A; Harting, J; Jonas, R; Lettenbaur, H; Minck, KO; Schelling, P, 1986
)
0.71
"The pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist, was investigated in four independent studies including 36 healthy male volunteers."( Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist.
Bühring, KU; Leopold, G; Pabst, J; Simane, Z; Ungethüm, W; Wiemann, H, 1986
)
0.85
" Intraindividual comparison of the pharmacokinetic data measured after oral and intravenous administration of 10 mg bisoprolol to 12 subjects yielded an absolute bioavailability of 90%."( Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist.
Bühring, KU; Leopold, G; Pabst, J; Ungethüm, W,
)
0.64
" In healthy subjects peak and trough steady-state concentrations of 52 micrograms/L and 11 micrograms/L, respectively, an elimination half-life of 10."( Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.
Demers, HG; Kirch, W; Leopold, G; Ohnhaus, EE; Pabst, J; Rose, I, 1987
)
0.6
"The pharmacokinetic profile of an oral single dose of the new cardioselective beta-blocking agent, bisoprolol, was studied in patients with moderate and severe liver disease (Pugh group B and C, respectively) and normal subjects."( Single oral dose pharmacokinetics of bisoprolol 10 mg in liver disease.
Dagap, K; Hayes, PC; Ioannides, C; Jenkins, D; Johnston, A; Thomas, P; Vavianos, P; Williams, R, 1987
)
0.76
" The oral bioavailability of bisoprolol is high (90%) and the drug has a long elimination half-life which allows once-daily administration; in addition, it is hepatically and renally cleared in equal proportions."( Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.
Lancaster, SG; Sorkin, EM, 1988
)
2.01
"The pharmacokinetic data for the three drugs were qualitatively similar."( Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers.
Carrupt, PA; Cheymol, G; Levron, JC; Poirier, JM; Snoeck, E; Testa, B; Weissenburger, J, 1997
)
0.3
" The AUC(infinity) and elimination half-life of (S)-(-)-bisoprolol were slightly larger than those of (R)-(+)-bisoprolol in all subjects."( Pharmacokinetics and metabolism of bisoprolol enantiomers in humans.
Horikiri, Y; Mizobe, M; Suzuki, T, 1998
)
0.82
" On nondialysis days, Cmax and T1/2 were significantly higher in patients than in healthy control subjects."( Pharmacokinetics of bisoprolol and its effect on dialysis refractory hypertension.
Hiroshige, K; Iwamoto, M; Kanegae, K; Nakashima, Y; Ohta, T; Ohtani, A; Suda, T, 1999
)
0.63
"The pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme (ACE) inhibitor imidapril with other therapeutic principles used in hypertension and heart failure were evaluated."( Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine.
Belz, GG; Breithaupt-Grögler, K; Meurer-Witt, B; Ungethüm, W, 2001
)
0.52
" Plasma concentrations of imidaprilat and H were followed up to 48 h, those of B and N up to 24 h and area under the concentration time curve (AUC), maximum plasma concentration (Cmax) and time to Cmax (tmax) were determined."( Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine.
Belz, GG; Breithaupt-Grögler, K; Meurer-Witt, B; Ungethüm, W, 2001
)
0.52
"The combination of imidapril with a diuretic, beta-adrenoceptor antagonist or calcium-channel blocker seems a reasonable and safe treatment option when striving for additive pharmacodynamic effects not accompanied by relevant pharmacokinetic interactions."( Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine.
Belz, GG; Breithaupt-Grögler, K; Meurer-Witt, B; Ungethüm, W, 2001
)
0.52
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" The pharmacokinetic variability of bisoprolol is small even in routinely treated Japanese patients, provided that both body weight and renal function are taken into account for the prediction of oral clearance of the drug."( Pharmacokinetic variability of routinely administered bisoprolol in middle-aged and elderly Japanese patients.
Hashimoto, Y; Igawa, A; Inoue, H; Nozawa, T; Taguchi, M; Tahara, K; Takesono, C, 2005
)
0.85
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"To compare the pharmacokinetic properties and bioavailability following oral and IV administration of bisoprolol, a second-generation beta1-adrenoceptor-selective blocking agent, with those of carvedilol, a third-generation beta1/beta2 and alpha1-adrenoceptor blocking agent, in dogs."( Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
Beddies, G; Fox, PR; Kanikanti, VR; Keene, BW; Krebber, R; Papich, MD, 2008
)
0.82
" Blood samples were collected before and after drug administration, and serum concentrations, pharmacokinetic variables, and bioavailability for each agent were assessed."( Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
Beddies, G; Fox, PR; Kanikanti, VR; Keene, BW; Krebber, R; Papich, MD, 2008
)
0.6
" Collectively, these differences suggested that, in dogs, bisoprolol has less interindividual pharmacokinetic variability, compared with carvedilol."( Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
Beddies, G; Fox, PR; Kanikanti, VR; Keene, BW; Krebber, R; Papich, MD, 2008
)
0.85
"The objective of this study was to evaluate whether pharmacokinetic parameters (clearance and volume of distribution of the central compartment) from a sparse sampling population pharmacokinetic study can be obtained with a very small sample size."( Population pharmacokinetics with a very small sample size.
Duan, J; Mahmood, I, 2009
)
0.35
" This method was applied in pharmacokinetic studies of bisoprolol preparations in healthy volunteers."( An HPLC method for the determination of bisoprolol in human plasma and its application to a pharmacokinetic study.
Aydoğmuş, Z; Ulu, ST, 2012
)
0.89
" The method was successfully applied to pharmacokinetic studies of amlodipine and bisoprolol in Sprague-Dawley (SD) rats."( Simultaneous determination of amlodipine and bisoprolol in rat plasma by a liquid chromatography/tandem mass spectrometry method and its application in pharmacokinetic study.
Bi, K; Chang, H; Fan, G; Guan, X; Li, J; Qian, Z; Sun, F, 2012
)
0.86
" The formulations were considered bioequivalent if 90% CI of geometric mean ratios (test/reference) for AUC0-t, AUC0-∞ and Cmax were within the range 80."( Bioequivalence and pharmacokinetics of two 10-mg bisoprolol formulations as film-coated tablets in healthy white volunteers: a randomized, crossover, open-label, 2-period, single-dose, fasting study.
Bielak, A; Bus-Kwasnik, K; Ksycinska, H; Lazowski, T; Les, A; Raszek, J; Rudzki, PJ; Serafin-Byczak, K; Wybraniec, A, 2012
)
0.63
" The geometric mean test/referenceratios (90% CI) for AUC0-t, AUC0-∞ and Cmax were 104."( Bioequivalence and pharmacokinetics of two 10-mg bisoprolol formulations as film-coated tablets in healthy white volunteers: a randomized, crossover, open-label, 2-period, single-dose, fasting study.
Bielak, A; Bus-Kwasnik, K; Ksycinska, H; Lazowski, T; Les, A; Raszek, J; Rudzki, PJ; Serafin-Byczak, K; Wybraniec, A, 2012
)
0.63
"To develop and evaluate a whole-body physiologically based pharmacokinetic (WB-PBPK) model of bisoprolol and to simulate its exposure and disposition in healthy adults and patients with renal function impairment."( Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.
Chen, R; Li, GF; Wang, K; Yang, J; Zhao, HR; Zheng, QS, 2012
)
0.87
" Model refinements were conducted after a comparison of the simulated concentration-time profiles and pharmacokinetic parameters with the observed data in healthy adults following intravenous and oral administration."( Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.
Chen, R; Li, GF; Wang, K; Yang, J; Zhao, HR; Zheng, QS, 2012
)
0.65
" The predicted pharmacokinetic parameters (AUC, C(max), and T(max)) were reasonably consistent (<1."( Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.
Chen, R; Li, GF; Wang, K; Yang, J; Zhao, HR; Zheng, QS, 2012
)
0.65
"The aim of the study was to develop a population pharmacokinetic (PK) model for clearance of bisoprolol in patients with congestive heart failure (CHF)."( Population pharmacokinetics of bisoprolol in patients with chronic heart failure.
Apostolović, S; Deljanin-Ilic, M; Ilic, S; Jankovic, SM; Jevtovic-Stoimenov, T; Marinkovic, D; Milovanovic, JR; Nikolic, VN; Pesic, S; Stanojevic, D; Stefanovic, N; Velickovic-Radovanović, R; Zecevic, DR; Zivanovic, S, 2013
)
0.9
" A validation set of 17 patients with heart failure was used to estimate the predictive performance of the pharmacokinetic model."( Population pharmacokinetics of bisoprolol in patients with chronic heart failure.
Apostolović, S; Deljanin-Ilic, M; Ilic, S; Jankovic, SM; Jevtovic-Stoimenov, T; Marinkovic, D; Milovanovic, JR; Nikolic, VN; Pesic, S; Stanojevic, D; Stefanovic, N; Velickovic-Radovanović, R; Zecevic, DR; Zivanovic, S, 2013
)
0.68
"The aim of our study was to estimate clearance of bisoprolol and reveal the factors that could influence its pharmacokinetic (PK) variability in hypertensive patients on hemodialysis, using the population PK analysis."( Population Pharmacokinetics of Bisoprolol in Hemodialysis Patients with Hypertension.
Andric, BR; Dimitrijevic, ZM; Jankovic, SM; Jevtovic-Stoimenov, T; Milovanovic, JR; Nikolic, VN; Petrovic, DS; Sokolovic, MJ; Zivanovic, S, 2016
)
0.97
" A bisoprolol pharmacokinetic model was built with non-linear mixed-effects modeling to analyze the association with various parameters of body composition."( Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study.
Anker, SD; Cvan Trobec, K; Grabnar, I; Kerec Kos, M; Lainscak, M; Rosano, G; Trontelj, J; Vovk, T, 2016
)
2.5
"The aim of this study was (1) to determine how closely physiologically based pharmacokinetic (PBPK) models can predict oral bioavailability using a priori knowledge of drug-specific properties and (2) to examine the influence of the biopharmaceutics classification system class on the simulation success."( Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models.
Aarons, L; Darwich, A; Dressman, J; Hansmann, S; Margolskee, A, 2016
)
0.43
" The aim of our analysis was to estimate and identify different factors that could affect bisoprolol clearance (CL) and develop a population pharmacokinetic model in patients with stable coronary artery disease (CAD)."( Population Pharmacokinetic Analysis of Bisoprolol in Patients with Stable Coronary Artery Disease.
Deljanin-Ilic, M; Jankovic, SM; Jevtovic-Stoimenov, T; Milovanovic, JR; Nikolic, ML; Nikolic, VN; Stojanovic, SS; Stokanovic, D; Zivanovic, S, 2018
)
0.97
"Population pharmacokinetic analysis was performed by using sixty-six plasma concentrations from the same number of patients (mean age 60."( Population Pharmacokinetic Analysis of Bisoprolol in Patients with Stable Coronary Artery Disease.
Deljanin-Ilic, M; Jankovic, SM; Jevtovic-Stoimenov, T; Milovanovic, JR; Nikolic, ML; Nikolic, VN; Stojanovic, SS; Stokanovic, D; Zivanovic, S, 2018
)
0.75
" The only demographic covariate which affected bisoprolol pharmacokinetic variability was creatinine clearance (CLcr)."( Population Pharmacokinetic Analysis of Bisoprolol in Patients with Stable Coronary Artery Disease.
Deljanin-Ilic, M; Jankovic, SM; Jevtovic-Stoimenov, T; Milovanovic, JR; Nikolic, ML; Nikolic, VN; Stojanovic, SS; Stokanovic, D; Zivanovic, S, 2018
)
1.01
" A literature review has been performed in order to analyze pharmacokinetic risk factors of beta-blockers overdosing in geriatrics."( [Pharmacokinetic risk factors of beta-blockers overdose in the elderly: Case report and pharmacology approach].
Bernard, N; Bourguignon, L; De La Gastine, B; Dehan-Moya, MJ; Goutelle, S; Lafarge, L; Vial, T, 2018
)
0.48
"This study was conducted to compare the pharmacokinetic profiles of the bisoprolol-amlodipine FDC tablet with the bisoprolol tablet and amlodipine tablet administered concomitantly under both fasting and fed conditions."( Bioequivalence and Pharmacokinetics of Bisoprolol-Amlodipine 5 mg/5 mg Combination Tablet versus Bisoprolol 5 mg Tablet and Amlodipine 5 mg Tablet: An Open-Label, Randomized, Two-Sequence Crossover Study in Healthy Chinese Subjects.
Chen, X; Gao, D; Hu, C; Hu, X; Huang, Y; Li, L; Wang, C; Zhang, L; Zhao, Z; Zhou, D, 2018
)
0.98
"To date, many questions about the extent and cause of pharmacokinetic (PK) variability of even the most widely studied and prescribed β1-adrenergic receptor blockers, such as metoprolol and bisoprolol, remain unanswered."( Population Pharmacokinetic Analysis of Bisoprolol in Patients With Acute Coronary Syndrome.
Damjanović, M; Janković, SM; Jovanović, A; Krstić, M; Maričić, B; Mihajlović, A; Milovanović, JR; Momčilović, S; Nikolić, VN; Radojković, DD; Ranković, G; Šalinger-Martinović, S; Stanojević, D; Tasić-Otašević, S; Živković, M, 2019
)
0.97
"Given that it has been reported that type 2 diabetes mellitus may affect the pharmacokinetics of a large number of drugs and that there are still no published population pharmacokinetic (PopPK) analyses in routinely treated patients with hypertension and type 2 diabetes mellitus as comorbid condition, the aim of this study was to determine PK variability of bisoprolol in 70 Serbian patients using the PopPK approach."( Population pharmacokinetic analysis of bisoprolol in type 2 diabetic patients with hypertension.
Janković, SM; Jovanović, A; Milovanović, JR; Momčilović, S; Nikolić, VN; Pešić, M; Radojković, D, 2020
)
1

Compound-Compound Interactions

Bisoprolol is effective and safe drug in the treatment of stable angi.

ExcerptReferenceRelevance
"To study effects of a cardioselective beta-adrenoblocker bisoprolol on vascular wall endothelium and external respiration function in stable angina of effort combined with chronic obstructive pulmonary disease (COPD)."( [Effects of beta 1-adrenoblocker bisoprolol on endothelial dysfunction in patients with stable angina pectoris in combination with chronic obstructive pulmonary disease].
Grigor'eva, NIu; Kontorshchikova, KN; Koroleva, EF; Kuznetsov, AN; Mazalov, KV; Sharabrin, EG, 2009
)
0.88
"Bisoprolol is effective and safe drug in the treatment of stable angina combined with COPD."( [Effects of beta 1-adrenoblocker bisoprolol on endothelial dysfunction in patients with stable angina pectoris in combination with chronic obstructive pulmonary disease].
Grigor'eva, NIu; Kontorshchikova, KN; Koroleva, EF; Kuznetsov, AN; Mazalov, KV; Sharabrin, EG, 2009
)
2.08
"The antianginal and anti-ischemic efficacy of the selective I (f) inhibitor ivabradine is established in patients with stable angina in monotherapy and in combination with other antianginals, including beta-blocker."( Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina.
Amosova, E; Andrejev, E; Ceconi, C; Ferrari, R; Rudenko, U; Zaderey, I, 2011
)
0.37
"To the best of our knowledge, there is no study that has conducted a review investigating the clinical efficacy and safety of bisoprolol combined with trimetazidine on chronic heart failure (CHF) patients with chronic obstructive pulmonary disease (COPD)."( Effects of trimetazidine in combination with bisoprolol in patients with chronic heart failure and concomitant chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis.
Fu, B; Ma, S; Zhang, X, 2021
)
1.09
"To analyze the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI)."( Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI).
Chen, C; Li, Y; Peng, Y; Wu, X, 2021
)
1.17
"Patients were divided into a control group (bisoprolol), with 39 cases, and a combination group (bisoprolol combined with sacubitril valsartan sodium tablets), with 42 cases, according to their different medications after surgery."( Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI).
Chen, C; Li, Y; Peng, Y; Wu, X, 2021
)
1.16
"Bisoprolol combined with sacubitril valsartan sodium tablets has a good application effect in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after PCI."( Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI).
Chen, C; Li, Y; Peng, Y; Wu, X, 2021
)
2.34
" In addition, this case used amiodarone (AMD), and it has been reported that the RDV concentration increases when used in combination with AMD."( [Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir].
Bando, Y; Ishii, H; Otori, K; Yokota, N, 2022
)
0.72
"In the present study, five simple, feasible, and sensitive Ultra-high-speed liquid chromatography combined with mass spectrometry detection methods, using electrospray ionization are proposed."( Ultra-high-speed liquid chromatography combined with mass spectrometry detection analytical methods for the determination of nitrosamine drug substance-related impurities.
Bessa-Jambrina, S; Galán-Rodríguez, C; López-García, R; Marlés-Torres, A, 2023
)
0.91

Bioavailability

Bisoprolol exhibits a high absolute bioavailability. Intraindividual comparison of the pharmacokinetic data measured after oral and intravenous administration of 10 mg bisoproll to 12 subjects yielded anabsolute bioavailability of 90%.

ExcerptReferenceRelevance
" This finding reflects the high absolute bioavailability of bisoprolol."( Pharmacokinetics of bisoprolol and influence on serum thyroid hormones in hyperthyroid patients.
Adam, W; Baew-Christow, T; Bux, B; Cordes, M; Disselhoff, G; Pabst, J; Panitz, N; Pfannenstiel, P; Rummeny, E, 1986
)
0.84
"Bisoprolol exhibits a high absolute bioavailability (90%) because of its nearly complete absorption (greater than 90%) and small first-pass effect (10%)."( Balanced pharmacokinetics and metabolism of bisoprolol.
Leopold, G, 1986
)
1.97
" Bisoprolol is well absorbed in these species; independent of the route of administration (i."( Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans.
Bühring, KU; Faro, HP; Garbe, A; Leopold, G; Pabst, J; Sailer, H, 1986
)
1.46
" Intraindividual comparison of the pharmacokinetic data measured after oral and intravenous administration of 10 mg bisoprolol to 12 subjects yielded an absolute bioavailability of 90%."( Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist.
Bühring, KU; Leopold, G; Pabst, J; Ungethüm, W,
)
0.64
" The oral bioavailability of bisoprolol is high (90%) and the drug has a long elimination half-life which allows once-daily administration; in addition, it is hepatically and renally cleared in equal proportions."( Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.
Lancaster, SG; Sorkin, EM, 1988
)
2.01
"The bioavailability patterns of a 100 mg metoprolol controlled release tablet and a 10 mg bisoprolol normal release tablet were compared in a single dose crossover study in 12 healthy subjects."( Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers.
Demblon, C; Deroubaix, X; Jeanbaptiste, B; Lens, S; Lins, RL; Poelaert, D; Stockis, A, 1996
)
0.74
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" The method had been successfully applied to study the relative bioavailability of bisoprolol fumarate tablets in healthy Chinese volunteers."( LC-ESI-MS method for the determination of bisoprolol in human plasma.
Ding, L; Guo, X; He, J; Song, Q; Xu, G; Zhou, X, 2007
)
0.83
"To compare the pharmacokinetic properties and bioavailability following oral and IV administration of bisoprolol, a second-generation beta1-adrenoceptor-selective blocking agent, with those of carvedilol, a third-generation beta1/beta2 and alpha1-adrenoceptor blocking agent, in dogs."( Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
Beddies, G; Fox, PR; Kanikanti, VR; Keene, BW; Krebber, R; Papich, MD, 2008
)
0.82
" Blood samples were collected before and after drug administration, and serum concentrations, pharmacokinetic variables, and bioavailability for each agent were assessed."( Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
Beddies, G; Fox, PR; Kanikanti, VR; Keene, BW; Krebber, R; Papich, MD, 2008
)
0.6
" Oral bioavailability of bisoprolol was 91."( Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
Beddies, G; Fox, PR; Kanikanti, VR; Keene, BW; Krebber, R; Papich, MD, 2008
)
0.91
" The validated method was successfully applied to analyze human plasma samples in a bisoprolol bioavailability study."( Liquid chromatography tandem mass spectrometry method for determination of bisoprolol in human plasma using d5-bisoprolol as the internal standard.
Jia, JY; Li, SJ; Liu, GY; Liu, Y; Liu, YM; Lu, C; Wang, W; Yu, C; Zhang, MQ, 2010
)
0.82
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The aim of the study was to investigate the bioavailability of a generic formulation of 10-mg bisoprolol film coated tablets (test) as compared to that of a branded formulation (reference) at the same strength to determine bioequivalence and to apply for regulatory approval."( Bioequivalence and pharmacokinetics of two 10-mg bisoprolol formulations as film-coated tablets in healthy white volunteers: a randomized, crossover, open-label, 2-period, single-dose, fasting study.
Bielak, A; Bus-Kwasnik, K; Ksycinska, H; Lazowski, T; Les, A; Raszek, J; Rudzki, PJ; Serafin-Byczak, K; Wybraniec, A, 2012
)
0.85
"The present study was conducted to compare the bioavailability of two bisoprolol fumarate 5 mg film-coated tablet formulations (test and reference formulations)."( Bioequivalence study of two formulations of bisoprolol fumarate film-coated tablets in healthy subjects.
Santoso, ID; Setiawati, A; Setiawati, E; Susanto, LW; Tjandrawinata, RR; Yunaidi, DA, 2012
)
0.87
" The aim of the present study was to examine the variability of bioavailability (F) of bisoprolol in routinely treated Japanese patients and intestinal absorption characteristics of the drug."( Variability of bioavailability and intestinal absorption characteristics of bisoprolol.
Fujii, N; Hashimoto, Y; Horie, A; Inoue, H; Ishida, K; Nishimura, M; Nozawa, T; Taguchi, M, 2013
)
0.84
" The Pharmacokinetics and relative bioavailability of the BF nasal formulation were evaluated in Wistar rats."( Preparation of bisoprolol fumarate nasal spray and its nasal delivery in rats.
Chunzhi, W; Duo, H; Fugen, G; Gendalai, M; Yi, W, 2015
)
0.77
" During follow-up, we observed minor changes in the absorption rate constant (2."( Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study.
Anker, SD; Cvan Trobec, K; Grabnar, I; Kerec Kos, M; Lainscak, M; Rosano, G; Trontelj, J; Vovk, T, 2016
)
1.88
"A randomised, open-label, two-period, crossover, single-dose, relative bioavailability study was conducted in fasted healthy Caucasian volunteers."( Bioequivalence study of 2.5 mg film-coated bisoprolol tablets in healthy volunteers.
Bielak, A; Buś-Kwaśnik, K; Ksycińska, H; Leś, A; Płatek, AE; Raszek, J; Rudzki, PJ; Serafin-Byczak, K; Szymański, FM; Wybraniec, A; Łazowski, T, 2017
)
0.72
"The aim of this study was (1) to determine how closely physiologically based pharmacokinetic (PBPK) models can predict oral bioavailability using a priori knowledge of drug-specific properties and (2) to examine the influence of the biopharmaceutics classification system class on the simulation success."( Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models.
Aarons, L; Darwich, A; Dressman, J; Hansmann, S; Margolskee, A, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" A validated ultra-performance liquid chromatography method was used for the analysis and quantification of bisoprolol in the accelerated stability and bioavailability studies."( Patient-friendly extemporaneous formulation of bisoprolol: application to stability and bioavailability studies.
El-Masry, SM; Helmy, SA; Helmy, SAM; Mazyed, EA, 2023
)
1.38

Dosage Studied

Bisoprolol was well tolerated in the dosage studied, it can be recommended for noninsulin-dependent diabetics with hypertension. The apparent volume of distribution (Vz) was greater for bisoproll than for atenolol after single dosing and at steady state.

ExcerptRelevanceReference
" Dose-response curves were constructed, and doses of isoprenaline required to increase finger tremor by 100% (IT100), heart rate by 25 beats/min (IH25), SBP by 25 mmHg (IS25), cardiac output by 35% (IC35), and decrease DBP by 10 mmHg (ID10), after each treatment were calculated."( A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol.
Irvine, NA; Lipworth, BJ; McDevitt, DG, 1991
)
0.51
" The apparent volume of distribution (Vz) was greater for bisoprolol than for atenolol after single dosing (235 1 vs 146 1) and at steady state (216 1 vs 137 1), but clearances were similar for both drugs."( A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension.
Dixon, MS; Sheridan, DJ; Thomas, P, 1990
)
0.8
" No accumulation of radioactivity in tissues was observed after repeated dosing (1 mg/kg/day)."( Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans.
Bühring, KU; Faro, HP; Garbe, A; Leopold, G; Pabst, J; Sailer, H, 1986
)
0.55
" Since bisoprolol was well tolerated in the dosage studied, it can be recommended for noninsulin-dependent diabetics with hypertension."( Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics.
Disselhoff, G; Janka, HU; Mehnert, H; Ziegler, AG, 1986
)
1.1
" From the right shifts of isoprenaline dose-response curves 0 to 84 hr after administration of propranolol and the beta-1 selective bisoprolol, in vivo beta blockade was assessed."( Beta adrenoceptor subtype binding activity in plasma and beta blockade by propranolol and beta-1 selective bisoprolol in humans. Evaluation with Schild-plots.
Belz, GG; Palm, D; Wellstein, A, 1988
)
0.69
" The 20 mg dosage regimen was more effective than that of 5 mg and 10 mg."( Antihypertensive effects of bisoprolol during once daily administration in patients with essential hypertension. A dose-ranging study with parallel groups.
Frithz, G; Weiner, L, 1986
)
0.57
" The dose-response relationship using individual maximal reduction of ET showed, on a molar basis, that bisoprolol is about 5, 7 and 10 times more effective than propranolol, atenolol and metoprolol, respectively."( Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist.
Bühring, KU; Leopold, G; Pabst, J; Simane, Z; Ungethüm, W; Wiemann, H, 1986
)
0.78
"21 mg/24 hours of unchanged bisoprolol were recovered following urinary excretion during the dosage interval."( Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.
Demers, HG; Kirch, W; Leopold, G; Ohnhaus, EE; Pabst, J; Rose, I, 1987
)
0.89
" This may have been a dosage phenomenon or reflects the longer plasma elimination half-life of bisoprolol, and requires confirmation."( Bisoprolol: a new beta-adrenoceptor blocking drug.
Prichard, BN, 1987
)
1.93
" Because of its balanced clearance, it is unlikely that accumulation of bisoprolol would occur beyond a factor of 2 on dosing to a steady state."( The single dose pharmacokinetics of bisoprolol (10 mg) in renal insufficiency: the clinical significance of balanced clearance.
Boulton-Jones, JM; Fox, JG; Ioannides, C; Johnston, A; Pauleau, NF; Payton, CD; Thomas, P, 1987
)
0.78
" In conclusion, the delayed absorption in these patients results in lower plasma concentrations and indicates that dose adjustment is not necessary but it is recommended that the upper limit for the daily dose should be set at 10 mg; this also applies under chronic dosing of bisoprolol."( Single oral dose pharmacokinetics of bisoprolol 10 mg in liver disease.
Dagap, K; Hayes, PC; Ioannides, C; Jenkins, D; Johnston, A; Thomas, P; Vavianos, P; Williams, R, 1987
)
0.72
"Changes in systolic and diastolic blood pressure, heart rate, arterial blood flow and vascular resistance in the arm and in the leg were investigated in 9 healthy volunteers (22-40 years) after oral dosing with bisoprolol 10 mg, propranolol 40 mg, and placebo in a randomized double-blind cross-over study."( Effects of bisoprolol on local vascular resistance.
Bailliart, O; Bonnin, P; Kedra, AW; Martineaud, JP; Savin, E, 1987
)
0.85
" Under pindolol, on the other hand, a significant impairment of sleep quality was observed after acute dosage and a decrease in feeling refreshed after sleep, continuing up to day 14 of treatment."( [Comparative study of the central nervous system effect of the beta receptor blockaders pindolol and bisoprolol].
Görtelmeyer, R; Klingmann, I, 1985
)
0.49
" All three dosage regimens were well tolerated."( A comparison of once daily bisoprolol, 5 and 10 mg, and atenolol 100 mg in the treatment of angina pectoris.
Camm, AJ; Dymond, DS; Maltz, MB; Nathan, AW, 1987
)
0.57
" In anesthetized, bivagotomized dogs, isoprenaline dose-response relations for increase in heart rate and decrease in diastolic blood pressure were established."( Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs.
Harting, J; Schliep, HJ,
)
0.45
" Bronchial beta-adrenoceptor blockade was assessed as the displacement of the bronchodilator dose-response curve to inhaled isoprenaline after each beta-adrenoceptor blocking drug compared to placebo and expressed as the dose ratio."( Assessment of beta-adrenoceptor selectivity of a new beta-adrenoceptor antagonist, bisoprolol, in man.
Bacon, RJ; Cragg, DJ; Tattersfield, AE, 1984
)
0.49
"01), although the once-daily dosing of enalapril and the maximum dose of 20 mg might not have been optimal for this agent."( Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment.
Adegbile, IA; Alemayehu, D; Carr, AA; Lefkowitz, MP; Papademetriou, V; Prisant, LM; Weber, MA; Weir, MR, 1995
)
0.29
"Bisoprolol reduces systolic and diastolic blood pressures in patients with hypertension for a 24-hour dosing interval and is associated with beneficial hemodynamic effects in patients with myocardial ischemia."( Bisoprolol: is this just another beta-blocker for hypertension or angina?
Johns, TE; Lopez, LM, 1995
)
3.18
" Antihypertensive effects were maintained during the 24-hour dosing interval."( First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension.
Alemayehu, D; Bryzinski, BS; Burris, JF; Chen, SY; Frishman, WH; Mroczek, WJ; Simon, JS; Weir, MR, 1995
)
0.56
"Dose proportionality of racemic bisoprolol and the stereoselectivity of its enantiomers were studied after single oral dosing of 5 to 40 mg of bisoprolol hemifumarate in eight healthy male volunteers in an open-label, randomized, four-way cross-over trial."( Dose proportionality of bisoprolol enantiomers in humans after oral administration of the racemate.
Begg, E; Desjardins, R; Dukart, G; Dutta, A; Lanc, R; Robson, R; Sia, L; Yacobi, A, 1994
)
0.88
" A once-daily dosing schedule was evaluated by comparing bisoprolol's antihypertensive effectivness and safety at 24 h postdose and 3 h postdose, the latter time intended to correspond to peak effectiveness."( Bisoprolol, a once-a-day beta-blocking agent for patients with mild to moderate hypertension.
Alemayehu, D; Blumenthal, JB; Bryzinski, BS; Davidov, ME; Koury, KJ; Simon, JS; Singh, SP; Vlachakis, ND, 1994
)
1.98
"The effects of bisoprolol and hydrochlorothiazide were additive with respect to reductions in diastolic and systolic blood pressures over the dosage ranges studied."( A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide.
Alemayehu, D; Bryzinski, BS; Coulson, LR; DeQuattro, VL; Dukart, G; Frishman, WH; Goldberg, JD; Koury, K; Mroczek, WJ; Vlachakis, ND, 1994
)
0.86
"The utility of factorial design trials to characterize dose-response relationships and to test the potential interactions between various antihypertensive agents has been demonstrated."( A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide.
Alemayehu, D; Bryzinski, BS; Coulson, LR; DeQuattro, VL; Dukart, G; Frishman, WH; Goldberg, JD; Koury, K; Mroczek, WJ; Vlachakis, ND, 1994
)
0.51
" Recommended dosage is 10-15 mg once a day."( [Bisoprolol in the treatment of hypertension].
Spinar, J; Vítovec, J; Zicha, J, 1993
)
1.2
" Results of both studies demonstrated that this once-a-day, low-dose option effectively reduced sitting diastolic and systolic blood pressure measured at the end of the 24-hour dosing period."( Low-dose bisoprolol/hydrochlorothiazide: an option in first-line, antihypertensive treatment.
Messerli, FH; Mroczek, W; Zachariah, PK,
)
0.55
" Office BPs were recorded at the end of the 24-hour dosing interval (trough)."( Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents.
Fagan, TC; Kaplan, NM; Kazempour, MK; Lefkowitz, MP; Neutel, JM; Papademetriou, V; Ram, CV; Smith, DH; Weber, MA, 1993
)
0.29
"01) BPs were also noted for bisoprolol compared with atenolol during the final 4 hours of the dosing interval (-13."( Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents.
Fagan, TC; Kaplan, NM; Kazempour, MK; Lefkowitz, MP; Neutel, JM; Papademetriou, V; Ram, CV; Smith, DH; Weber, MA, 1993
)
0.58
" The dose-response curve for dopamine to stimulate the heart rate (HR) closely resembled that for the norepinephrine release."( The mechanisms underlying heart stimulation by dopamine, with special reference to direct and indirect beta adrenoceptor stimulation.
Habuchi, Y; Komori, T; Nishio, M; Tanaka, H; Yamamoto, T; Yoshimura, M,
)
0.13
" It is also necessary to define the initiation and increase of dosage and the target dose of the beta-blocker."( [Beta-blockers in the treatment of chronic heart failure. How should results of clinical studies be introduced into clinical practice].
Spinar, J; Vítovec, J, 2000
)
0.31
" In the preliminary session a dose-response curve to the vasoconstrictor effect of phenylephrine was constructed and the dose producing 50-75% maximal response was determined for each individual."( Comparison of the effects of nadolol and bisoprolol on the isoprenaline-evoked dilatation of the dorsal hand vein in man.
Abdelmawla, AH; Bradshaw, CM; Langley, RW; Szabadi, E, 2001
)
0.58
" Forty-six outpatients suffering from mild to moderate essential hypertension [diastolic blood pressure (DBP) ranging between 95 and 120 mm Hg] were randomly given either 10 mg of bisoprolol or 400 mg of acebutolol once a day for 8 weeks; this dosage was doubled after 4 weeks if DBP was still above 90 mm Hg."( Effect of bisoprolol and acebutolol on resting blood pressure and on exercise blood pressure profile in hypertensive patients: a comparative, single-blind study.
Bouvier, JM; Herrero, G; Rabot, D, 1990
)
0.87
" The dosage of the drugs was titrated to match that of the the Cardiac Insufficiency Bisoprolol Study protocol."( Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging.
Bonetti, P; Dubach, P; Froelicher, V; Hess, O; Luchinger, R; Myers, J; Scheidegger, M; Schertler, T; Schwitter, J; Stuber, M; Wagner, D, 2002
)
0.93
" All centres were provided with carvedilol, metoprolol, and bisoprolol at appropriate doses; the choice of the drug and dosage was left to the responsible clinician."( Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience.
Balli, E; Geraci, E; Gorini, M; Gronda, E; Lucci, D; Maggioni, AP; Opasich, C; Sinagra, G; Tavazzi, L; Tognoni, G, 2003
)
0.56
" Starting treatment with beta blockers did not affect the prescription or dosage of other recommended drugs."( Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience.
Balli, E; Geraci, E; Gorini, M; Gronda, E; Lucci, D; Maggioni, AP; Opasich, C; Sinagra, G; Tavazzi, L; Tognoni, G, 2003
)
0.32
" We analyze the problems with the trial design of COMET from the standpoint of comparing 2 therapeutic agents at different positions on a common dose-response curve, and discuss the theoretical reasons why postjunctional adrenergic receptor blockade that is in addition to beta1-receptor antagonism will likely produce only minimal or no incremental benefit in chronic heart failure."( Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
Adams, KF; Bristow, MR; Feldman, AM; Goldstein, S, 2003
)
0.32
"10, NYHA III-IV 29%) to treatment with either bisoprolol or carvedilol, in order to assess and compare the maximally achievable number of patients on treatment with these BB and the maximally achieved dosage during a minimum of 2 months attendance at our out patient heart failure clinic."( Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison.
Atar, D; Galatius, S; Gustafsson, F; Hildebrandt, PR, 2004
)
0.83
" Results from the recently published trials are summarized to emphasize the proper selection and dosage of beta blocker therapy to optimize the care of this high risk population."( The effects of beta blockers on morbidity and mortality in heart failure.
Jafri, SM, 2004
)
0.32
" Data on the plasma concentration of bisoprolol from 94 blood samples obtained at steady-state following repetitive oral administration were analyzed using the NONMEM program, where a one-compartment model with repetitive bolus dosing was parameterized in terms of oral clearance (CL/F) and apparent volume of distribution (V/F)."( Pharmacokinetic variability of routinely administered bisoprolol in middle-aged and elderly Japanese patients.
Hashimoto, Y; Igawa, A; Inoue, H; Nozawa, T; Taguchi, M; Tahara, K; Takesono, C, 2005
)
0.85
" The dosage of beta-blockers were increased gradually to target or the tolerant dosages (bisoprolol 10 mg qd, carvedilol 25 mg bid) during 3 months in 36 patients."( [Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure].
Bian, WY; Duan, B; Jia, X; Li, W; Li, YS; Wang, F; Wang, L; Xu, ZM, 2005
)
0.55
" The clinical group had beta-blocker dosage increased according to standard care, whereas the BNP group had beta-blocker dosage up-titrated according to plasma BNP levels plus standard care."( BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure.
Beck-da-Silva, L; de Bold, A; Fraser, M; Haddad, H; Williams, K,
)
0.13
" As a patient-friendly, convenient, and multi-day dosing therapeutic system, the transdermal patches incorporating ISDN and BP could be promising for prevention and treatment of hypertension."( A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization.
Fu, JH; Kong, SJ; Li, L; Lu, WL; Pei, QL; Shan, Y; Su, CH; Wang, JC; Wang, L; Wang, SM; Wang, Y; Zhang, EH; Zhang, H; Zhang, Q; Zhang, S; Zhang, X; Zhao, JH, 2007
)
0.58
"Two analytical methods have been developed for simultaneous quantification of bisoprolol fumarate and hydrochlorothiazide in combined pharmaceutical dosage form using spectrophotometer."( Simultaneous spectrophotometric estimation of Bisoprolol fumarate and hydrochlorothiazide in tablet dosage form.
A, SA; J, SS; R, TR, 2008
)
0.83
"A simple, precise and stability-indicating HPLC method was developed and validated for the simultaneous determination of bisoprolol fumarate and hydrochlorothiazide in pharmaceutical dosage form."( RP-HPLC method for simultaneous estimation of bisoprolol fumarate and hydrochlorothiazide in tablet formulation.
Bhoir, SI; Bindu, KS; Das, C; Joshi, SJ; Karbhari, PA, 2010
)
0.83
" Standard 12-lead ECG was measured in anesthetized rats at basal conditions and at various pharmacological conditions such as beta-adrenergic stimulation with isoproterenol or medication with clarithromycin (single- or repeated dosing for seven days), bisoprolol or ivabradine."( Heart rate correction of the QT duration in rats.
Klimas, J; Kmecova, J, 2010
)
0.54
" A dosage adjustment of bisoprolol is necessary if the clinical status of the patient requires treatment with the antituberculosis drug rifampicin."( [Urinary bladder tuberculosis and Bacillus Calmette-Guérin instillation: reduced efficacy of bisoprolol in hypertension].
Drechsler, A; Kirch, W, 2010
)
0.89
" A dosage adjustment of bisoprolol is necessary if the clinical status of the patient requires treatment with the antituberculosis drug rifampicin."( [Urinary bladder tuberculosis and bacillus calmette-guérin instillation: reduced efficacy of bisoprolol in hypertension].
Drechsler, A; Kirch, W, 2010
)
0.89
" Although potentially of major public health importance, whether one agent is superior in terms of tolerability and optimal dosing has not been investigated."( Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.
Anker, SD; Apostolovic, S; Dietz, R; Doehner, W; Düngen, HD; Edelmann, F; Eschenhagen, T; Gelbrich, G; Herrmann-Lingen, C; Inkrot, S; Krotin, M; Lainscak, M; Mehrhof, F; Neskovic, AN; Prettin, C; Putnikovic, B; Rau, T; Sakac, D; Tahirovic, E; Töpper, A; Waagstein, F; Wachter, R, 2011
)
0.66
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
"A couple of days after increasing the dosage of betaadrenergic- and adding calcium channel blockers due to an increased heart rate in atrial fibrillation, a 77 year old female was found in cardiogenic shock."( [The choked heart].
Furrer, F; Giambarba, C, 2012
)
0.38
"The simulated and observed data after both intravenous and oral dosing showed good agreement for all of the dose levels in the reported normal adult population groups."( Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.
Chen, R; Li, GF; Wang, K; Yang, J; Zhao, HR; Zheng, QS, 2012
)
0.65
"0078 mg/kg/min for 120 min and orally in dosage of 300 mg three times every 8 hours if arrhythmia persisted."( Effect of selective beta-blockade with bisoprolol in the treatment of recent-onset atrial fibrillation.
Negreva, MN; Penev, AP,
)
0.4
" All the proposed methods were effectively applied for the simultaneous determination of BIS and HCZ in tablet dosage forms without any time-consuming extraction, sample preparation, or derivatization procedures."( Fully validated simultaneous determination of bisoprolol fumarate and hydrochlorothiazide in their dosage forms using different voltammetric, chromatographic, and spectrophotometric analytical methods.
Bozal, B; Dogan-Topal, B; Gumustas, M; Ozkan, SA; Uslu, B,
)
0.39
" However, its most common adverse effects, dizziness and hypotension, often discourage continuation or dosage increase."( Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension.
Asano, Y; Ichibori, Y; Kanzaki, M; Komuro, I; Minamiguchi, H; Mizote, I; Ohtani, T; Sakata, Y; Taniguchi, T, 2013
)
0.68
"Data were retrospectively collected from 23 patients with HF [age 57±18 years, left ventricular ejection fraction (LVEF) 33±15%] who could not increase the dosage of carvedilol because of dizziness or hypotension, defined as systolic blood pressure<90 mmHg."( Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension.
Asano, Y; Ichibori, Y; Kanzaki, M; Komuro, I; Minamiguchi, H; Mizote, I; Ohtani, T; Sakata, Y; Taniguchi, T, 2013
)
0.68
"Switching from carvedilol to bisoprolol may help with continuation of β-blocker treatment as well as dosage increase in HF patients with adverse symptoms or signs, allowing them to reach the target dose."( Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension.
Asano, Y; Ichibori, Y; Kanzaki, M; Komuro, I; Minamiguchi, H; Mizote, I; Ohtani, T; Sakata, Y; Taniguchi, T, 2013
)
0.97
" Floating pulsatile concept was applied to increase the gastric residence of the dosage form having lag phase followed by a burst release."( Optimization studies on compression coated floating-pulsatile drug delivery of bisoprolol.
Bari, NA; Chabukswar, AR; Jagdale, SC; Kuchekar, BS, 2013
)
0.62
"Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate-release (IR) solid oral dosage forms containing bisoprolol as the sole active pharmaceutical ingredient (API) are reviewed."( Biowaiver monograph for immediate-release solid oral dosage forms: bisoprolol fumarate.
Abrahamsson, B; Charoo, NA; Cristofoletti, R; Dressman, J; Groot, DW; Kopp, S; Langguth, P; Lian, LY; Polli, J; Shah, VP; Shamsher, AA, 2014
)
0.83
" The dosage of carvedilol had no detectable effect and there were no unexpected safety issues."( Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
Bocchi, EA; Böhm, M; Borer, JS; Ford, I; Komajda, M; Swedberg, K; Tavazzi, L, 2015
)
0.42
" After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR) = 0."( Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease.
Chang, YS; Chen, TJ; Chou, KT; Hu, YW; Hung, MH; Lee, FY; Liu, CJ; Ou, SM; Perng, DW; Su, VY; Yang, KY, 2016
)
1.04
"The objective of this study was to establish the benefit of bisoprolol up-titration toward recommended dosage targets, versus lower-dose maintenance, in heart failure (HF) patients with systolic dysfunction."( Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction.
Cha, TJ; Choi, DJ; Choi, SW; Han, SW; Hwang, KK; Jeon, H; Kim, HJ; Kim, JH; Kim, SH; Kim, YJ; Ryu, KH; Shim, WJ; Shin, MS; Yoo, BS, 2016
)
0.92
" Not being dose-dependent (initiation dosage used), it seemed partially explained by drug-drug interaction with bisoprolol."( Complete Atrioventricular Block in an Elderly Patient Treated with Low-Dose Lacosamide.
Bézie, Y; Corny, J; Durand-Gasselin, B; Ferchichi, S; Lachuer, C, 2018
)
0.69
" In addition, we have shown that this increase is affected by dabigatran dosage and concomitant treatment with proton-pump inhibitor and digoxin."( Effect of Bisoprolol on the Level of Dabigatran.
Ivankova, J; Mokan, M; Nehaj, F; Sokol, J,
)
0.53
"This study demonstrated the interaction between dabigatran and bisoprolol, which is modulated with dabigatran dosage and concomitant treatment with proton-pump inhibitor and digoxin."( Effect of Bisoprolol on the Level of Dabigatran.
Ivankova, J; Mokan, M; Nehaj, F; Sokol, J,
)
0.77
"With the use of the cohort of 15,205 Medicare beneficiaries hospitalized for HFrEF from 2007 to 2013 in the 5% Medicare random sample, we described prescription fills (30 days after discharge) and dosage patterns (1 year after discharge) for beta-blockers."( Low Utilization of Beta-Blockers Among Medicare Beneficiaries Hospitalized for Heart Failure With Reduced Ejection Fraction.
Brown, TM; Chen, L; Durant, RW; Kilgore, ML; Levitan, EB; Loop, MS; Safford, MM; van Dyke, MK, 2019
)
0.51
" The whole procedure summarizes the results obtained for over a thousand different dosage forms of tablets."( Detection of counterfeit and substandard tablets using non-invasive NIR and chemometrics - A conceptual framework for a big screening system.
Balyklova, KS; Pomerantsev, AL; Rodionova, OY; Titova, AV, 2019
)
0.51
" The primary outcome was the change in equivalent dosing of ramipril and bisoprolol at 6-months."( Impact of the COVID-19 pandemic on the management of chronic heart failure.
Gierula, J; Jagger, J; McGinlay, M; Nouri, B; Straw, S; Witte, KK, 2021
)
0.85
"Many patients with HFrEF are not receiving optimal dosing of β-blockers, and in around half, there was no clear contraindication in terms of heart rate or blood pressure."( Suboptimal Dosing of β-Blockers in Chronic Heart Failure: A Missed Opportunity?
Byrom-Goulthorp, R; Cubbon, RM; Gierula, J; Kearney, MT; McGinlay, M; Relton, SD; Straw, S; Witte, KK,
)
0.13
" The prevalence of use (patients treated/1000 inhabitants) and of continuous treatment (patients treated for ≥80% period from the supply to the end of the same year - by means of dosage units - per 1000 inhabitants) of each single active substance were assessed."( [Chronic use of the unfixed combination of ACE-inhibitors and beta-blockers in Italy from 2013 to 2019 through the healthcare administrative data.]
Addesi, A; Calabria, S; Cinconze, E; Dondi, L; Esposito, I; Maggioni, AP; Martini, N; Pedrini, A; Piccinni, C; Ronconi, G, 2021
)
0.62
" Careful monitoring is recommended for possible new symptoms, such as emergence/increase of shortness of breath, cough or changes in dosing of other drugs (for example, increased frequency of using short-acting bronchodilators)."( [Possibilities and limitations of the use of beta-blockers in patients with cardiovascular disease and chronic obstructive pulmonary disease].
Karoli, NA; Rebrov, AP, 2021
)
0.62
"A novel, facile, rapid, and precise synchronous spectrofluorimetric method was evolved for the simultaneous estimation of bisoprolol fumarate and ivabradine in dosage forms and biological fluids."( First derivative synchronous spectrofluorimetric analysis of bisoprolol fumarate and ivabradine in pharmaceutical and biological matrices. Investigation of the method greenness.
Abo Elkheir, SM; Nasr, JJM; Walash, MI; Zeid, AM, 2022
)
1.17
" Small and mostly insignificant differences in average daily metoprolol dosage were found between patients treated with the various antidepressants."( Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway.
Gedde-Dahl, A; Molden, E; Spigset, O, 2022
)
0.72
" Through a simple and direct technique based on deconvolution and synchronous of the spectrofluorometric spectra, the innovative method enables simultaneous quantification of bisoprolol and atorvastatin as single or co-formulated dosage forms in bulk and plasma."( Novel Deconvoluted Synchronous Spectrofluorimetric Method For Simultaneous Determination Of Bisoprolol and Atorvastatin As Single or Co-administrated Drugs in Bulk and Plasma; Green Assessment.
Abdel-Monem, AH; Abdel-Raoof, AM; Attia, KAM; Eissa, AS, 2023
)
1.32
"Antihypertensives bisoprolol fumarate (BIS) and perindopril arginine (PER) were simultaneously determined in their pure, bulk, and combined tablet dosage form."( Chromatographic Techniques for Assessment of Bisoprolol Fumarate and Perindopril Arginine in Solid Formulations under Various Stress Conditions and Application to Six Sigma, Content Uniformity, and Comparative Dissolution Approaches.
Almalki, MA; Binsaleh, AY; Mahmoud, OA; Mohamed, MA; Omran, AA, 2023
)
1.5
" A content uniformity test demonstrated that the drugs in their dosage form met the acceptance limit (85-115%)."( Chromatographic Techniques for Assessment of Bisoprolol Fumarate and Perindopril Arginine in Solid Formulations under Various Stress Conditions and Application to Six Sigma, Content Uniformity, and Comparative Dissolution Approaches.
Almalki, MA; Binsaleh, AY; Mahmoud, OA; Mohamed, MA; Omran, AA, 2023
)
1.17
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (2 Items)

ItemProcessFrequency
Open Beauty Factscore-ingredient1
Non food productscore-ingredient1

Roles (4)

RoleDescription
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
beta-adrenergic antagonistAn agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
anti-arrhythmia drugA drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
sympatholytic agentAny compound which inhibits the postganglionic functioning of the sympathetic nervous system (SNS).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
secondary amineA compound formally derived from ammonia by replacing two hydrogen atoms by hydrocarbyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Bisoprolol Action Pathway478

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency0.08200.004110.890331.5287AID493107
arylsulfatase AHomo sapiens (human)Potency0.37931.069113.955137.9330AID720538
chromobox protein homolog 1Homo sapiens (human)Potency0.00600.006026.168889.1251AID488953
DNA polymerase kappa isoform 1Homo sapiens (human)Potency9.46620.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorHomo sapiens (human)Ki0.25000.00000.66359.5499AID1603579
Beta-1 adrenergic receptorMus musculus (house mouse)Ki0.00530.00010.13100.5500AID1603578
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorHomo sapiens (human)Kd7.10060.00000.62888.9130AID1626022; AID1626023; AID1798580
Beta-1 adrenergic receptorHomo sapiens (human)Kd0.78430.00010.803910.0000AID1798580
Beta-3 adrenergic receptorHomo sapiens (human)Kd0.78430.00010.76318.9130AID1798580
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (42)

Processvia Protein(s)Taxonomy
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
carbohydrate metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
generation of precursor metabolites and energyBeta-3 adrenergic receptorHomo sapiens (human)
energy reserve metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
response to coldBeta-3 adrenergic receptorHomo sapiens (human)
heat generationBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-3 adrenergic receptorHomo sapiens (human)
eating behaviorBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-3 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-3 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta3-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
beta-3 adrenergic receptor bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-3 adrenergic receptorHomo sapiens (human)
epinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
receptor complexBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (151)

Assay IDTitleYearJournalArticle
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1626023Displacement of [3H]DHA from inactive/G protein-uncoupled human beta2-AR expressed in CHO cell membranes assessed as intrinsic Kd by liquid scintillation counting2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Uncoupling the Structure-Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID312896Partition coefficient, log P by UPLC method2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.
AID1603577Selectivity index, ratio of Ki for displacement of [3H]CGP12177 from human beta2 adrenoceptor expressed in CHO cell membranes to Ki for displacement of [3H]CGP12177 from mouse beta1 adrenoceptor expressed in HEK293T cell membranes
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID312895Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1603582Displacement of [3H]CGP12177 from human beta2 adrenoceptor H2.64C mutant expressed in HEK293T cell membranes
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID350220Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 100% water as mobile phase2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID350218Octanol-water partition coefficient, log PC of the compound2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1603581Displacement of [3H]CGP12177 from mouse beta1 adrenoceptor I2.64C mutant expressed in HEK293T cell membranes
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID41892Tested for intrinsic sympathomimetic activity (ISA); pure antagonist1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID1603578Displacement of [3H]CGP12177 from mouse beta1 adrenoceptor expressed in HEK293T cell membranes
AID1668033Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1668034Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1668042Antiproliferative activity against human A375 cells assessed as cell growth inhibition at 100 uM measured after 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID781328pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 20052014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID41489Selectivity towards beta-2 adrenergic receptor;Not selective towards beta-2 adrenergic receptor1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1626024Binding affinity to inactive/G protein-uncoupled human beta2-AR by immobilized artificial membrane HPLC analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Uncoupling the Structure-Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1668041Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition at 100 uM measured after 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID350217Octanol-water partition coefficient, log P of the cationic form of the compound2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1626022Displacement of [3H]DHA from inactive/G protein-uncoupled human beta2-AR expressed in CHO cell membranes by liquid scintillation counting2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Uncoupling the Structure-Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID350216Dissociation constant, pKa of the compound2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID40539Selectivity for beta-1 receptor1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1668032Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition at 100 uM incubated for 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1603579Displacement of [3H]CGP12177 from human beta2 adrenoceptor expressed in CHO cell membranes
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID350219Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 95% acetonitrile as mobile phase2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1668035Antiproliferative activity against human A375 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID17985803H-CGP 12177 Whole Cell Binding Assay from Article 10.1038/sj.bjp.0706048: \\The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.\\2005British journal of pharmacology, Feb, Volume: 144, Issue:3
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,186)

TimeframeStudies, This Drug (%)All Drugs %
pre-199095 (8.01)18.7374
1990's220 (18.55)18.2507
2000's337 (28.41)29.6817
2010's392 (33.05)24.3611
2020's142 (11.97)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 130.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index130.48 (24.57)
Research Supply Index7.40 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index245.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (130.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials392 (31.39%)5.53%
Reviews95 (7.61%)6.00%
Case Studies126 (10.09%)4.05%
Observational23 (1.84%)0.25%
Other613 (49.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (89)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Preventing Adverse Cardiac Events in Chronic Obstructive Pulmonary Disease [NCT03917914]Phase 3280 participants (Actual)Interventional2020-06-30Active, not recruiting
Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction (DANBLOCK) [NCT03778554]Phase 42,760 participants (Anticipated)Interventional2018-12-17Recruiting
Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation [NCT01162902]Phase 4150 participants (Anticipated)Interventional2013-09-30Not yet recruiting
b. p. m Study (Beats Per Minute): Heart Rate Development Whilst Treating Patients With Hypertension With Concor or Concor Plus [NCT01109043]351 participants (Actual)Observational2009-06-30Completed
Bisoprolol Plasma Residual Concentrations for the Optimization of Drug Management in Heart Failure With Mild to Reduced Ejection Fraction [NCT03644446]81 participants (Anticipated)Observational [Patient Registry]2017-11-02Recruiting
N-of-1 Trials for Deprescribing Beta-blockers in HFpEF [NCT04767061]Phase 49 participants (Actual)Interventional2021-04-01Completed
A Randomised Double-blind Cross-over Single-centre Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension [NCT03276598]Phase 4233 participants (Actual)Interventional1999-11-25Completed
Role of ACE Inhibitors and Beta Blockers as Cardiotoxicity Prevention in Breast Cancer Patients Treated With (Neo)Adjuvant Anthracyclines and/or Trastuzumab: a Four Arm, Placebo Control, Randomized Trial [NCT02236806]Phase 3262 participants (Actual)Interventional2015-07-31Active, not recruiting
The Impact of Ivabradine Administration on Clinical Outcome and Biomarkers of Decompensated Heart Failure [NCT03701880]50 participants (Anticipated)Interventional2018-09-16Active, not recruiting
A Single-arm, Interventional, Multi-center, Pilot Study to Evaluate the Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Patients With NYHA Class II - IV (Biso-CHF Study) [NCT03026088]Phase 420 participants (Actual)Interventional2017-03-21Terminated(stopped due to Limited beta-blocker naive participants among newly diagnosed heart failure participants, which led barrier to the recruitments.)
The Influence of Beta-blockade on Cardiopulmonary Function Measured by Cardiopulmonary Exercise Testing [NCT02106286]Early Phase 155 participants (Actual)Interventional2011-02-28Completed
An Exploratory Study Into the Mechanism of Mirabegron-induced Cardiovascular Effects in Healthy Male Subjects. [NCT01284868]Phase 112 participants (Actual)Interventional2009-07-31Completed
Assessment of Immediate Postoperative Delirium (IPD) in Adult Patients: Incidence, Implication of Type of Anesthesia and Identification of Other Etiological Factors [NCT03967496]402 participants (Actual)Observational [Patient Registry]2019-01-01Completed
Use of Determination of Drug Levels to Optimize Pharmacotherapy of Heart Failure [NCT06035978]Phase 4100 participants (Anticipated)Interventional2023-11-30Not yet recruiting
A Prospective, Multi-center, Open-label, Single Arm Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II DIAbetic patieNTs With Suboptimal Blood Pressure Control (GIANT Study) [NCT01066039]Phase 4202 participants (Actual)Interventional2010-04-30Completed
A Randomised, Open Label, Four-way Crossover Phase I Trial to Investigate the in Vivo Specificity of a Single Oral Dose of 320 mg KUC 7483 CL Co-administered With Bisoprolol (10 mg Daily), Propranolol (160 mg Daily), and Acipimox (500 mg Daily) Over 5 Day [NCT02256722]Phase 112 participants (Actual)Interventional2005-10-31Completed
Acute Management of Paroxysmal Atrial Fibrillation With Beta Blockers Plus Intravenous Flecainide: a Real-world Chios Registry (BETAFLEC-CHIOS) [NCT04991896]81 participants (Actual)Observational [Patient Registry]2020-01-01Completed
Comparison of Effect of Propranolol, Bisoprolol, Pyridosgitmine in Postural Orthostatic Tachycardia Syndrome (POTS) and Prognosis After Medical Treatment [NCT02171988]Phase 4150 participants (Actual)Interventional2014-03-31Completed
Comparative Study Between the Efficacy of Verapamil and Bisoprolol on Reduction of Bleeding During Endoscopic Sinus Surgery Under General Anaesthesia. [NCT04356196]Early Phase 1135 participants (Anticipated)Interventional2021-06-15Active, not recruiting
Pharmacokinetic Drug-Drug Interaction Between Bisoprolol and Ivabradine in Healthy Volunteers: An Open-Label, Randomized, Crossover Clinical Study [NCT03485482]Phase 318 participants (Actual)Interventional2018-03-01Completed
Can Bisoprolol Administration Prevent Anthracycline-induced Cardiotoxicity?: a Double-blind Randomized Trial. [NCT05175066]Phase 380 participants (Actual)Interventional2020-11-12Completed
A Randomized, Two-period Crossover Trial Examining Bioequivalence of Bisoprolol-Amlodipine 5 mg/5 mg Combination Tablets Versus Bisoprolol 5 mg Tablets and Amlodipine 5 mg Tablets Given Concomitantly in Healthy Subjects in Fasting and Fed State [NCT03226275]Phase 132 participants (Actual)Interventional2017-08-09Completed
A Prospective, Multi-center, Randomized, Open-label, Clinical Trial to Compare the Aortic Pulse Pressure Effects of Bisoprolol and Atenolol in 12 Weeks Treatment of Hypertension [NCT01079962]Phase 4209 participants (Actual)Interventional2009-12-31Completed
A Randomized, Open-label, 2-way-crossover Study Assessing the Bioequivalence Between Single Doses of 5 mg Concor® Tablets (Manufactured by Merck/China Nantong) and 5 mg Concor® Tablets (Manufactured by Merck/Germany Darmstadt) in Chinese Healthy Participa [NCT05930808]Phase 146 participants (Actual)Interventional2023-02-28Completed
An Open Label, Pharmacogenetic Study of Bisoprolol Treatment in Patients With Uncontrolled Essential Hypertension (BRAVE) [NCT02398929]Phase 4100 participants (Actual)Interventional2013-01-31Completed
Proof of Concept Study to Assess the Differential Effects of Chronic Beta-blockade (Celiprolol Versus Bisoprolol) on Cardiopulmonary Outcomes at Rest and During Exercise in Chronic Obstructive Pulmonary Disease [NCT02380053]Phase 410 participants (Anticipated)Interventional2016-06-07Completed
A Prospective Randomised Controlled Trial [NCT02086019]250 participants (Actual)Interventional2014-05-01Completed
The Cardiac Insufficiency BIsoprolol Study in Japanese Patients With Chronic Heart Failure (CIBIS-J) [NCT02137733]220 participants (Anticipated)Interventional2013-06-30Recruiting
Left Atrium Reservoir Function Modulation in Patients With Atrial Fibrillation: A Randomized Digoxin Versus Beta Blocker Study [NCT05540600]Phase 330 participants (Anticipated)Interventional2022-09-12Recruiting
TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion [NCT03596385]Phase 48,468 participants (Anticipated)Interventional2018-10-31Recruiting
A Randomised, Single Blind, Multicentre, 9-month, Phase IV Study, Comparing Treatment Guided by Clinical Symptoms and Signs and NT-proBNP vs Treatment Guided by Clinical Symptoms and Signs Alone, in Patients With Heart Failure (HF) and Left Ventricular Sy [NCT00391846]Phase 4252 participants (Actual)Interventional2006-10-31Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
Echocardiographic Study of a Single Dose Bisoprolol Versus Nebivolol in Healthy Subjects: a Randomized, Double-blind, Cross-over Study [NCT04432610]Phase 40 participants (Actual)Interventional2030-01-31Withdrawn(stopped due to COVID pandemic)
A Prospective Study to See if Cardiac Effects of Herceptin Can be Prevented With Standard Heart Medications [NCT01016886]Phase 1/Phase 299 participants (Actual)Interventional2010-09-30Active, not recruiting
Cardioselective Beta-Blockade Using Bisoprolol in Patients With Chronic Heart Failure (CHF) and Coexistent Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) With or Without Significant Reversibility. [NCT00702156]Phase 227 participants (Actual)Interventional2005-03-31Terminated(stopped due to Inadequate patient recruitment)
The Effects of a CONCOR Smartphone Application on Arrhythmia, Heart Failure Events and Quality of Life in Patients With Congenital Heart Disease: a Randomized Controlled Trial [NCT02599857]0 participants (Actual)Interventional2017-01-01Withdrawn(stopped due to never started)
Preoperative Gabapentin Versus Bisoprolol for Intraoperative Hemodynamic and Surgical Field Optimization During Endoscopic Sinus Surgery [NCT03850093]Phase 463 participants (Actual)Interventional2015-08-31Completed
Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis. [NCT04085562]Phase 446 participants (Actual)Interventional2019-09-01Completed
A Study on the Efficacy of Bisoprolol and Its Influence on Selected Biochemical Parameters in Filipino Hypertensive Patients With Diabetes [NCT01190436]Phase 4125 participants (Actual)Interventional2009-12-31Completed
Treating Clozapine-induced Sinustachycardia With Bisoprolol - a Double Blinded Placebo Controlled Cross Over Study [NCT00882856]21 participants (Actual)Interventional2009-04-30Completed
Association Between Beta-1 and Beta-2 Adrenergic Receptor Polymorphism and Beta-blocker (Bisoprolol) Therapy in Heart Failure [NCT01104558]Phase 4100 participants (Actual)Interventional2008-12-31Completed
Newer vs Older Antihypertensive Agents in African Hypertensive Patients Trial [NCT01030458]Phase 4183 participants (Actual)Interventional2010-09-30Completed
NT-proBNP Selected PreventiOn of Cardiac eveNts in a populaTion of dIabetic Patients Without A History of Cardiac Disease: a Prospective Randomized Trial [NCT02817360]Phase 42,400 participants (Anticipated)Interventional2016-02-29Recruiting
Sympathomimetics and Sympatholytics in Type 2 Diabetes: Teaching Old Drugs New Tricks [NCT04823442]9 participants (Actual)Interventional2021-01-21Completed
Effect of Pioglitazone on Insulin Resistance, Progression of Atherosclerosis and Clinical Course of Coronary Heart Disease [NCT03011775]Phase 443 participants (Actual)Interventional2012-11-30Completed
Comparative Effects of Moxonidine and Bisoprolol on Bone Metabolism, Vascular and Cellular Markers of Aging, Blood Pressure in Hypertensive Postmenopausal Women (COMPASS) [NCT02355821]114 participants (Actual)Interventional2015-04-30Completed
Effect of Heart Rate Control Using Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Ventricular Pacing in Heart Failure Patients With an Implanted Cardioverter Defibrillator. [NCT01868880]Phase 40 participants (Actual)Interventional2016-02-29Withdrawn(stopped due to difficulties in recruiting patients)
N-of-1 Trials for Deprescribing Beta-blockers in HFpEF [NCT04757584]Phase 49 participants (Actual)Interventional2021-04-01Completed
A Prospective Observational Study to Evaluate the Efficacy of Lodoz in a Population of Hypertensive Patients [NCT01080742]1,007 participants (Actual)Observational2010-01-31Completed
Comparison of the Hemodynamic Changes in Patients Under Treatment With Bisoprolol Versus Atenolol [NCT01939509]Phase 480 participants (Anticipated)Interventional2012-02-29Completed
Pharmacologic Prophylaxis for Atrial Fibrillation Following Coronary By-Pass Surgery [NCT01955759]Early Phase 1260 participants (Anticipated)Interventional2013-12-31Not yet recruiting
To Develop and Implement a Method for Medical Prevention of Cardiovascular Diseases Caused by Complex Treatment of Patients With Primary Operated Breast Cancer [NCT04588935]Phase 2100 participants (Actual)Interventional2019-07-01Completed
Nt-proBNP Guided Prevention of Cardiovascular Events in a Population of Diabetic Patients Without a History of Cardiac Disease [NCT00562952]Phase 2/Phase 3300 participants (Actual)Interventional2007-11-30Completed
Prospective, Open-labeled Trial in Patients With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea (PRISM) [NCT01074307]Phase 4180 participants (Actual)Interventional2009-10-31Completed
Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure [NCT00832442]18,240 participants (Anticipated)Observational2008-08-31Enrolling by invitation
Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Patients With Essential Hypertension [NCT01251146]Phase 4177 participants (Actual)Interventional2010-11-30Completed
Resistant Hypertension On Treatment - Sequential Nephron Blockade Compared to Dual Blockade of the Renin-angiotensin-aldosterone System Plus Bisoprolol in the Treatment of Resistant Arterial Hypertension: A Randomized Trial (ResHypOT) [NCT02832973]Phase 472 participants (Actual)Interventional2015-09-30Completed
Multicenter Observational Open Program. Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril in Patients With Arterial Hypertension and Stable CAD in Daily Clinical Practice (STYLE) [NCT03730116]1,909 participants (Actual)Observational2018-11-14Completed
Comparison of Effect of cARvedilol Compared To bISoprolol on cenTral Pulse Pressure in Hypertension (ARTIST) Study [NCT01243827]Phase 4200 participants (Anticipated)Interventional2010-11-30Recruiting
The Surrogate Marker of Rate Control in Patients With Atrial Fibrillation [NCT04513509]50 participants (Anticipated)Interventional2020-08-07Not yet recruiting
Beta-blocker Therapy in Idiopathic Pulmonary Arterial Hypertension [NCT01246037]Phase 1/Phase 230 participants (Anticipated)Interventional2011-02-28Active, not recruiting
Potential Drug Interactions With Bisoprolol in Egyptian Patients With Acute Coronary Syndrome [NCT05536284]Phase 2128 participants (Actual)Interventional2021-09-01Completed
A Randomized Controlled Study: Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension [NCT01762436]Phase 4109 participants (Actual)Interventional2010-11-30Completed
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol [NCT05794997]817,337 participants (Actual)Observational2022-11-30Active, not recruiting
Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy [NCT05569382]Phase 4140 participants (Anticipated)Interventional2022-08-10Recruiting
Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function [NCT00517725]Phase 460 participants (Actual)Interventional2007-07-31Completed
Pharmacogenetic Study of Bisoprolol in Egyptian Patients With Acute Coronary Syndrome [NCT05536271]Phase 2127 participants (Actual)Interventional2021-09-01Completed
Once Versus Twice Bisoprolol Dosage Regimen in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft Surgery [NCT05730413]Phase 4122 participants (Anticipated)Interventional2021-08-25Recruiting
A Randomized Double-blind Placebo Force-titration Controlled Study With Bisoprolol in Patients With Chronic Heart Failure Secondary to Chagas´ Cardiomyopathy. [NCT00323973]Phase 3500 participants (Actual)Interventional2003-07-31Completed
Evaluation of Effects of Chronic Dose Exposure to Cardioselective and Non-cardioselective Beta Blockers on Measures of Cardiopulmonary Function in Moderate to Severe COPD. [NCT01656005]Phase 418 participants (Actual)Interventional2012-08-31Completed
First Prospective Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease After Coronary Physiological Testing [NCT05294887]Phase 4132 participants (Anticipated)Interventional2022-03-04Recruiting
A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg of With Zebeta® 10 mg in Normal, Healthy, Adult, Human Subjects Under Fasting Condition. [NCT01741623]Phase 124 participants (Actual)Interventional2012-08-31Completed
Non-Invasive HaemoDYNAMICs in Primary and Secondary Hypertension: the DYNAMIC-study [NCT01742702]2,000 participants (Anticipated)Observational2006-05-25Recruiting
A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg of With Zebeta® 10 mg in Normal, Healthy, Adult, Human Subjects Under Fed Condition. [NCT01744873]Phase 124 participants (Actual)Interventional2012-08-31Completed
Optimum Treatment for Drug-Resistant Hypertension [NCT02369081]Phase 4348 participants (Actual)Interventional2009-05-31Active, not recruiting
A Randomized, Open-label, Repeated-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Bisoprolol and Rosuvastatin in Healthy Adult Volunteers [NCT01925300]Phase 10 participants (Actual)Interventional2013-07-31Withdrawn
Randomized Evaluation of Decreased Usage of betablocCkErs After Myocardial Infarction in the SWEDEHEART Registry - A Registry-based, Randomized, Parallel, Open-label, Multicenter Trial (REDUCE-SWEDEHEART) [NCT03278509]Phase 45,000 participants (Anticipated)Interventional2017-09-11Active, not recruiting
A Randomized Trial of Beta-blocker Therapy in Aortic Stenosis [NCT01579058]Phase 420 participants (Actual)Interventional2012-07-31Terminated(stopped due to The sponsor discontinued to support the study.)
Swiss Interventional Study on Silent Ischemia (SWISSI 1) [NCT00382421]0 participants Interventional1992-02-29Completed
Preoperative Nasal Desmopressin Versus Oral Bisoprolol for Controlling Bleeding and Improving Surgical Field During Unilateral Functional Endoscopic Sinus Surgery [NCT05430048]Phase 2100 participants (Actual)Interventional2022-07-01Completed
Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients (CREATIVE Study) [NCT01508325]Phase 4186 participants (Actual)Interventional2011-12-31Completed
Radiofrequency Ablation for Atrial Fibrillation in Advanced Chronic Heart Failure [NCT00292162]41 participants (Actual)Interventional2007-01-31Completed
Bisoprolol for Early Cardiomyopathy in Duchenne Muscular Dystrophy: a Randomized, Controlled Trial [NCT03779646]Phase 2/Phase 342 participants (Anticipated)Interventional2019-01-16Recruiting
Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension. A Multicentre [NCT05288400]Phase 3150 participants (Actual)Interventional2018-05-14Completed
Effects of Cardioselective Beta-blockers on Dynamic Hyperinflation in Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) [NCT01273298]27 participants (Actual)Interventional2008-06-30Completed
Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery [NCT03800264]Phase 4176 participants (Actual)Interventional2018-05-02Completed
A Randomized, Comparative Trial of Concor AM, a Fixed Dose Combination of Bisoprolol and Amlodipine, on the Treatment of Essential Hypertensive Patients Whose Blood Pressure is Not Well Controlled by Monotherapy of Bisoprolol 5mg or Amlodipine 5mg [NCT01977794]Phase 3200 participants (Actual)Interventional2014-03-31Completed
Perindopril+Bisoprolol in Therapy of Patients With Atrial Fibrilation [NCT04484688]50 participants (Anticipated)Observational2020-08-01Not yet recruiting
Evaluating Different Rate Control Therapies in Permanent Atrial Fibrillation: A Prospective, Randomised, Open-label, Blinded Endpoint Feasibility Pilot Comparing Digoxin and Beta-blockers as Initial Rate Control Therapy [NCT02391337]Phase 4161 participants (Actual)Interventional2016-12-20Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00292162 (6) [back to overview]Plasma B-type Natriuretic Peptide (BNP)
NCT00292162 (6) [back to overview]Plasma B-type Natriuretic Peptide (BNP) at Baseline
NCT00292162 (6) [back to overview]Plasma B-type Natriuretic Peptide (BNP) at 6 Months
NCT00292162 (6) [back to overview]Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)at 6 Months
NCT00292162 (6) [back to overview]Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)%
NCT00292162 (6) [back to overview]Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)
NCT00391846 (8) [back to overview]Changes in Health-related Quality of Life
NCT00391846 (8) [back to overview]Total Number of Titration Steps in Prescribed Heart Failure Treatment
NCT00391846 (8) [back to overview]Number of Days in Hospital for CV Reason
NCT00391846 (8) [back to overview]Number of CV Deaths
NCT00391846 (8) [back to overview]Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom Score Subset of the Kansas City Cardiomyopathy Questionnaire - Questions 3,5,7,9)
NCT00391846 (8) [back to overview]Discontinuations
NCT00391846 (8) [back to overview]Changes in NT-proBNP Values Over Time in All Patients
NCT00391846 (8) [back to overview]Changes in Heart Failure Symptoms
NCT01030458 (4) [back to overview]Time to Blood Pressure Control
NCT01030458 (4) [back to overview]Sitting Systolic Blood Pressure on Automated Measurement
NCT01030458 (4) [back to overview]Side-effects to Study Medications
NCT01030458 (4) [back to overview]Proportion of Patients Reaching Blood Pressure Control at the End of Follow-up
NCT01066039 (10) [back to overview]Change From Baseline in Insulin Level at Months 3 and 6
NCT01066039 (10) [back to overview]Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Blood Pressure (BP) at Month 6
NCT01066039 (10) [back to overview]Change From Baseline in Total Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL) Cholesterol and Triglyceride Level at Month 6
NCT01066039 (10) [back to overview]Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01066039 (10) [back to overview]Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Month 3
NCT01066039 (10) [back to overview]Change From Baseline in Albumin/Creatinine Ratio at Month 6
NCT01066039 (10) [back to overview]Change From Baseline in C-Peptide Level at Months 3 and 6
NCT01066039 (10) [back to overview]Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Month 6
NCT01066039 (10) [back to overview]Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at Months 3 and 6
NCT01066039 (10) [back to overview]Change From Baseline in Microalbumin Level at Month 6
NCT01074307 (8) [back to overview]Change From Baseline in Echocardiographic Left Ventricular Ejection Fraction (LVEF) at Week 26
NCT01074307 (8) [back to overview]Change From Baseline in 6-minute Walking Test (6-MWT) Distance at Week 26
NCT01074307 (8) [back to overview]Percent Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 26
NCT01074307 (8) [back to overview]Percentage of Participants Classified as Class I to IV According to New York Heart Association (NYHA)
NCT01074307 (8) [back to overview]Number of Participants Who Were Re-hospitalized Due to Heart Failure and Who Died Due to Cardiovascular Disorder
NCT01074307 (8) [back to overview]Mean Change From Baseline in Global Assessment of Congestive Heart Failure (CHF) Score at Week 26
NCT01074307 (8) [back to overview]Change From Baseline in Echocardiographic Left Ventricular Size at Week 26
NCT01074307 (8) [back to overview]Number of Participants With Adverse Events (AEs)
NCT01079962 (11) [back to overview]Change From Baseline in Heart Rate at Week 4 and Week 12
NCT01079962 (11) [back to overview]Change From Baseline in Lipid Levels at Week 12
NCT01079962 (11) [back to overview]Change From Baseline in Aortic Augmentation Index (AIx) at Week 4 and Week 12
NCT01079962 (11) [back to overview]Change From Baseline in Aortic Pulse Pressure (APP) at Week 4
NCT01079962 (11) [back to overview]Number of Participants With Adverse Events (AEs)
NCT01079962 (11) [back to overview]Change From Baseline in Aortic Blood Pressure (BP) at Week 4 and Week 12
NCT01079962 (11) [back to overview]Change From Baseline in Blood Glucose Levels at Week 12
NCT01079962 (11) [back to overview]Change From Baseline in Aortic Pulse Pressure (APP) in Intention to Treat (ITT) Population at Week 12
NCT01079962 (11) [back to overview]Change From Baseline in Aortic Pulse Pressure (APP) in Per Protocol (PP) Population at Week 12
NCT01079962 (11) [back to overview]Change From Baseline in Brachial Blood Pressure (BP) at Week 4 and Week 12
NCT01079962 (11) [back to overview]Change From Baseline in Carotid-femoral Pulse Wave Velocity (cfPWV) at Week 4 and Week 12
NCT01104558 (38) [back to overview]Change From Baseline in DBP (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in DBP (6 MWT- After Walking) According to the Genetic Polymorphism of GRK5-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in DBP (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in DBP (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in DBP (6 MWT- Before Walking) According to the Genetic Polymorphism of GRK5-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in Diastolic Blood Pressure (DBP) (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in DBP (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in SBP (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in SBP (6 MWT- Before Walking) According to the Genetic Polymorphism of GRK5-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in Systolic Blood Pressure (SBP) (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in SBP (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in SBP (6 MWT- After Walking) According to the Genetic Polymorphism of GRK5-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in SBP (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in SBP (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in SBP (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in Pro-BNP Levels According to the Genetic Polymorphism of GRK5-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in Pro-BNP Levels According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in Pro-BNP Levels According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in Pro-B-type Natriuretic Peptide (BNP) Levels According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in Heart Rate (6 MWT- Before Walking) According to the Genetic Polymorphism of GRK5-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in Echocardiographic Left Ventricular Ejection Fraction (LVEF) According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or End of Treatment (EOT)
NCT01104558 (38) [back to overview]Change From Baseline in Echocardiographic LVEF According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in Echocardiographic LVEF According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in Echocardiographic LVEF According to the Genetic Polymorphism of G Protein-coupled Receptor Kinase 5 (GRK5)-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in Heart Rate (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in Heart Rate (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in Heart Rate (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in Heart Rate (6 MWT- After Walking) According to the Genetic Polymorphism of GRK5-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in Heart Rate (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in Heart Rate (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in Heart Rate (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT
NCT01104558 (38) [back to overview]Duration of Hospitalization Due to Heart Failure
NCT01104558 (38) [back to overview]Number of Participants With Hospitalization Due to Heart Failure
NCT01104558 (38) [back to overview]Change From Baseline in 6-minute Walking Test (6-MWT) Distance According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in 6-minute Walking Test (6-MWT) Distance According to the Genetic Polymorphism of GRK5-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in 6-MWT Distance According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in 6-MWT Distance According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT
NCT01104558 (38) [back to overview]Change From Baseline in DBP (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or EOT
NCT01190436 (11) [back to overview]Percentage of Participants With Increased Glycosylated Hemoglobin (HbA1c) at Week 12
NCT01190436 (11) [back to overview]Percentage of Participants With Response to Study Drug
NCT01190436 (11) [back to overview]Mean Change From Baseline in Fasting Blood Sugar (FBS) Level at Week 12
NCT01190436 (11) [back to overview]Mean Change From Baseline in HbA1c at Week 12
NCT01190436 (11) [back to overview]Mean Change From Baseline in Heart Rate at Week 12
NCT01190436 (11) [back to overview]Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Week 12
NCT01190436 (11) [back to overview]Mean Change From Baseline in Total Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL) Cholesterol and Triglyceride Level at Week 12
NCT01190436 (11) [back to overview]Number of Participants With Adverse Events (AEs)
NCT01190436 (11) [back to overview]Percentage of Participants With Controlled BP
NCT01190436 (11) [back to overview]Percentage of Participants With Decrease in Heart Rate by at Least 10 Bpm at Week 12
NCT01190436 (11) [back to overview]Percentage of Participants With Increased Fasting Blood Sugar (FBS) at Week 12
NCT01251146 (8) [back to overview]Change From Baseline in Baroreflex Sensitivity (BRS) at End of Follow-up
NCT01251146 (8) [back to overview]Percentage of Participants Attaining Heart Rate Goal at Week 2, 4 and 6
NCT01251146 (8) [back to overview]Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01251146 (8) [back to overview]Number of Participants Compliant With Study Treatment
NCT01251146 (8) [back to overview]Change From Baseline in Baroreflex Sensitivity (BRS) at Attainment of Heart Rate Goal
NCT01251146 (8) [back to overview]Change From Baseline in Heart Rate Variability (HRV) for Low Frequency Power (LF) and for High Frequency Power (HF) at Attainment of Heart Rate Goal and End of Follow-up
NCT01251146 (8) [back to overview]Change From Baseline in Ratio of Heart Rate Variability (HRV) for Low Frequency Power (LF) to Heart Rate Variability Power (HRV) for High Frequency (HF) (LF/HF) at Attainment of Heart Rate Goal and End of Follow-up
NCT01251146 (8) [back to overview]Number of Participants Attaining Heart Rate Goal at Dosage 1, 2 and 3 of Study Treatment
NCT01508325 (12) [back to overview]Blood Pressure Response Rate
NCT01508325 (12) [back to overview]Change From Baseline in Mean Ambulatory 24-hour Blood Pressure at Week 12
NCT01508325 (12) [back to overview]Change From Baseline in Mean Ambulatory 24-hour Heart Rate at Week 12
NCT01508325 (12) [back to overview]Change From Baseline in Mean Ambulatory Systolic Blood Pressure (SBP) in the Last 4 Hours After 12-week Treatment
NCT01508325 (12) [back to overview]Change From Baseline in Mean Ambulatory Night-time Heart Rate at Week 12
NCT01508325 (12) [back to overview]Change From Baseline in Mean Ambulatory Night-time Blood Pressure at Week 12
NCT01508325 (12) [back to overview]Change From Baseline in Mean Ambulatory Diastolic Blood Pressure (DBP) in the Last 4 Hours After 12-week Treatment
NCT01508325 (12) [back to overview]Change From Baseline in Mean Ambulatory Daytime Heart Rate at Week 12
NCT01508325 (12) [back to overview]Change From Baseline in Mean Ambulatory Daytime Blood Pressure at Week 12
NCT01508325 (12) [back to overview]Change From Baseline in Mean Heart Rate in the Last 4 Hours After 12-week Treatment
NCT01508325 (12) [back to overview]Change From Baseline in 24-hour Blood Pressure Variability at Week 12
NCT01508325 (12) [back to overview]Heart Rate Response Rate
NCT01977794 (5) [back to overview]Change From Baseline in Diastolic Blood Pressure (DBP) After 18 Weeks of Treatment
NCT01977794 (5) [back to overview]Change From Baseline in Heart Rate (HR) After 18 Weeks of Treatment
NCT01977794 (5) [back to overview]Mean Reduction In Systolic Blood Pressure (SBP) After 18 Weeks of Treatment From Baseline
NCT01977794 (5) [back to overview]Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, AEs Leading to Discontinuation and AEs Leading to Death
NCT01977794 (5) [back to overview]Percentage of Subjects With Controlled Blood Pressure
NCT02355821 (9) [back to overview]Bone Mineral Density (BMD) Using Control Dual-energy X-ray Absorptiometry
NCT02355821 (9) [back to overview]THe Number (Percentage) of the Treatment Responders
NCT02355821 (9) [back to overview]Number of Participants With Adverse Events (AE)
NCT02355821 (9) [back to overview]Pulse Wave Velocity (PWV)
NCT02355821 (9) [back to overview]Osteocalcin
NCT02355821 (9) [back to overview]Intima-media Thickness (IMT)
NCT02355821 (9) [back to overview]Collagen Type 1 C-telopeptide
NCT02355821 (9) [back to overview]Telomerase Activity
NCT02355821 (9) [back to overview]Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL).
NCT02391337 (14) [back to overview]B-type Natriuretic Peptide (BNP) at 6 Months.
NCT02391337 (14) [back to overview]Ambulatory Heart-rate.
NCT02391337 (14) [back to overview]Drug Discontinuation Rate Within 12 Months.
NCT02391337 (14) [back to overview]Cardiovascular Events
NCT02391337 (14) [back to overview]Composite Functional Status Measures- 6 Minute Walking Distance at 12 Months.
NCT02391337 (14) [back to overview]Diastolic Function- Measured by the E/e'.
NCT02391337 (14) [back to overview]Hospital Admission Rate
NCT02391337 (14) [back to overview]Left Ventricular Ejection Fraction
NCT02391337 (14) [back to overview]Number of Participants With Unplanned Hospital Admissions.
NCT02391337 (14) [back to overview]Patient Reported Outcomes (EQ-5D-5L)
NCT02391337 (14) [back to overview]Patient Reported Outcomes- (AFEQT) at 12 Months.
NCT02391337 (14) [back to overview]Patient Reported Quality of Life (SF-36)
NCT02391337 (14) [back to overview]Patient Reported Outcomes (SF36) Version 2 at 12 Months.
NCT02391337 (14) [back to overview]Retention of Participants
NCT03011775 (17) [back to overview]Coronary Artery Bypass [Coronary Revascularization]
NCT03011775 (17) [back to overview]Percutaneous Coronary Intervention [Coronary Revascularization]
NCT03011775 (17) [back to overview]Safety and Tolerability 1
NCT03011775 (17) [back to overview]Safety and Tolerability 2
NCT03011775 (17) [back to overview]Safety and Tolerability 3
NCT03011775 (17) [back to overview]Safety and Tolerability 4
NCT03011775 (17) [back to overview]Systemic Inflammation Level
NCT03011775 (17) [back to overview]Thickness of the Intima-media Complex
NCT03011775 (17) [back to overview]Lipid Metabolism 3
NCT03011775 (17) [back to overview]Сardiovascular Death
NCT03011775 (17) [back to overview]Lipid Metabolism 2
NCT03011775 (17) [back to overview]Lipid Metabolism 1
NCT03011775 (17) [back to overview]Level of Insulin Resistance 2
NCT03011775 (17) [back to overview]Level of Insulin Resistance 1
NCT03011775 (17) [back to overview]Diameter of Stenosis [Carotic Atherosclerotic Lesions]
NCT03011775 (17) [back to overview]Carotic Atherosclerotic Lesions
NCT03011775 (17) [back to overview]Cardiovascular Hospitalization
NCT03026088 (8) [back to overview]Percentage of Participants With Resting Heart Rate Less Than 70 Beats Per Minute (Bpm) and More Than 55 Bpm
NCT03026088 (8) [back to overview]Number of Participants With Clinically Relevant Systolic and Diastolic Blood Pressure
NCT03026088 (8) [back to overview]Number of Participants With Arrhythmia
NCT03026088 (8) [back to overview]Number of Participants With Abnormal Value of N-terminal Pro-B-type Natriuretic Peptide (NT Pro-BNP)
NCT03026088 (8) [back to overview]Number of Participants With 24 Hour Heart Rate With More Than 70 Beats Per Minute (Bpm) and Less Than 55 Bpm
NCT03026088 (8) [back to overview]Number of Participants With New York Heart Association (NYHA) Class
NCT03026088 (8) [back to overview]Number of Participants With Medicine Compliance Assessed by Medication Procession Ratio (MPR)
NCT03026088 (8) [back to overview]Number of Participants With All Cause Mortality, Cardiac Death, or Re-admission Due to Heart Failure
NCT03226275 (10) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, AEs Leading to Death, and AEs Leading to Discontinuation
NCT03226275 (10) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of Bisoprolol and Amlodipine
NCT03226275 (10) [back to overview]Maximum Observed Plasma Concentration (Cmax) of Bisoprolol and Amlodipine
NCT03226275 (10) [back to overview]Apparent Terminal Elimination Rate Constant (λz) of Bisoprolol and Amlodipine
NCT03226275 (10) [back to overview]Apparent Terminal Half-life (t1/2) of Bisoprolol and Amlodipine
NCT03226275 (10) [back to overview]Apparent Total Body Clearance From Plasma (CL/f) of Bisoprolol and Amlodipine
NCT03226275 (10) [back to overview]Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/f) of Bisoprolol and Amlodipine
NCT03226275 (10) [back to overview]Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC 0-inf) of Bisoprolol and Amlodipine
NCT03226275 (10) [back to overview]Area Under the Plasma Concentration-Time Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Bisoprolol and Amlodipine
NCT03226275 (10) [back to overview]Extrapolated Part of Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUCextra%) of Bisoprolol and Amlodipine
NCT03730116 (6) [back to overview]Changes in the Mean Office Diastolic BP Levels (in mm Hg) in the Sitting Position
NCT03730116 (6) [back to overview]Efficacy of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice Regarding the BP: % of Patients Achieving Target Levels
NCT03730116 (6) [back to overview]Efficacy of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice: # of Angina Attacks
NCT03730116 (6) [back to overview]Good and Moderate Adherence to Bisoprolol/Perindopril FDC Therapy in Patients With HT and Stable CAD in Everyday Practice
NCT03730116 (6) [back to overview]Impact on the Quality of Life of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice: VAS
NCT03730116 (6) [back to overview]The Mean SBP Changes (mm Hg) at the Visit 3 vs. Baseline
NCT03850093 (10) [back to overview]Blood Loss
NCT03850093 (10) [back to overview]Number of Patients Who Recieve Both IV Nitroglycerin and Propranolol During Operative Procedure
NCT03850093 (10) [back to overview]Number of Patients Who Recieved Intraoperative IV Nitroglycerin During Operative Procedure
NCT03850093 (10) [back to overview]Time to 1st Postoperative Rescue Analgesia
NCT03850093 (10) [back to overview]Changes in Surgical Field Visibility
NCT03850093 (10) [back to overview]Heart Rate Change
NCT03850093 (10) [back to overview]Mean Arterial Blood Pressure Change
NCT03850093 (10) [back to overview]Surgeon Satisfaction (Categorical)
NCT03850093 (10) [back to overview]Visual Analogue Scale (VAS) for Postoperative Pain
NCT03850093 (10) [back to overview]Number of Patients Who Recieved Intraoperative IV Propranolol During Operative Procedure
NCT04767061 (10) [back to overview]Change in Exercise Capacity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Peak Oxygen Consumption (VO2) During Cardiopulmonary Exercise Test (CPET)
NCT04767061 (10) [back to overview]Change in Patient-reported Quality of Life When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-29 (PROMIS-29)
NCT04767061 (10) [back to overview]Change in Physical Activity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Step Count on Wearable Activity Monitoring Device
NCT04767061 (10) [back to overview]Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Gait Speed Portion of a Modified Version of the Short Physical Performance Battery.
NCT04767061 (10) [back to overview]Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Chair Rise Portion of a Modified Version of the Short Physical Performance Battery.
NCT04767061 (10) [back to overview]Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Balance Portion of a Modified Version of the Short Physical Performance Battery.
NCT04767061 (10) [back to overview]Change in Patient-reported Health When on Beta-blocker Versus When Off Beta-blocker, as Measured by the EuroQol-5D Visual Analogue System (EQ-5D VAS)
NCT04767061 (10) [back to overview]Change in Patient-reported Health Status When on Beta-blocker Versus When Off Beta-blocker, as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ-12)
NCT04767061 (10) [back to overview]Change in Patient-reported Cognitive Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Short Form 6a (PROMIS SF-6a)
NCT04767061 (10) [back to overview]Change in Patient-reported Sexual Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Sexual Function (PROMIS-Sexual Function)

Plasma B-type Natriuretic Peptide (BNP)

venous blood taken to assess levels of the above peptide. High evels of the peptide are associated with adverse prognosis. Blood levels are taken at baseline and 6 months. The change over 6 months is assessed, thereore it is possible to have a negative number if the level falls. (NCT00292162)
Timeframe: baseline and 6 months

Interventionpicograms per millilitre (Mean)
Medical Therapy85
Radiofrequency Ablation-196

[back to top]

Plasma B-type Natriuretic Peptide (BNP) at Baseline

Plasma B-type Natriuretic Peptide (BNP) measured at basline (NCT00292162)
Timeframe: Baseline

Interventionpicograms per millilitre (Mean)
Medical Therapy1846
Radiofrequency Ablation2550

[back to top]

Plasma B-type Natriuretic Peptide (BNP) at 6 Months

Plasma B-type Natriuretic Peptide (BNP) (NCT00292162)
Timeframe: 6 months

Interventionpicograms per millilitre (Mean)
Medical Therapy1931
Radiofrequency Ablation2354

[back to top]

Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)at 6 Months

Left Ventricular Ejection Fraction as measured by Magnetic Resonance Imaging (MRI)at 6 months (NCT00292162)
Timeframe: 6 months

Interventionpercentage of blood ejected in one beat (Mean)
Medical Therapy46
Radiofrequency Ablation41

[back to top]

Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)%

left ventricular ejection fraction (LVEF) is a measure of the % of blood ejected from the ventricle in one heart beat. It is a measure of cardiac function. We measured LVEF at baseline and at 6 months, to assess whether there had been a change in the patients cardiac function over time. (NCT00292162)
Timeframe: baseline and 6 months

Interventionpercentage of blood ejected in one beat (Mean)
Medical Therapy2.8
Radiofrequency Ablation4.5

[back to top]

Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)

Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)in % (NCT00292162)
Timeframe: Baseline

Interventionpercentage of blood ejected in one beat (Mean)
Medical Therapy43
Radiofrequency Ablation36

[back to top] [back to top]

Total Number of Titration Steps in Prescribed Heart Failure Treatment

Each titration step in prescribed medication is counted as one step, either up or down. One step up indicates an increase of dose in prescribed medication and one step down indicates a decrease of dose in prescribed medication. The sum of steps is given as a score. Score is given for each arm as a total number of titration steps for all patients in arm. (NCT00391846)
Timeframe: 9 months

InterventionTitration steps (Number)
Guided by NT-proBNP517
Not Guided by NT-proBNP485

[back to top]

Number of Days in Hospital for CV Reason

Each overnight stay is counted as one day. The lower the better (NCT00391846)
Timeframe: 9 months

InterventionDays in hospital (Mean)
Guided by NT-proBNP5.79
Not Guided by NT-proBNP5.94

[back to top]

Number of CV Deaths

Number of deaths (NCT00391846)
Timeframe: 9 months

InterventionParticipants (Number)
Guided by NT-proBNP4
Not Guided by NT-proBNP5

[back to top]

Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom Score Subset of the Kansas City Cardiomyopathy Questionnaire - Questions 3,5,7,9)

The non-parametric scale is constructed from 3 variables, modified after Cleland. Each patient receives a rank score from 1 to 246 (246-number of patients in the study). The lowest score receive patients who die (due to CV event), next patients still alive at end-of-study with the worst composite score, the best alive patients with 0 days in hospital and the largest improvement in the KCCQ (self-administered by patient symptom score, where the higher score reflect better health status). Scores will be summarized using non-parametric calculations. The mean of non-parametric scores is presented (NCT00391846)
Timeframe: 9 months

InterventionScores on a scale (Mean)
Guided by NT-proBNP118.6
Not Guided by NT-proBNP128.4

[back to top]

Discontinuations

Number of patients discontinued due to adverse events' (NCT00391846)
Timeframe: 9 months

InterventionParticipants (Number)
Guided by NT-proBNP8
Not Guided by NT-proBNP6

[back to top]

Changes in NT-proBNP Values Over Time in All Patients

The 95% confidential interval (CI) is given as measure of dispersion (NCT00391846)
Timeframe: 9 months and baseline

Interventionng/L (Geometric Mean)
Guided by NT-proBNP2332.1
Not Guided by NT-proBNP2063

[back to top]

Changes in Heart Failure Symptoms

Changes from baseline in the symptom score subset (question 3, 5, 7 and 9) of KCCQ (swelling, fatigue, shortness of breath, shortness of breath night time). KCCQ is a self-administered by patient symptom score, where higher score reflect better health status. Scale scores are transformed to a 0 to 100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100. This mean that the KCCQ scale is from 0 to 100 with the higher value showing a better health status. (NCT00391846)
Timeframe: 9 months and baseline

InterventionCategorial scale (Mean)
Guided by NT-proBNP3.67
Not Guided by NT-proBNP6.11

[back to top]

Time to Blood Pressure Control

The time (in weeks) after randomisation that will be required to reach and maintain the target, defined as a blood pressure below 140 mmHg systolic and 90 mmHg diastolic. (NCT01030458)
Timeframe: 6 months follow-up after randomization

Interventionweeks (Median)
Amlodipine Plus Valsartan12
Hydrochlorothiazide Plus Bisoprolol18

[back to top]

Sitting Systolic Blood Pressure on Automated Measurement

Blood pressure is measured by means of validated oscillometric OMRON 705IT recorders (OMRON Healthcare Europe BV, Nieuwegein, Netherlands), after the patient has been seated for 5 minutes in a quiet room, according to the ESC/ESH guidelines. Three consecutive blood pressure readings are obtained and the average of these 3 measurements is used as the primary outcome. (NCT01030458)
Timeframe: 6 months follow-up after randomization

InterventionmmHg (Mean)
Amlodipine Plus Valsartan127.2
Hydrochlorothiazide Plus Bisoprolol134.1

[back to top]

Side-effects to Study Medications

(NCT01030458)
Timeframe: 6 months follow-up after randomization

Interventionparticipants (Number)
Amlodipine Plus Valsartan1
Hydrochlorothiazide Plus Bisoprolol1

[back to top]

Proportion of Patients Reaching Blood Pressure Control at the End of Follow-up

This variable gives the proportion of patients reaching blood pressure control over time (< 140 mmHg systolic and < 90 mmHg diastolic) (NCT01030458)
Timeframe: 6 months follow-up after randomization

Interventionparticipants (Number)
Amlodipine Plus Valsartan58
Hydrochlorothiazide Plus Bisoprolol40

[back to top]

Change From Baseline in Insulin Level at Months 3 and 6

The change in insulin level at Months 3 and 6 was calculated as insulin level at Months 3 and 6 minus insulin level at baseline. (NCT01066039)
Timeframe: Baseline, Months 3 and 6

InterventionmcIU/mL (Mean)
BaselineChange at Month 3Change at Month 6
Bisoprolol7.50.20.6

[back to top]

Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Blood Pressure (BP) at Month 6

The change in SBP, DBP, and mean BP at Month 6 were calculated as SBP, DBP, and mean BP at Month 6 minus SBP, DBP, and mean BP at baseline, respectively. Mean BP was calculated using the formula: (DBP plus [{SBP minus DBP} divided by 3]). (NCT01066039)
Timeframe: Baseline, Month 6

InterventionmmHg (Mean)
SBP: BaselineSBP: Change at Month 6DBP: BaselineDBP: Change at Month 6Mean BP: BaselineMean BP: Change at Month 6
Bisoprolol147.8-13.489.0-9.1108.6-10.5

[back to top]

Change From Baseline in Total Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL) Cholesterol and Triglyceride Level at Month 6

The change in total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels at Month 6 was calculated as total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride levels at Month 6 minus total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride levels at baseline, respectively. (NCT01066039)
Timeframe: Baseline, Month 6

Interventionmilligram per deciliter (mg/dL) (Mean)
Total Cholesterol: Baseline (n = 174)Total Cholesterol: Change at Month 6 (n = 173)LDL: Baseline (n = 174)LDL: Change at Month 6 (n = 173)HDL: Baseline (n = 174)HDL: Change at Month 6 (n = 173)Triglyceride: Baseline (n = 174)Triglyceride: Change at Month 6 (n = 173)
Bisoprolol168.6-0.893.3-1.649.2-3.4155.013.5

[back to top]

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An Adverse Event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A Serious Adverse Event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. (NCT01066039)
Timeframe: Baseline up to Month 6

Interventionparticipants (Number)
AEsSAEs
Bisoprolol687

[back to top]

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Month 3

HbA1c represents the percentage of glycosylated hemoglobin. The change in HbA1c at Month 3 was calculated as HbA1c at Month 3 minus HbA1c at baseline. (NCT01066039)
Timeframe: Baseline, Month 3

InterventionPercent HbA1c (Mean)
Bisoprolol0.15

[back to top]

Change From Baseline in Albumin/Creatinine Ratio at Month 6

The change in albumin/creatinine ratio at Month 6 was calculated as albumin/creatinine ratio at Month 6 minus albumin/creatinine ratio at baseline. (NCT01066039)
Timeframe: Baseline, Month 6

Interventionratio (Mean)
Baseline (n = 89)Change at Month 6 (n = 85)
Bisoprolol127.734.3

[back to top]

Change From Baseline in C-Peptide Level at Months 3 and 6

The change in C-peptide level at Months 3 and 6 was calculated as C-peptide level at Months 3 and 6 minus C-peptide level at baseline. (NCT01066039)
Timeframe: Baseline, Months 3 and 6

Interventionnanogram per milliliter (ng/mL) (Mean)
BaselineChange at Month 3Change at Month 6
Bisoprolol2.30.10.2

[back to top]

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Month 6

HbA1c represents the percentage of glycosylated hemoglobin. The change in HbA1c at Month 6 was calculated as HbA1c at Month 6 minus HbA1c at baseline. (NCT01066039)
Timeframe: Baseline, Month 6

InterventionPercent HbA1c (Mean)
BaselineChange at Month 6
Bisoprolol6.790.26

[back to top]

Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at Months 3 and 6

HOMA-IR is as an indicator of insulin resistance in participants with Type 2 diabetes mellitus and comorbid hypertension. HOMA-IR was derived from fasting plasma glucose (FPG) and fasting insulin (FI) using the formula: (FI [micro international units per milliliter {mcIU/mL}] * FPG [millimole per liter {mmol/L}]) divided by 22.5. The change in HOMA-IR at Months 3 and 6 was calculated as HOMA-IR at Months 3 and 6 minus HOMA-IR at baseline. (NCT01066039)
Timeframe: Baseline, Months 3 and 6

InterventionmcIU/mL * mmol/L (Mean)
BaselineChange at Month 3Change at Month 6
Bisoprolol2.30.10.4

[back to top]

Change From Baseline in Microalbumin Level at Month 6

The change in microalbumin level at Month 6 was calculated as microalbumin level at Month 6 minus microalbumin level at baseline. (NCT01066039)
Timeframe: Baseline, Month 6

Interventionmg/dL (Mean)
Baseline (n = 167)Change at Month 6 (n = 161)
Bisoprolol56.6-3.1

[back to top]

Change From Baseline in Echocardiographic Left Ventricular Ejection Fraction (LVEF) at Week 26

LVEF was defined as the fraction of blood (in percent) pumped out of the heart's left ventricular chamber with each heart beat and it is used to measure the cardiac output for the heart. (NCT01074307)
Timeframe: Baseline and Week 26

,
InterventionPercent LVEF (Mean)
Baseline (n=52, 106)Change at Week 26 (n=50, 106)
High Dose Bisoprolol27.6114.22
Low Dose Bisoprolol28.688.83

[back to top]

Change From Baseline in 6-minute Walking Test (6-MWT) Distance at Week 26

6-minute Walking Test (6-MWT) distance was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. (NCT01074307)
Timeframe: Baseline and Week 26

,
InterventionMeter (Mean)
Baseline (n=52, 103)Change at Week 26 (n=47, 102)
High Dose Bisoprolol368.1128.45
Low Dose Bisoprolol347.5841.59

[back to top]

Percent Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 26

B-type natriuretic peptide (BNP) is a substance secreted from the ventricles or lower chambers of the heart in response to changes in pressure that occur when heart failure develops and worsens. The level of BNP in the blood increases when heart failure symptoms worsen, and decreases when the heart failure condition is stable. The BNP level in a person with heart failure is higher than in a person with normal heart function. The percent change of NT-pro BNP was calculated according to the formula: N-terminal pro B-type natriuretic peptide (NT-proBNP) reduction ratio = 100*(Baseline NT-proBNP - Week 26 NT-proBNP)/Baseline NT-proBNP. (NCT01074307)
Timeframe: Baseline and Week 26

InterventionPercent change (Mean)
Low Dose Bisoprolol8.02
High Dose Bisoprolol9.50

[back to top]

Percentage of Participants Classified as Class I to IV According to New York Heart Association (NYHA)

New York Heart Association (NYHA) classification of heart failure: Class I: No limitation: ordinary physical exercise does not cause undue fatigue, dyspnea, or palpitations. Class II: Slight limitation of physical activity: comfortable at rest but ordinary activity results in fatigue, palpitations, or dyspnea. Class III: Marked limitation of physical activity: comfortable at rest but less than ordinary activity results in symptoms. Class IV: Unable to carry out any physical activity without discomfort: symptoms of heart failure are present even at rest with increased discomfort with any physical activity. (NCT01074307)
Timeframe: Baseline and Week 26

,
InterventionPercentage of participants (Number)
Baseline: Class IIBaseline: Class IIIBaseline: Class IVWeek 26: Class IWeek 26: Class IIWeek 26: Class III
High Dose Bisoprolol74.7724.300.9342.0654.213.74
Low Dose Bisoprolol73.0825.001.9221.1569.239.62

[back to top]

Number of Participants Who Were Re-hospitalized Due to Heart Failure and Who Died Due to Cardiovascular Disorder

(NCT01074307)
Timeframe: Baseline up to Week 26

,
InterventionParticipants (Number)
Re-hospitalization due to heart failureDeath due to cardiovascular disorder
High Dose Bisoprolol30
Low Dose Bisoprolol30

[back to top]

Mean Change From Baseline in Global Assessment of Congestive Heart Failure (CHF) Score at Week 26

Global assessment of CHF: The Investigator defined, graded, and recorded the participant's symptoms and signs by using a 6-point CHF scale ranging from 0 (unassessable), 1 (worsened), 2 (no change), 3 (mildly improved), 4 (moderately improved) and 5 (markedly improved). (NCT01074307)
Timeframe: Baseline and Week 26

,
InterventionUnits on a scale (Mean)
Baseline (n=52, 106)Change at Week 26 (n=51, 106)
High Dose Bisoprolol2.710.69
Low Dose Bisoprolol2.520.45

[back to top]

Change From Baseline in Echocardiographic Left Ventricular Size at Week 26

Left ventricle size was measured as systolic and diastolic Left Ventricular Internal Dimension (LVID). Diastolic dimension was measured of the left ventricle at the level of the chordae tendineae. The systolic dimension was measured as the smallest dimension between the left septal endocardium and the posterior wall endocardium during systole, whether or not the two walls were exactly apposed. (NCT01074307)
Timeframe: Baseline and Week 26

,
InterventionMilliliter LVID (Mean)
Baseline: Systolic LVID (n=51, 104)Change at Week 26: Systolic LVID (n=47, 102)Baseline: Diastolic LVID (n=52, 106)Change at Week 26: Diastolic LVID (n=50, 106)
High Dose Bisoprolol54.699.8463.405.49
Low Dose Bisoprolol54.255.4664.283.12

[back to top]

Number of Participants With Adverse Events (AEs)

An adverse event (AE) is defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. (NCT01074307)
Timeframe: Baseline up to Week 26

InterventionParticipants (Number)
Low Dose Bisoprolol45
High Dose Bisoprolol73

[back to top]

Change From Baseline in Heart Rate at Week 4 and Week 12

The change in heart rate at Week 4 and Week 12 was calculated as heart rate at Week 4 and Week 12 minus heart rate at baseline. (NCT01079962)
Timeframe: Baseline, Week 4 and Week 12

,
InterventionBeats per minute (bpm) (Mean)
Change in heart rate at Week 4 (n= 96, 95)Change heart rate at Week 12 (n= 90, 89)
Atenolol-6.20-7.84
Bisoprolol-6.21-8.64

[back to top]

Change From Baseline in Lipid Levels at Week 12

The lipid levels evaluated were total cholesterol, low density lipoprotein (LDL) cholesterol, and high density lipoprotein (HDL) cholesterol blood concentrations. The change in lipid levels at Week 12 was calculated as lipid levels at Week 12 minus lipid levels at baseline. (NCT01079962)
Timeframe: Baseline and Week 12

,
InterventionMilligram/decilitre (mg/dL) (Mean)
Change in Total cholesterol at Week 12Change in LDL-cholesterol at Week 12Change in HDL-cholesterol at Week 12
Atenolol-0.371.31-3.02
Bisoprolol-3.43-2.29-1.58

[back to top]

Change From Baseline in Aortic Augmentation Index (AIx) at Week 4 and Week 12

Augmentation index is a composite measure of wave reflection and systemic arterial stiffness which was calculated as the difference between the second and first systolic peaks. The change in AIx at Week 4 and Week 12 was calculated as AIx at Week 4 and Week 12 minus AIx at baseline. (NCT01079962)
Timeframe: Baseline, Week 4 and Week 12

,
InterventionRatio (Mean)
Change in AIx at Week 4 (n=96, 95)Change in AIx at Week 12 (n=90, 89)
Atenolol-0.011.21
Bisoprolol-1.560.61

[back to top]

Change From Baseline in Aortic Pulse Pressure (APP) at Week 4

The APP was calculated as aortic systolic pressure minus aortic diastolic pressure. The change in APP at Week 4 was calculated as APP at Week 4 minus APP at baseline. (NCT01079962)
Timeframe: Baseline and Week 4

InterventionmmHg (Mean)
Bisoprolol-3.02
Atenolol-4.09

[back to top]

Number of Participants With Adverse Events (AEs)

An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. (NCT01079962)
Timeframe: Baseline up to Week 14 (follow-up visit)

InterventionParticipants (Number)
Bisoprolol36
Atenolol32

[back to top]

Change From Baseline in Aortic Blood Pressure (BP) at Week 4 and Week 12

The change in aortic BP (aortic systolic blood pressure [SBP], aortic diastolic blood pressure [DBP] and aortic mean blood pressure [BP]) at Week 4 and Week 12 was calculated as aortic BP (aortic SBP, aortic DBP and aortic mean BP) at Week 4 and Week 12 minus aortic BP (aortic SBP, aortic DBP and aortic mean BP) at baseline. (NCT01079962)
Timeframe: Baseline, Week 4 and Week 12

,
InterventionmmHg (Mean)
Change in aortic SBP at Week 4 (n=96, 95)Change in aortic SBP at Week 12 (n=90, 89)Change in aortic DBP at Week 4 (n=96, 95)Change in aortic DBP at Week 12 (n=90, 89)Change in aortic mean BP at Week 4 (n=96, 95)Change in aortic mean BP at Week 12 (n=90, 89)
Atenolol-13.57-12.71-9.47-9.01-10.84-10.24
Bisoprolol-13.90-15.34-10.86-10.94-11.88-12.41

[back to top]

Change From Baseline in Blood Glucose Levels at Week 12

The change in blood glucose level at Week 12 was calculated as blood glucose level at Week 12 minus blood glucose level at baseline. (NCT01079962)
Timeframe: Baseline and Week 12

InterventionMillimoles per liter (mmol/L) (Mean)
Bisoprolol-0.23
Atenolol-0.45

[back to top]

Change From Baseline in Aortic Pulse Pressure (APP) in Intention to Treat (ITT) Population at Week 12

The APP was calculated as aortic systolic pressure minus aortic diastolic pressure. The change in APP at Week 12 was calculated as APP at Week 12 minus APP at baseline. (NCT01079962)
Timeframe: Baseline and Week 12

,
InterventionMillimeter of mercury (mmHg) (Mean)
Baseline (n=96, 95)Change in APP at Week 12 (n=90, 89)
Atenolol45.93-3.69
Bisoprolol47.49-4.40

[back to top]

Change From Baseline in Aortic Pulse Pressure (APP) in Per Protocol (PP) Population at Week 12

The APP was calculated as aortic systolic pressure minus aortic diastolic pressure. The change in APP at Week 12 was calculated as APP at Week 12 minus APP at baseline. (NCT01079962)
Timeframe: Baseline and Week 12

,
InterventionmmHg (Mean)
BaselineChange in APP at Week 12
Atenolol46.53-3.89
Bisoprolol46.87-4.33

[back to top]

Change From Baseline in Brachial Blood Pressure (BP) at Week 4 and Week 12

The change in brachial BP (brachial SBP, brachial DBP and brachial mean BP) at Week 4 and Week 12 was calculated as brachial BP (brachial SBP, brachial DBP and brachial mean BP) at Week 4 and Week 12 minus brachial BP (brachial SBP, brachial DBP and brachial mean BP) at baseline. (NCT01079962)
Timeframe: Baseline, Week 4 and Week 12

,
InterventionmmHg (Mean)
Change in brachial SBP at Week 4 (n=96, 95)Change in brachial SBP at Week 12 (n=90, 89)Change in brachial DBP at Week 4 (n=96, 95)Change in brachial DBP at Week 12 (n=90, 89)Change in brachial mean BP at Week 4 (n=96, 95)Change in brachial mean BP at Week 12 (n=90, 89)
Atenolol-17.52-17.63-11.36-10.61-13.41-12.95
Bisoprolol-17.45-19.10-12.70-13.39-14.28-15.29

[back to top]

Change From Baseline in Carotid-femoral Pulse Wave Velocity (cfPWV) at Week 4 and Week 12

Pulse wave velocity (PWV) is used as a measure of arterial stiffness, which is a measure of the cushioning functioning of major vessels like the aorta. The velocity of the Pulse wave (PW) along an artery is dependent on the stiffness of that artery. The change in cfPWV at Week 4 and Week 12 was calculated as cfPWV at Week 4 and Week 12 minus cfPWV at baseline. (NCT01079962)
Timeframe: Baseline, Week 4 and Week 12

,
InterventionMeters per second (m/s) (Mean)
Change in cfPWV at Week 4 (n=96, 95)Change cfPWV at Week 12 (n=90, 89)
Atenolol-0.81-0.87
Bisoprolol-0.60-0.72

[back to top]

Change From Baseline in DBP (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT

The change in DBP was calculated as 6-MWT after walking DBP at Week 26 minus 6-MWT after walking DBP at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionmmHg (Mean)
Baseline: Glu27Glu (n= 1)Baseline: Glu27Gln (n= 15)Baseline: Gln27Gln (n= 65)Change at Week 26 or EOT: Glu27Glu (n= 1)Change at Week 26 or EOT: Glu27Gln (n= 15)Change at Week 26 or EOT: Gln27Gln (n= 65)
Bisoprolol65.0077.4081.28-21.000.871.51

[back to top]

Change From Baseline in DBP (6 MWT- After Walking) According to the Genetic Polymorphism of GRK5-AG at Week 26 or EOT

The change in DBP was calculated as 6-MWT after walking DBP at Week 26 minus 6-MWT after walking DBP at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionmmHg (Mean)
Baseline: GRK5-Arg304 (n= 48)Baseline: GRK5-Arg304His (n= 30)Baseline: GRK5-His304 (n= 3)Change at Week 26 or EOT: GRK5-Arg304 (n= 48)Change at Week 26 or EOT: GRK5-Arg304His (n= 30)Change at Week 26 or EOT: GRK5-His304 (n= 3)
Bisoprolol79.1081.9784.330.791.274.67

[back to top]

Change From Baseline in DBP (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT

The change in DBP was calculated as 6-MWT before walking DBP at Week 26 minus 6-MWT before walking DBP at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionmmHg (Mean)
Baseline: Arg16Arg (n= 14)Baseline: Arg16Gly (n= 41)Baseline: Gly16Gly (n= 26)Change at Week 26 or EOT: Arg16Arg (n= 14)Change at Week 26 or EOT: Arg16Gly (n= 41)Change at Week 26 or EOT: Gly16Gly (n= 26)
Bisoprolol83.1475.5974.854.07-0.88-0.23

[back to top]

Change From Baseline in DBP (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT

The change in DBP was calculated as 6-MWT before walking DBP at Week 26 minus 6-MWT before walking DBP at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionmmHg (Mean)
Baseline: Glu27Glu (n= 1)Baseline: Glu27Gln (n= 15)Baseline: Gln27Gln (n= 65)Change at Week 26 or EOT: Glu27Glu (n= 1)Change at Week 26 or EOT: Glu27Gln (n= 15)Change at Week 26 or EOT: Gln27Gln (n= 65)
Bisoprolol68.0071.8077.91-28.00-1.931.11

[back to top]

Change From Baseline in DBP (6 MWT- Before Walking) According to the Genetic Polymorphism of GRK5-AG at Week 26 or EOT

The change in DBP was calculated as 6-MWT before walking DBP at Week 26 minus 6-MWT before walking DBP at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionmmHg (Mean)
Baseline: GRK5-Arg304 (n= 48)Baseline: GRK5-Arg304His (n= 30)Baseline: GRK5-His304 (n= 3)Change at Week 26 or EOT: GRK5-Arg304 (n= 48)Change at Week 26 or EOT: GRK5-Arg304His (n= 30)Change at Week 26 or EOT: GRK5-His304 (n= 3)
Bisoprolol74.9078.8782.670.06-0.135.33

[back to top]

Change From Baseline in Diastolic Blood Pressure (DBP) (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or EOT

The change in DBP was calculated as 6-MWT before walking DBP at Week 26 minus 6-MWT before walking DBP at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionmmHg (Mean)
Baseline: Arg389Arg (n= 52)Baseline: Arg389Gly (n= 24)Baseline: Gly389Gly (n= 5)Change at Week 26 or EOT: Arg389Arg (n= 52)Change at Week 26 or EOT: Arg389Gly (n= 24)Change at Week 26 or EOT: Gly389Gly (n= 5)
Bisoprolol75.6978.1779.400.100.290.60

[back to top]

Change From Baseline in DBP (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT

The change in DBP was calculated as 6-MWT after walking DBP at Week 26 minus 6-MWT after walking DBP at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionmmHg (Mean)
Baseline: Arg16Arg (n= 14)Baseline: Arg16Gly (n= 41)Baseline: Gly16Gly (n= 26)Change at Week 26 or EOT: Arg16Arg (n= 14)Change at Week 26 or EOT: Arg16Gly (n= 41)Change at Week 26 or EOT: Gly16Gly (n= 26)
Bisoprolol86.1479.6678.354.21-0.542.04

[back to top]

Change From Baseline in SBP (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT

The change in SBP was calculated as 6-MWT before walking SBP at Week 26 minus 6-MWT before walking SBP at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionmmHg (Mean)
Baseline: Glu27Glu (n= 1)Baseline: Glu27Gln (n= 15)Baseline: Gln27Gln (n= 65)Change at Week 26 or EOT: Glu27Glu (n= 1)Change at Week 26 or EOT: Glu27Gln (n= 15)Change at Week 26 or EOT: Gln27Gln (n= 65)
Bisoprolol130.00115.53123.43-13.00-4.33-0.62

[back to top]

Change From Baseline in SBP (6 MWT- Before Walking) According to the Genetic Polymorphism of GRK5-AG at Week 26 or EOT

The change in SBP was calculated as 6-MWT before walking SBP at Week 26 minus 6-MWT before walking SBP at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionmmHg (Mean)
Baseline: GRK5-Arg304 (n= 48)Baseline: GRK5-Arg304His (n= 30)Baseline: GRK5-His304 (n= 3)Change at Week 26 or EOT: GRK5-Arg304 (n= 48)Change at Week 26 or EOT: GRK5-Arg304His (n= 30)Change at Week 26 or EOT: GRK5-His304 (n= 3)
Bisoprolol118.92126.53127.33-2.25-1.138.00

[back to top]

Change From Baseline in Systolic Blood Pressure (SBP) (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or EOT

The change in SBP was calculated as 6-MWT before walking SBP at Week 26 minus 6-MWT before walking SBP at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

Interventionmillimeters of mercury (mmHg) (Mean)
Baseline: Arg389Arg (n= 52)Baseline: Arg389Gly (n= 24)Baseline: Gly389Gly (n= 5)Change at Week 26 or EOT: Arg389Arg (n= 52)Change at Week 26 or EOT: Arg389Gly (n= 24)Change at Week 26 or EOT: Gly389Gly (n= 5)
Bisoprolol121.81123.54117.40-0.96-2.75-0.40

[back to top]

Change From Baseline in SBP (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT

The change in SBP was calculated as 6-MWT before walking SBP at Week 26 minus 6-MWT before walking SBP at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionmmHg (Mean)
Baseline: Arg16Arg (n= 14)Baseline: Arg16Gly (n= 41)Baseline: Gly16Gly (n= 26)Change at Week 26 or EOT: Arg16Arg (n= 14)Change at Week 26 or EOT: Arg16Gly (n= 41)Change at Week 26 or EOT: Gly16Gly (n= 26)
Bisoprolol132.36117.83123.152.50-4.320.92

[back to top]

Change From Baseline in SBP (6 MWT- After Walking) According to the Genetic Polymorphism of GRK5-AG at Week 26 or EOT

The change in SBP was calculated as 6-MWT after walking SBP at Week 26 minus 6-MWT after walking SBP at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionmmHg (Mean)
Baseline: GRK5-Arg304 (n= 48)Baseline: GRK5-Arg304His (n= 30)Baseline: GRK5-His304 (n= 3)Change at Week 26 or EOT: GRK5-Arg304 (n= 48)Change at Week 26 or EOT: GRK5-Arg304His (n= 30)Change at Week 26 or EOT: GRK5-His304 (n= 3)
Bisoprolol127.52131.27135.33-2.10-2.3712.00

[back to top]

Change From Baseline in SBP (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT

The change in SBP was calculated as 6-MWT after walking SBP at Week 26 minus 6-MWT after walking SBP at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionmmHg (Mean)
Baseline: Glu27Glu (n= 1)Baseline: Glu27Gln (n= 15)Baseline: Gln27Gln (n= 65)Change at Week 26 or EOT: Glu27Glu (n= 1)Change at Week 26 or EOT: Glu27Gln (n= 15)Change at Week 26 or EOT: Gln27Gln (n= 65)
Bisoprolol113.00124.47130.54-18.00-4.93-0.68

[back to top]

Change From Baseline in SBP (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT

The change in SBP was calculated as 6-MWT after walking SBP at Week 26 minus 6-MWT after walking SBP at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionmmHg (Mean)
Baseline: Arg16Arg (n= 14)Baseline: Arg16Gly (n= 41)Baseline: Gly16Gly (n= 26)Change at Week 26 or EOT: Arg16Arg (n= 14)Change at Week 26 or EOT: Arg16Gly (n= 41)Change at Week 26 or EOT: Gly16Gly (n= 26)
Bisoprolol138.71126.56128.233.29-4.34-0.15

[back to top]

Change From Baseline in SBP (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or EOT

The change in SBP was calculated as 6-MWT after walking SBP at Week 26 minus 6-MWT after walking SBP at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionmmHg (Mean)
Baseline: Arg389Arg (n= 52)Baseline: Arg389Gly (n= 24)Baseline: Gly389Gly (n= 5)Change at Week 26 or EOT: Arg389Arg (n= 52)Change at Week 26 or EOT: Arg389Gly (n= 24)Change at Week 26 or EOT: Gly389Gly (n= 5)
Bisoprolol128.77130.25128.60-2.92-0.465.40

[back to top]

Change From Baseline in Pro-BNP Levels According to the Genetic Polymorphism of GRK5-AG at Week 26 or EOT

BNP is a substance secreted from the ventricles or lower chambers of the heart in response to changes in pressure that occur when heart failure develops and worsens. The level of BNP in the blood increases when heart failure symptoms worsen, and decreases when the heart failure condition is stable. The BNP level in a person with heart failure is higher than in a person with normal heart function. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

Interventionpg/mL (Mean)
Baseline: GRK5-Arg304 (n= 50)Baseline: GRK5-Arg304His (n= 30)Baseline: GRK5-His304 (n= 3)Change at Week 26 or EOT: GRK5-Arg304 (n= 49)Change at Week 26 or EOT: GRK5-Arg304His (n= 30)Change at Week 26 or EOT: GRK5-His304 (n= 3)
Bisoprolol895.521854.631527.09-33.78799.31861.39

[back to top]

Change From Baseline in Pro-BNP Levels According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT

BNP is a substance secreted from the ventricles or lower chambers of the heart in response to changes in pressure that occur when heart failure develops and worsens. The level of BNP in the blood increases when heart failure symptoms worsen, and decreases when the heart failure condition is stable. The BNP level in a person with heart failure is higher than in a person with normal heart function. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

Interventionpg/mL (Mean)
Baseline: Glu27Glu (n= 1)Baseline: Glu27Gln (n= 15)Baseline: Gln27Gln (n= 67)Change at Week 26 or EOT: Glu27Glu (n= 1)Change at Week 26 or EOT: Glu27Gln (n= 15)Change at Week 26 or EOT: Gln27Gln (n= 66)
Bisoprolol120.80878.311368.6784.91131.60346.20

[back to top]

Change From Baseline in Pro-BNP Levels According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT

BNP is a substance secreted from the ventricles or lower chambers of the heart in response to changes in pressure that occur when heart failure develops and worsens. The level of BNP in the blood increases when heart failure symptoms worsen, and decreases when the heart failure condition is stable. The BNP level in a person with heart failure is higher than in a person with normal heart function. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

Interventionpg/mL (Mean)
Baseline: Arg16Arg (n= 14)Baseline: Arg16Gly (n= 41)Baseline: Gly16Gly (n= 28)Change at Week 26 or EOT: Arg16Arg (n= 14)Change at Week 26 or EOT: Arg16Gly (n= 40)Change at Week 26 or EOT: Gly16Gly (n= 28)
Bisoprolol2809.30823.711139.071600.88-33.98137.68

[back to top]

Change From Baseline in Pro-B-type Natriuretic Peptide (BNP) Levels According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or EOT

BNP is a substance secreted from the ventricles or lower chambers of the heart in response to changes in pressure that occur when heart failure develops and worsens. The level of BNP in the blood increases when heart failure symptoms worsen, and decreases when the heart failure condition is stable. The BNP level in a person with heart failure is higher than in a person with normal heart function. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

Interventionpicograms (pg)/ milliliter (mL) (Mean)
Baseline: Arg389Arg (n= 53)Baseline: Arg389Gly (n= 25)Baseline: Gly389Gly (n= 5)Change at Week 26 or EOT: Arg389Arg (n= 53)Change at Week 26 or EOT: Arg389Gly (n= 24)Change at Week 26 or EOT: Gly389Gly (n= 5)
Bisoprolol1484.02851.471011.30292.10310.63394.32

[back to top]

Change From Baseline in Heart Rate (6 MWT- Before Walking) According to the Genetic Polymorphism of GRK5-AG at Week 26 or EOT

The change in heart rate was calculated as 6-MWT before walking heart rate at Week 26 minus 6-MWT before walking heart rate at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

Interventionbpm (Mean)
Baseline: GRK5-Arg304 (n= 49)Baseline: GRK5-Arg304His (n= 30)Baseline: GRK5-His304 (n= 3)Change at Week 26 or EOT: GRK5-Arg304 (n= 49)Change at Week 26 or EOT: GRK5-Arg304His (n= 30)Change at Week 26 or EOT: GRK5-His304 (n= 3)
Bisoprolol77.2980.8077.3310.927.8315.00

[back to top]

Change From Baseline in Echocardiographic Left Ventricular Ejection Fraction (LVEF) According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or End of Treatment (EOT)

(NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionPercent LVEF (Mean)
Baseline: Arg389Arg (n= 53)Baseline: Arg389Gly (n= 25)Baseline: Gly389Gly (n= 5)Change at Week 26 or EOT: Arg389Arg (n= 53)Change at Week 26 or EOT: Arg389Gly (n= 25)Change at Week 26 or EOT: Gly389Gly (n= 5)
Bisoprolol32.4432.8932.20-8.44-9.36-9.20

[back to top]

Change From Baseline in Echocardiographic LVEF According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT

(NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionPercent LVEF (Mean)
Baseline: Arg16Arg (n= 14)Baseline: Arg16Gly (n= 41)Baseline: Gly16Gly (n= 28)Change at Week 26 or EOT: Arg16Arg (n= 14)Change at Week 26 or EOT: Arg16Gly (n= 41)Change at Week 26 or EOT: Gly16Gly (n= 28)
Bisoprolol31.3132.6733.03-9.39-7.87-9.76

[back to top]

Change From Baseline in Echocardiographic LVEF According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT

(NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionPercent LVEF (Mean)
Baseline: Glu27Glu (n= 1)Baseline: Glu27Gln (n= 15)Baseline: Gln27Gln (n= 67)Change at Week 26 or EOT: Glu27Glu (n= 1)Change at Week 26 or EOT: Glu27Gln (n= 15)Change at Week 26 or EOT: Gln27Gln (n= 67)
Bisoprolol38.0033.0132.38-13.00-8.71-8.71

[back to top]

Change From Baseline in Echocardiographic LVEF According to the Genetic Polymorphism of G Protein-coupled Receptor Kinase 5 (GRK5)-AG at Week 26 or EOT

(NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionPercent LVEF (Mean)
Baseline: GRK5-Arg304 (n= 50)Baseline: GRK5-Arg304His (n= 30)Baseline: GRK5-His304 (n= 3)Change at Week 26 or EOT: GRK5-Arg304 (n= 50)Change at Week 26 or EOT: GRK5-Arg304His (n= 30)Change at Week 26 or EOT: GRK5-His304 (n= 3)
Bisoprolol32.3733.1429.87-7.69-10.19-12.47

[back to top]

Change From Baseline in Heart Rate (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or EOT

The change in heart rate was calculated as 6-MWT after walking heart rate at Week 26 minus 6-MWT after walking heart rate at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

Interventionbpm (Mean)
Baseline: Arg389Arg (n= 53)Baseline: Arg389Gly (n= 24)Baseline: Gly389Gly (n= 5)Change at Week 26 or EOT: Arg389Arg (n= 53)Change at Week 26 or EOT: Arg389Gly (n= 24)Change at Week 26 or EOT: Gly389Gly (n= 5)
Bisoprolol92.0290.9292.8011.8315.884.60

[back to top]

Change From Baseline in Heart Rate (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT

The change in heart rate was calculated as 6-MWT after walking heart rate at Week 26 minus 6-MWT after walking heart rate at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

Interventionbpm (Mean)
Baseline: Arg16Arg (n= 14)Baseline: Arg16Gly (n= 41)Baseline: Gly16Gly (n= 27)Change at Week 26 or EOT: Arg16Arg (n= 14)Change at Week 26 or EOT: Arg16Gly (n= 41)Change at Week 26 or EOT: Gly16Gly (n= 27)
Bisoprolol87.8695.0588.7411.2112.3713.59

[back to top]

Change From Baseline in Heart Rate (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT

The change in heart rate was calculated as 6-MWT after walking heart rate at Week 26 minus 6-MWT after walking heart rate at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

Interventionbpm (Mean)
Baseline: Glu27Glu (n= 1)Baseline: Glu27Gln (n= 15)Baseline: Gln27Gln (n= 66)Change at Week 26 or EOT: Glu27Glu (n= 1)Change at Week 26 or EOT: Glu27Gln (n= 15)Change at Week 26 or EOT: Gln27Gln (n= 66)
Bisoprolol90.0084.4093.44-3.009.7313.45

[back to top]

Change From Baseline in Heart Rate (6 MWT- After Walking) According to the Genetic Polymorphism of GRK5-AG at Week 26 or EOT

The change in heart rate was calculated as 6-MWT after walking heart rate at Week 26 minus 6-MWT after walking heart rate at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

Interventionbpm (Mean)
Baseline: GRK5-Arg304 (n= 49)Baseline: GRK5-Arg304His (n= 30)Baseline: GRK5-His304 (n= 3)Change at Week 26 or EOT: GRK5-Arg304 (n= 49)Change at Week 26 or EOT: GRK5-Arg304His (n= 30)Change at Week 26 or EOT: GRK5-His304 (n= 3)
Bisoprolol92.4189.30105.3314.598.5320.00

[back to top]

Change From Baseline in Heart Rate (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or EOT

The change in heart rate was calculated as 6-MWT before walking heart rate at Week 26 minus 6-MWT before walking heart rate at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionBeats per minute (bpm) (Mean)
Baseline: Arg389Arg (n= 53)Baseline: Arg389Gly (n= 24)Baseline: Gly389Gly (n= 5)Change at Week 26 or EOT: Arg389Arg (n= 53)Change at Week 26 or EOT: Arg389Gly (n= 24)Change at Week 26 or EOT: Gly389Gly (n= 5)
Bisoprolol76.4782.2583.208.9111.7912.00

[back to top]

Change From Baseline in Heart Rate (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT

The change in heart rate was calculated as 6-MWT before walking heart rate at Week 26 minus 6-MWT before walking heart rate at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

Interventionbpm (Mean)
Baseline: Arg16Arg (n= 14)Baseline: Arg16Gly (n= 41)Baseline: Gly16Gly (n= 27)Change at Week 26 or EOT: Arg16Arg (n= 14)Change at Week 26 or EOT: Arg16Gly (n= 41)Change at Week 26 or EOT: Gly16Gly (n= 27)
Bisoprolol79.2179.0277.5613.219.209.37

[back to top]

Change From Baseline in Heart Rate (6 MWT- Before Walking) According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT

The change in heart rate was calculated as 6-MWT before walking heart rate at Week 26 minus 6-MWT before walking heart rate at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

Interventionbpm (Mean)
Baseline: Glu27Glu (n= 1)Baseline: Glu27Gln (n= 15)Baseline: Gln27Gln (n= 66)Change at Week 26 or EOT: Glu27Glu (n= 1)Change at Week 26 or EOT: Glu27Gln (n= 15)Change at Week 26 or EOT: Gln27Gln (n= 66)
Bisoprolol92.0076.6078.829.0010.339.86

[back to top]

Duration of Hospitalization Due to Heart Failure

(NCT01104558)
Timeframe: Baseline to Week 26 (or EOT)

InterventionDays (Number)
Bisoprolol41

[back to top]

Number of Participants With Hospitalization Due to Heart Failure

(NCT01104558)
Timeframe: Baseline to Week 26 (or EOT)

InterventionParticipants (Number)
Bisoprolol1

[back to top]

Change From Baseline in 6-minute Walking Test (6-MWT) Distance According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or EOT

6 MWT distance was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionMeter (Mean)
Baseline: Arg389Arg (n= 53)Baseline: Arg389Gly (n= 24)Baseline: Gly389Gly (n= 5)Change at Week 26 or EOT: Arg389Arg (n= 53)Change at Week 26 or EOT: Arg389Gly (n= 24)Change at Week 26 or EOT: Gly389Gly (n= 5)
Bisoprolol401.36381.71371.70-20.85-0.90-20.10

[back to top]

Change From Baseline in 6-minute Walking Test (6-MWT) Distance According to the Genetic Polymorphism of GRK5-AG at Week 26 or EOT

6 MWT distance was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionMeter (Mean)
Baseline: GRK5-Arg304 (n= 49)Baseline: GRK5-Arg304His (n= 30)Baseline: GRK5-His304 (n= 3)Change at Week 26 or EOT: GRK5-Arg304 (n= 49)Change at Week 26 or EOT: GRK5-Arg304His (n= 30)Change at Week 26 or EOT: GRK5-His304 (n= 3)
Bisoprolol390.68395.11431.67-13.86-17.61-6.67

[back to top]

Change From Baseline in 6-MWT Distance According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-AG at Week 26 or EOT

6 MWT distance was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionMeter (Mean)
Baseline: Arg16Arg (n= 14)Baseline: Arg16Gly (n= 41)Baseline: Gly16Gly (n= 27)Change at Week 26 or EOT: Arg16Arg (n= 14)Change at Week 26 or EOT: Arg16Gly (n= 41)Change at Week 26 or EOT: Gly16Gly (n= 27)
Bisoprolol449.43414.73333.190.46-12.18-27.20

[back to top]

Change From Baseline in 6-MWT Distance According to the Genetic Polymorphism of Beta-2 Adrenergic Receptor-CG at Week 26 or EOT

6 MWT distance was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionMeter (Mean)
Baseline: Glu27Glu (n= 1)Baseline: Glu27Gln (n= 15)Baseline: Gln27Gln (n= 66)Change at Week 26 or EOT: Glu27Glu (n= 1)Change at Week 26 or EOT: Glu27Gln (n= 15)Change at Week 26 or EOT: Gln27Gln (n= 66)
Bisoprolol468.00404.63390.22-57.0012.23-20.51

[back to top]

Change From Baseline in DBP (6 MWT- After Walking) According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or EOT

The change in DBP was calculated as 6-MWT after walking DBP at Week 26 minus 6-MWT after walking DBP at baseline. (NCT01104558)
Timeframe: Baseline and Week 26 (or EOT)

InterventionmmHg (Mean)
Baseline: Arg389Arg (n= 52)Baseline: Arg389Gly (n= 24)Baseline: Gly389Gly (n= 5)Change at Week 26 or EOT: Arg389Arg (n= 52)Change at Week 26 or EOT: Arg389Gly (n= 24)Change at Week 26 or EOT: Gly389Gly (n= 5)
Bisoprolol80.1580.5081.80-0.043.631.00

[back to top]

Percentage of Participants With Increased Glycosylated Hemoglobin (HbA1c) at Week 12

HbA1c represents the percentage of glycosylated hemoglobin. Percentage of participants with increased HbA1c (greater than 0.5% from baseline) at Week 12 was reported. (NCT01190436)
Timeframe: Week 12

Interventionpercentage of participants (Number)
Bisoprolol16.8

[back to top]

Percentage of Participants With Response to Study Drug

Response to study drug was defined as lowering of systolic BP by at least 10 mmHg from baseline. (NCT01190436)
Timeframe: Week 12

Interventionpercentage of participants (Number)
Bisoprolol44.0

[back to top]

Mean Change From Baseline in Fasting Blood Sugar (FBS) Level at Week 12

The change in FBS level at Week 12 was calculated as FBS level at Week 12 minus FBS level at baseline. (NCT01190436)
Timeframe: Baseline, Week 12

Interventionmg/dL (Mean)
BaselineChange at Week 12
Bisoprolol117.1-5.49

[back to top]

Mean Change From Baseline in HbA1c at Week 12

HbA1c represents the percentage of glycosylated hemoglobin. The change in HbA1c at Week 12 was calculated as HbA1c at Week 12 minus HbA1c at baseline. (NCT01190436)
Timeframe: Baseline, Week 12

InterventionPercent HbA1c (Mean)
BaselineChange at Week 12
Bisoprolol6.280.02

[back to top]

Mean Change From Baseline in Heart Rate at Week 12

The change in heart rate at Week 12 was calculated as the heart rate at Week 12 minus heart rate at baseline. (NCT01190436)
Timeframe: Baseline, Week 12

Interventionbeats per minute (bpm) (Mean)
BaselineChange at Week 12
Bisoprolol78.28.55

[back to top]

Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Week 12

The change in diastolic and systolic BP at Week 12 was calculated as diastolic and systolic BP at Week 12 minus diastolic and systolic BP at baseline, respectively. (NCT01190436)
Timeframe: Baseline, Week 12

InterventionmmHg (Mean)
Systolic BP: BaselineSystolic BP: Change at Week 12Diastolic BP: BaselineDiastolic BP: Change at Week 12
Bisoprolol151.712.5487.68.48

[back to top]

Mean Change From Baseline in Total Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL) Cholesterol and Triglyceride Level at Week 12

The change in total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride level at Week 12 was calculated as total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride level at Week 12 minus total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride level at baseline, respectively. (NCT01190436)
Timeframe: Baseline, Week 12

Interventionmg/dL (Mean)
Total cholesterol: BaselineTotal cholesterol: Change at Week 12LDL cholesterol: BaselineLDL cholesterol: Change at Week 12HDL cholesterol: BaselineHDL cholesterol: Change at Week 12Triglyceride: BaselineTriglyceride: Change at Week 12
Bisoprolol183.71.25105.5-1.2052.00.88122.82.59

[back to top]

Number of Participants With Adverse Events (AEs)

An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. (NCT01190436)
Timeframe: Baseline up to Week 12

Interventionparticipants (Number)
Bisoprolol8

[back to top]

Percentage of Participants With Controlled BP

Controlled BP was defined as BP less than 130/80 mmHg. (NCT01190436)
Timeframe: Week 12

Interventionpercentage of participants (Number)
Bisoprolol42.4

[back to top]

Percentage of Participants With Decrease in Heart Rate by at Least 10 Bpm at Week 12

(NCT01190436)
Timeframe: Week 12

Interventionpercentage of participants (Number)
Bisoprolol36.8

[back to top]

Percentage of Participants With Increased Fasting Blood Sugar (FBS) at Week 12

Percentage of participants with increased FBS (greater than 16 milligram per deciliter [mg/dL] from baseline) at Week 12 was reported. (NCT01190436)
Timeframe: Week 12

Interventionpercentage of participants (Number)
Bisoprolol15.2

[back to top]

Change From Baseline in Baroreflex Sensitivity (BRS) at End of Follow-up

Baroreflex sensitivity (BRS) is an important characteristic of baroreflex control and often noninvasively assessed by relating heart rate (HR) fluctuations to blood pressure (BP) fluctuations. Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm. (NCT01251146)
Timeframe: Baseline and end of follow-up (Week 4 or Week 6 or Week 8)

Interventionmillisecond per millimeter of mercury (Mean)
Bisoprolol4.08
Atenolol3.31

[back to top]

Percentage of Participants Attaining Heart Rate Goal at Week 2, 4 and 6

Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm. (NCT01251146)
Timeframe: Attainment of heart rate goal (Week 2 or Week 4 or Week 6)

,
Interventionpercentage of participants (Number)
Week 2Week 4Week 6
Atenolol79.1285.7185.71
Bisoprolol83.7291.8693.02

[back to top]

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition (NCT01251146)
Timeframe: Baseline up to end of follow-up (Week 4 or Week 6 or Week 8)

,
Interventionparticipants (Number)
Number of participants with AEsNumber of participants with SAEs
Atenolol60
Bisoprolol60

[back to top]

Number of Participants Compliant With Study Treatment

Participants compliant with study treatment were the participants who have completed the study treatment regimen. (NCT01251146)
Timeframe: Baseline up to end of follow-up (Week 4 or Week 6 or Week 8)

Interventionparticipants (Number)
Bisoprolol83
Atenolol81

[back to top]

Change From Baseline in Baroreflex Sensitivity (BRS) at Attainment of Heart Rate Goal

Baroreflex sensitivity (BRS) is an important characteristic of baroreflex control and often noninvasively assessed by relating heart rate (HR) fluctuations to blood pressure (BP) fluctuations. Heart rate goal was defined as attainment of heart rate less than or equal to 65 beats per minute (bpm). (NCT01251146)
Timeframe: Baseline and attainment of heart rate goal (Week 2 or Week 4 or Week 6)

,
Interventionmillisecond per millimeter of mercury (Mean)
Baseline (n=75,79)Change at attainment of heart rate goal (n=67,66)
Atenolol7.922.88
Bisoprolol7.783.27

[back to top]

Change From Baseline in Heart Rate Variability (HRV) for Low Frequency Power (LF) and for High Frequency Power (HF) at Attainment of Heart Rate Goal and End of Follow-up

Heart rate variability (HRV) is used to describe the variations of both instantaneous HR and resting rate (RR) intervals and was evaluated for low frequency power (LF) and for high frequency power (HF). Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm. (NCT01251146)
Timeframe: Baseline, attainment of heart rate goal (Week 2 or Week 4 or Week 6) and end of follow-up (Week 4 or Week 6 or Week 8)

,
Interventionmillisecond square (ms^2) (Mean)
HRV for LF at Baseline (n=75,79)Change for LF: heart rate goal (n=71,71)Change at end of follow-up for LF (n=71,66)HRV for HF at Baseline (n=75,79)Change for HF: heart rate goal (n=71,71)Change at end of follow-up for HF (n=71,66)
Atenolol322.0926.14-22.00193.48136.67178.05
Bisoprolol261.8090.0489.40171.26148.91186.46

[back to top]

Change From Baseline in Ratio of Heart Rate Variability (HRV) for Low Frequency Power (LF) to Heart Rate Variability Power (HRV) for High Frequency (HF) (LF/HF) at Attainment of Heart Rate Goal and End of Follow-up

Heart rate variability (HRV) is used to describe the variations of both instantaneous HR and resting rate (RR) intervals and was evaluated for low frequency power (LF) and for high frequency power (HF). Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm. (NCT01251146)
Timeframe: Baseline, attainment of heart rate goal (Week 2 or Week 4 or Week 6) and end of follow-up (Week 4 or Week 6 or Week 8)

,
Interventionratio (Mean)
Baseline (n=75,79)Change at attainment of heart rate goal (n=71,71)Change at end of follow-up (n=71,66)
Atenolol2.40-0.90-1.15
Bisoprolol2.16-0.70-0.69

[back to top]

Number of Participants Attaining Heart Rate Goal at Dosage 1, 2 and 3 of Study Treatment

Dosage 1, 2 and 3 for bisoprolol group was defined as 5 mg, 7.5 mg and 10 mg once daily and for atenolol group as 50 mg, 75 mg and 100 mg once daily, respectively. Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm. (NCT01251146)
Timeframe: Baseline up to attainment of heart rate goal (Week 2 or Week 4 or Week 6)

,
Interventionparticipants (Number)
Dosage 1Dosage 2Dosage 3
Atenolol7260
Bisoprolol7271

[back to top]

Blood Pressure Response Rate

Blood pressure response was defined as DBP less than or equal to (=<) 90 mmHg or >=10 mmHg decrease in DBP from baseline. Blood pressure response rate was calculated as: number of subjects with blood pressure response divided by total number of subjects and multiplied by 100. (NCT01508325)
Timeframe: Week 12

Interventionpercentage of subjects (Number)
Bisoprolol86.67
Metoprolol83.33

[back to top]

Change From Baseline in Mean Ambulatory 24-hour Blood Pressure at Week 12

The ABPM determined blood pressure 3 times hourly in the daytime and once hourly in the nighttime. Only monitoring data with valid data >=80% was used for analysis. Each ABPM lasted for at least 24 hours. The first dynamic blood pressure monitoring was used as baseline. The difference between the mean ABPM observed in the last 24 hours at Week 12 and baseline was calculated to find out the change of mean ABPM at the end of the treatment. (NCT01508325)
Timeframe: Baseline and Week 12

,
InterventionmmHg (Mean)
SBP: Baseline (n=92, 93)SBP: Change at Week 12 (n=68, 67)DBP: Baseline (n=92, 93)DBP: Change at Week 12 (n=68, 67)
Bisoprolol132.76-5.4084.60-4.58
Metoprolol135.43-4.5486.94-3.78

[back to top]

Change From Baseline in Mean Ambulatory 24-hour Heart Rate at Week 12

Pulse rate was measured by palpation on radial artery for 1 minute. Two measurements were made at least 1 to 2 minutes apart. Finally mean heart rate was recorded. The first measured heart rate was used as baseline heart rate. The difference between the last 24 hours heart rate at Week 12 and of the baseline heart rate was calculated. (NCT01508325)
Timeframe: Baseline and Week 12

,
Interventionbeats/min (Mean)
Baseline (n=92, 93)Change at Week 12 (n=67, 67)
Bisoprolol77.45-8.46
Metoprolol75.80-3.24

[back to top]

Change From Baseline in Mean Ambulatory Systolic Blood Pressure (SBP) in the Last 4 Hours After 12-week Treatment

The ABPM determined blood pressure 3 times hourly in the daytime and once hourly in the nighttime. Only monitoring data with valid data >=80% was used for analysis. Each ABPM lasted for at least 24 hours. The first dynamic blood pressure monitoring was used as baseline. The difference between the mean ambulatory SBP observed in the last 4 hours after 12-week treatment and baseline was calculated to find out the change of mean ambulatory SBP at the end of the treatment. (NCT01508325)
Timeframe: Baseline and Week 12

,
InterventionmmHg (Mean)
Baseline (n=92, 93)Change at Week 12 (n=65, 66)
Bisoprolol132.68-5.97
Metoprolol133.24-5.12

[back to top]

Change From Baseline in Mean Ambulatory Night-time Heart Rate at Week 12

Pulse rate was measured by palpation on radial artery for 1 minute. Two measurements were made at least 1 to 2 minutes apart. Finally mean heart rate was recorded. The first measured heart rate was used as baseline heart rate. The difference between the nighttime heart rate at Week 12 treatment and of the baseline heart rate was calculated to measure the change of mean ambulatory nighttime heart rate at the end of the treatment. Nighttime was defined as 10:00 pm to 06:00 am. (NCT01508325)
Timeframe: Baseline and Week 12

,
Interventionbeats/min (Mean)
Baseline (n=92, 93)Change at Week 12 (n=66, 66)
Bisoprolol67.73-4.72
Metoprolol66.85-1.50

[back to top]

Change From Baseline in Mean Ambulatory Night-time Blood Pressure at Week 12

The ABPM determined blood pressure once hourly in the nighttime. Only monitoring data with valid data >=80% was used for analysis. Each ABPM lasted for at least 24 hours. The first nighttime blood pressure monitoring was used as baseline. The difference between the mean ambulatory nighttime blood pressure observed at Week 12 and baseline was calculated to find out the change of mean ambulatory nighttime blood pressure at the end of the treatment. Nighttime in this study was defined as 10:00 pm to 06:00 am. (NCT01508325)
Timeframe: Baseline and Week 12

,
InterventionmmHg (Mean)
SBP: Baseline (n=92, 93)SBP: Change at Week 12 (n=68, 66)DBP: Baseline (n=92, 93)DBP: Change at Week 12 (n=68, 66)
Bisoprolol125.16-4.8179.14-5.08
Metoprolol127.15-2.6581.19-3.39

[back to top]

Change From Baseline in Mean Ambulatory Diastolic Blood Pressure (DBP) in the Last 4 Hours After 12-week Treatment

Ambulatory blood pressure monitoring (ABPM) determined blood pressure 3 times hourly in the daytime and once hourly in the nighttime. Only monitoring data with valid data greater than or equal to (>=) 80 percent (%) was used for analysis. Each ABPM lasted for at least 24 hours. The first dynamic blood pressure monitoring was used as baseline. The difference between the mean ambulatory DBP observed in the last 4 hours after 12-week treatment and baseline was calculated to find out the change of mean ambulatory DBP at the end of the treatment. (NCT01508325)
Timeframe: Baseline and Week 12

,
InterventionmmHg (Mean)
Baseline (n=92, 93)Change at Week 12 (n=65, 66)
Bisoprolol85.28-4.45
Metoprolol85.68-3.39

[back to top]

Change From Baseline in Mean Ambulatory Daytime Heart Rate at Week 12

Pulse rate was measured by palpation on radial artery for 1 minute. Two measurements were made at least 1 to 2 minutes apart. Finally mean heart rate was recorded. The first measured daytime heart rate was used as baseline heart rate. The difference between the daytime heart rate at Week 12 treatment and of the baseline heart rate was calculated to measure the change of mean ambulatory daytime heart rate at the end of the treatment. Daytime in this study was defined as 06:00 am to 10:00 pm. (NCT01508325)
Timeframe: Baseline and Week 12

,
Interventionbeats/min (Mean)
Baseline (n=92, 93)Change at Week 12 (n=66, 67)
Bisoprolol80.66-9.60
Metoprolol78.94-3.85

[back to top]

Change From Baseline in Mean Ambulatory Daytime Blood Pressure at Week 12

The ABPM determined blood pressure 3 times hourly in the daytime. Only monitoring data with valid data >=80% was used for analysis. Each ABPM lasted for at least 24 hours. The first dynamic daytime blood pressure monitoring was used as baseline. The difference between the mean ambulatory daytime blood pressure observed at Week 12 and baseline was calculated to find out the change of mean ambulatory daytime blood pressure at the end of the treatment. Daytime in this study was defined as time between 06:00 am to 10:00 pm. (NCT01508325)
Timeframe: Baseline and Week 12

,
InterventionmmHg (Mean)
SBP: Baseline (n=92, 93)SBP: Change at Week 12 (n=68, 67)DBP: Baseline (n=92, 93)DBP: Change at Week 12 (n=68, 67)
Bisoprolol135.40-5.8786.43-4.76
Metoprolol138.31-5.1688.86-3.82

[back to top]

Change From Baseline in Mean Heart Rate in the Last 4 Hours After 12-week Treatment

Pulse rate was measured by palpation on radial artery for 1 minute. Two measurements were made at least 1 to 2 minutes apart. Finally mean heart rate was recorded. The first measured heart rate was used as baseline heart rate. The difference between the last 4 hours heart rate after 12-week treatment and of the baseline heart rate was calculated to measure the change in mean heart rate at the end of the treatment. (NCT01508325)
Timeframe: Baseline and Week 12

,
Interventionbeats/min (Mean)
Baseline (n=92, 93)Change at Week 12 (n=65, 66)
Bisoprolol75.67-8.04
Metoprolol73.99-4.75

[back to top]

Change From Baseline in 24-hour Blood Pressure Variability at Week 12

The ABPM determined blood pressure 3 times hourly in the daytime and once hourly in the nighttime. Only monitoring data with valid data >=80% was used for analysis. Each ABPM lasted for at least 24 hours. The first dynamic blood pressure monitoring was used as baseline. The mean change in the blood pressure variability between the 24-hour blood pressure observed at Week 12 and baseline was calculated. (NCT01508325)
Timeframe: Baseline and Week 12

,
InterventionmmHg (Mean)
SBP variability: Baseline (n=91, 92)SBP variability: Change at Week 12 (n=66, 66)DBP variability: Baseline (n=91, 92)DBP variability: Change at Week 12 (n=66, 66)
Bisoprolol10.89-0.1212.680.02
Metoprolol10.450.0912.090.76

[back to top]

Heart Rate Response Rate

Heart rate response was defined as decrease in heart rate from baseline >=10 percent (%). Heart rate response rate was calculated by using the number of subjects with heart rate response divided by total number of subjects and multiplied by 100. (NCT01508325)
Timeframe: Week 12

Interventionpercentage of subjects (Number)
Bisoprolol72.00
Metoprolol55.56

[back to top]

Change From Baseline in Diastolic Blood Pressure (DBP) After 18 Weeks of Treatment

Baseline was defined as the latest DBP before study treatment administration. (NCT01977794)
Timeframe: Baseline, Week 18

,
InterventionmmHg (Mean)
BaselineChange at Week 18
Amlodipine Failed Group90.5-13.0
Bisoprolol Failed Group92.0-14.0

[back to top]

Change From Baseline in Heart Rate (HR) After 18 Weeks of Treatment

Baseline was defined as the latest HR before study treatment administration (NCT01977794)
Timeframe: Baseline, Week 18

,
Interventionbeats per minute (Mean)
BaselineChange from baseline at Week 18
Amlodipine Failed Group73.6-11.5
Bisoprolol Failed Group69.9-6.6

[back to top]

Mean Reduction In Systolic Blood Pressure (SBP) After 18 Weeks of Treatment From Baseline

Baseline was defined as the latest SBP under monotherapy. (NCT01977794)
Timeframe: Baseline, Week 18

,
Interventionmillimeters of mercury (mmHg) (Mean)
BaselineChange at Week 18
Amlodipine Failed Group150.6-24.7
Bisoprolol Failed Group151.6-25.9

[back to top]

Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, AEs Leading to Discontinuation and AEs Leading to Death

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent AEs was AEs that started or worsened in severity on or after the date of first dose of IMP until the end of the study. AEs leading to death and discontinued were also presented. (NCT01977794)
Timeframe: Baseline up to Day 127 (end of trial)

,
Interventionsubjects (Number)
TEAEsSerious TEAEsAEs leading to discontinuationAEs leading to death
Amlodipine Failed Group78131
Bisoprolol Failed Group71231

[back to top]

Percentage of Subjects With Controlled Blood Pressure

(NCT01977794)
Timeframe: Baseline up to Week 18

,
Interventionpercentage of subjects (Number)
Week 6Week 12Week 18
Amlodipine Failed Group85.686.886.7
Bisoprolol Failed Group80.887.989.0

[back to top]

Bone Mineral Density (BMD) Using Control Dual-energy X-ray Absorptiometry

Changes in Median (Inter-Quartile Range) values of Bone mineral density (BMD) at final visit versus baseline level using control dual-energy X-ray absorptiometry and in comparison between the groups (NCT02355821)
Timeframe: 12 months

,
Interventiong/cm2 (Median)
Baseline12 months
Bisoprolol-0.55-1.2
Moxonidine-1.0-0.6

[back to top]

THe Number (Percentage) of the Treatment Responders

Proportion of the treatment responders (defined as the proportion (%) of patients who achieved target blood pressure <140/90 mmHg) after 8 and 48 weeks of the investigated treatment (V2, V3 and V4) and to compare the values between the groups. (NCT02355821)
Timeframe: baseline (Visit 1) and 12 months (Visit 4)

InterventionParticipants (Count of Participants)
Moxonidine55
Bisoprolol53

[back to top]

Number of Participants With Adverse Events (AE)

Number of Participants with Adverse Events (AE) (NCT02355821)
Timeframe: baseline (Visit 1) and 12 months (Visit 4)

InterventionParticipants (Count of Participants)
Moxonidine3
Bisoprolol3

[back to top]

Pulse Wave Velocity (PWV)

Changes in mean pulse wave velocity (PWV) at final visit versus baseline level and in comparison between the groups (NCT02355821)
Timeframe: baseline (Visit 1) and 12 months (Visit 4)

,
Interventionm/s (Mean)
Baseline12 months
Bisoprolol10.3611.26
Moxonidine10.3510.05

[back to top]

Osteocalcin

Changes in Median (Inter-Quartile Range) values of the bone synthesis marker (osteocalcin) at the end of the study (V4) from the baseline (V1) and to compare the values between the groups. (NCT02355821)
Timeframe: baseline (Visit 1) and 12 months (Visit 4)

,
Interventionng/ml (Median)
Baseline12 months
Bisoprolol19.418.7
Moxonidine18.219.6

[back to top]

Intima-media Thickness (IMT)

Changes in mean intima-media thickness (IMT) at final visit in comparison between the groups. (NCT02355821)
Timeframe: baseline (Visit 1) and 12 months (Visit 4)

,
Interventionmm (Mean)
Baseline12 months
Bisoprolol0.980.88
Moxonidine0.980.77

[back to top]

Collagen Type 1 C-telopeptide

Changes in Median (Inter-Quartile Range) of the bone resorption marker (collagen type 1 C-telopeptide) at the end of the study from the baseline are evaluated in comparison between the groups (NCT02355821)
Timeframe: baseline (Visit 1) and 12 months (Visit 4)

,
Interventionng/ml (Median)
Baseline12 months
Bisoprolol0.40.4
Moxonidine0.40.3

[back to top]

Telomerase Activity

Changes in Median (Inter-Quartile Range) telomerase activity at final visit versus baseline level in comparison between the groups Telomerase activity is measured in arbitrary units. Currently, there are no established reference values for telomerase activity in the world. Its activity is considered high or low in relation to the median. (NCT02355821)
Timeframe: baseline (Visit 1) and 12 months (Visit 4)

,
Interventionarbitrary units (Median)
Baseline12 months
Bisoprolol0.890.64
Moxonidine0.871.15

[back to top]

Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL).

Changes in Median (Inter-Quartile Range) values of the receptor activator of nuclear factor kappa-B ligand (RANKL) at final visit versus baseline level in comparison between the groups (NCT02355821)
Timeframe: baseline (Visit 1) and 12 months (Visit 4)

,
Interventionpmol/ml (Median)
Baseline12 month
Bisoprolol0.1330.111
Moxonidine0.1090.09

[back to top]

B-type Natriuretic Peptide (BNP) at 6 Months.

B-type natriuretic peptide (BNP) at 6 months. (NCT02391337)
Timeframe: 6 months

Interventionng/L (Median)
Beta-blocker1209
Digoxin1057.5

[back to top]

Ambulatory Heart-rate.

24 hour ambulatory heart-rate. (NCT02391337)
Timeframe: Within 12 months

Interventionbpm (Mean)
Beta-blocker73.7
Digoxin78.9

[back to top]

Drug Discontinuation Rate Within 12 Months.

Number of participants requiring drug discontinuation due to adverse reactions. (NCT02391337)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Beta-blocker9
Digoxin2

[back to top]

Cardiovascular Events

Number of Participants with hospital admissions for cardiovascular events. (NCT02391337)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Beta-blocker12
Digoxin2

[back to top]

Composite Functional Status Measures- 6 Minute Walking Distance at 12 Months.

Composite functional status measures- 6 minute walking distance at 12 months. (NCT02391337)
Timeframe: 12 months

Interventionmetres (Median)
Beta-blocker329
Digoxin366

[back to top]

Diastolic Function- Measured by the E/e'.

"The above parameters will be measured using echocardiography and diastolic indices.~E/e' - the ratio between early mitral inflow velocity and mitral annular early diastolic velocity." (NCT02391337)
Timeframe: 12 months

InterventionRatio of E/e' (Mean)
Beta-blocker10.8
Digoxin10.8

[back to top]

Hospital Admission Rate

A composite of adverse clinical events (NCT02391337)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Beta-blocker19
Digoxin11

[back to top]

Left Ventricular Ejection Fraction

The above parameters will be measured using echocardiography and diastolic indices (NCT02391337)
Timeframe: 12 months

Interventionpercentage of ejection fraction (Mean)
Beta-blocker59.8
Digoxin59.7

[back to top]

Number of Participants With Unplanned Hospital Admissions.

Number of Participants with Unplanned Hospital Admissions. (NCT02391337)
Timeframe: During the 12 month follow-up period.

InterventionParticipants (Count of Participants)
Beta-blocker19
Digoxin11

[back to top]

Patient Reported Outcomes (EQ-5D-5L)

"As assessed using the EQ-5D-5L summary index questionnaires at both 6 and 12 months.~The range for summary index is from -0.594=worst score to 1=best score" (NCT02391337)
Timeframe: 12 months

Interventionunits on a scale (Mean)
Beta-blocker0.62
Digoxin0.66

[back to top]

Patient Reported Outcomes- (AFEQT) at 12 Months.

As assessed using the AFEQT overall score at 12 months. The range for AFEQT overall score is from 0= complete disability to 100=no disability. (NCT02391337)
Timeframe: 12 months

Interventionscore on a scale (Mean)
Beta-blocker68.1
Digoxin75.6

[back to top]

Patient Reported Quality of Life (SF-36)

"Patient-reported outcomes as assessed by the SF-36 questionnaire physical component score.~The physical component score ranges from 0-100 where higher value indicates better outcome." (NCT02391337)
Timeframe: Primary outcome at 6 months timepoint.

Interventionscore on a scale (Mean)
Beta-blocker29.7
Digoxin31.9

[back to top]

Patient Reported Outcomes (SF36) Version 2 at 12 Months.

As assessed using the SF-36 version 2 global and specific scores at 12 months. All domains presented are between 0 to 100 scale where the higher score indicates better outcomes. (NCT02391337)
Timeframe: 12 months

,
Interventionscore on a scale (Mean)
Physical Component SummaryMental Component SummaryPhysical Function Domain ScoreRole Limitation Due to Physical Domain scoreRole Limitation Due to Emotional Problems Domain scoreSocial Functioning Domain ScoreMental Health DomainEnergy/Vitality Domain ScorePain ScoreGeneral Health Perception Domain Score
Beta-blocker29.451.327.53240.743.351.84241.939.6
Digoxin32.553.631.53745.245.651.347.140.542.8

[back to top]

Retention of Participants

Convenience, compliance and cross-over data (NCT02391337)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Death71940422Death71940423Lost to follow-up71940422Lost to follow-up71940423Withdrawn consent71940422Withdrawn consent71940423
yesNo
Beta-blocker7
Digoxin4
Beta-blocker73
Digoxin77
Beta-blocker0
Digoxin2
Beta-blocker80
Beta-blocker1
Beta-blocker79
Digoxin79

[back to top]

Coronary Artery Bypass [Coronary Revascularization]

Number of Participants with revascularization coronary procedures (coronary artery bypass grafting) (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
Baseline1 year
Pioglitazone + Standard Care00
Standard Care00

[back to top]

Percutaneous Coronary Intervention [Coronary Revascularization]

Number of Participants with incidence of percutaneous coronary intervention. (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
Baseline1 year
Pioglitazone + Standard Care00
Standard Care00

[back to top]

Safety and Tolerability 1

Liver injury: mean values of ALT (NCT03011775)
Timeframe: Baseline, 6 month and 1 year

,
Interventionunits per liter (U/L) (Mean)
BaselineMean values of ALT in 6 monthsMean values of ALT in 1 year
Pioglitazone + Standard Care23.427.419.9
Standard Care26.926.123.9

[back to top]

Safety and Tolerability 2

Liver injury: mean levels of total bilirubin (NCT03011775)
Timeframe: Baseline, 6 month and 1 year

,
Interventionμmol/l (Mean)
BaselineMean values of total bilirubin in 6 monthMean values of total bilirubin in 1 year
Pioglitazone + Standard Care12.312.415.7
Standard Care10.812.715.0

[back to top]

Safety and Tolerability 3

Kidney injury: mean values of the microalbuminuria (NCT03011775)
Timeframe: Baseline and 1 year

,
Interventionmg/mol (Mean)
Baseline1 year
Pioglitazone + Standard Care31.4431.10
Standard Care41.137.70

[back to top]

Safety and Tolerability 4

Kidneys injury: mean values of creatinine (NCT03011775)
Timeframe: Baseline and 1 year

,
Interventionμmol/l (Mean)
Mean values of creatinine in men baselineMean values of creatinine in men in 1 yearMean values of creatinine in women baselineMean values of creatinine in women in 1 year
Pioglitazone + Standard Care105.685.066.872.5
Standard Care102.382.088.277.5

[back to top]

Systemic Inflammation Level

Number of Participants with C-reactive protein level above 3 mg/L (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
BaselineIn 1 year
Pioglitazone + Standard Care1012
Standard Care713

[back to top]

Thickness of the Intima-media Complex

Mean thickness of carotid intima-media complex (NCT03011775)
Timeframe: Baseline, 6 month and 1 year

,
Interventioncm (Mean)
Mean thickness of the right carotid intima-media baselineMean thickness of the right carotid intima-media in 6 monthMean thickness of the right carotid intima-media in 1 yearMean thickness of the left carotid intima-media baselineMean thickness of the left carotid intima-media in 6 monthMean thickness of the left carotid intima-media in 1 year
Pioglitazone + Standard Care1.081.051.011.11.061.02
Standard Care0.980.971.011.01.000.97

[back to top]

Lipid Metabolism 3

Lipoproteine fractions:mean values of high-density lipoproteins and low density lipoproteins (NCT03011775)
Timeframe: Baseline and 1 year

,
Interventionmmol/L (Mean)
Mean values of high-density lipoproteins in men baselineMean values of high-density lipoproteins in men in 1 yearMean values of high-density lipoproteins in women baselineMean values of high-density lipoproteins in women in 1 yearMean values of low density lipoproteins in men baselineMean values of low density lipoproteins in men in 1 yearMean values of low density lipoproteins in women baselineMean values of low density lipoproteins in women in 1 year
Pioglitazone + Standard Care0.81.10.91.23.92.94.53.3
Standard Care0.91.01.11.04.43.03.52.7

[back to top]

Сardiovascular Death

Number of Participants with cardiovascular death (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
Baseline1 year
Pioglitazone + Standard Care00
Standard Care00

[back to top]

Lipid Metabolism 2

Mean values of the triglyceride levels (NCT03011775)
Timeframe: Baseline, 6 month and 1 year

,
Intervention1 mmol/L (Mean)
Mean values of triglyceride baselineMean values of triglyceride in 6 monthMean values of triglyceride in 1 year
Pioglitazone + Standard Care0.690.720.9
Standard Care0.610.730.7

[back to top]

Lipid Metabolism 1

Mean levels of total serum cholesterol (NCT03011775)
Timeframe: Baseline, 6 month and 1 year

,
Interventionmmol / l (Mean)
Mean values of the total cholesterol level baselineMean values of the total cholesterol level in 6 monthMean values of the total cholesterol level in 1 year
Pioglitazone + Standard Care5.274.54.5
Standard Care5.284.34.3

[back to top]

Level of Insulin Resistance 2

Mean levels of blood glucose (NCT03011775)
Timeframe: Baseline and 6 months

,
Interventionmmol/L (Mean)
BaselineIn 6 month
Pioglitazone + Standard Care6.05.97
Standard Care5.95.60

[back to top]

Level of Insulin Resistance 1

Oral glucose tolerance test: number of Participants with impaired glucose tolerance (NCT03011775)
Timeframe: 6 months

,
InterventionParticipants (Count of Participants)
Number of Participants with glucose level in the range of 7.8 to 11 mmol/L baselineNumber of Participants with glucose level in the range of 7.8 to 11 mmol/L in 6 monthNumber of Participants with glucose level above 11 mmol/L baselineNumber of Participants with glucose level above 11 mmol/L in 6 month
Pioglitazone + Standard Care713105
Standard Care141643

[back to top]

Diameter of Stenosis [Carotic Atherosclerotic Lesions]

Mean diameters of the stenosis of the right and left common carotid arteries (NCT03011775)
Timeframe: Baseline and 1 year

,
Interventionmm (Mean)
Mean diameter of the stenosis of the right common carotid artery baselineMean diameter of the stenosis of the right common carotid artery in 1 yearMean diameter of the stenosis of the left common carotid artery baselineMean diameter of the stenosis of the left common carotid artery in 1 year
Pioglitazone + Standard Care9.85.011.64.1
Standard Care8.74.810.15.6

[back to top]

Carotic Atherosclerotic Lesions

Number of Participants with presence of atherosclerotic plaque of the intima media of common carotid artery greater than 1.4 mm (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
Baseline1 year
Pioglitazone + Standard Care00
Standard Care00

[back to top]

Cardiovascular Hospitalization

Number of Participants with acute coronary syndrome (ACS) or unstable angina (UA) (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
Baseline1 year
Pioglitazone + Standard Care00
Standard Care00

[back to top]

Percentage of Participants With Resting Heart Rate Less Than 70 Beats Per Minute (Bpm) and More Than 55 Bpm

Resting heart rate measurement was taken at sitting position for a continuous record of 3 minutes. Heartbeats in each minute was calculated and averaged to obtain the resting heart rate. (NCT03026088)
Timeframe: Baseline up to Week 26

Interventionpercentage of participants (Number)
Bisoprolol0

[back to top]

Number of Participants With Clinically Relevant Systolic and Diastolic Blood Pressure

Blood pressure (systolic and diastolic) measurement was taken at sitting position, with the elbow at the same level with the heart. Number of participants with clinically relevant systolic and diastolic blood pressure reported based on the assessment of the investigator. (NCT03026088)
Timeframe: Screening (Week -2) up to Week 26

InterventionParticipants (Count of Participants)
Bisoprolol0

[back to top]

Number of Participants With Arrhythmia

Holter monitor was used to diagnose arrhythmia. (NCT03026088)
Timeframe: Baseline up to end of treatment (Week 26)

InterventionParticipants (Count of Participants)
Bisoprolol0

[back to top]

Number of Participants With Abnormal Value of N-terminal Pro-B-type Natriuretic Peptide (NT Pro-BNP)

Routine blood tests was performed to measure NT Pro-BNP. The normal range for NT Pro-BNP varies from 0 picograms/milliliter (pg/mL) (lower limit of normal value) -125 pg/mL (upper limit of normal value). (NCT03026088)
Timeframe: Baseline up to End of treatment (Week 26)

InterventionParticipants (Count of Participants)
Bisoprolol19

[back to top]

Number of Participants With 24 Hour Heart Rate With More Than 70 Beats Per Minute (Bpm) and Less Than 55 Bpm

Holter monitor was used to measure heart rate. (NCT03026088)
Timeframe: Baseline, week 6, 14 and end of treatment (Week 26)

InterventionParticipants (Count of Participants)
Bisoprolol0

[back to top]

Number of Participants With New York Heart Association (NYHA) Class

The NYHA classification assesses the severity of symptoms of heart failure. Here NYHA class of II - IV was assessed. NYHA II: Slight limitation of physical activity, comfortable at rest, but ordinary physical activity results in undue breathlessness, fatigue or palpitation. NYHA III: Marked limitation of physical activity, comfortable at rest, but less than ordinary activity causes undue breathlessness, fatigue or palpitation. NYHA IV: Unable to carry on any physical activity without discomfort, symptoms at rest can be present. If any physical activity is undertaken, discomfort increased. (NCT03026088)
Timeframe: Baseline, Week 26

InterventionParticipants (Count of Participants)
Baseline: NYHA class IIBaseline: NYHA class IIIBaseline: NYHA class IVWeek 26: NYHA class IIWeek 26: NYHA class IIIWeek 26: NYHA class IVWeek 26: Not evaluated
Bisoprolol1010021017

[back to top]

Number of Participants With Medicine Compliance Assessed by Medication Procession Ratio (MPR)

MPR is used to assess the medicine compliance. MPR is defined as the actual drug number taken by the participants divided by the drug number should be taken by the participants according to the protocol. MPR between 80%-100% is defined as good compliance. Medication rate of less than (<) 80% or greater than (>)100% is defined as insufficient compliance. (NCT03026088)
Timeframe: Up to Week 26

InterventionParticipants (Count of Participants)
MPR: Good ComplianceMPR: Insufficient complianceNot evaluated
Bisoprolol1802

[back to top]

Number of Participants With All Cause Mortality, Cardiac Death, or Re-admission Due to Heart Failure

Number of participants with all-cause mortality, cardiac death, or re-admission due to heart failure was reported. (NCT03026088)
Timeframe: Up to Week 26

InterventionParticipants (Count of Participants)
All-cause mortalityCardiac deathRe-admission due to heart failure
Bisoprolol100

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, AEs Leading to Death, and AEs Leading to Discontinuation

An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. An AE was considered as 'treatment emergent' if it occurred after the first drug administration of each period or if it was present prior to drug administration but exacerbated after the drug administration. TEAEs included both Serious TEAEs and non-serious TEAEs. (NCT03226275)
Timeframe: Baseline up to Day 29

,,,
InterventionParticipants (Count of Participants)
TEAEsSerious TEAEsAEs Leading to DeathAEs Leading to Discontinuation
Fasting: Bisoprolol and Amlodipine Separately0000
Fasting: Bisoprolol-Amlodipine FDC0000
Fed: Bisoprolol and Amlodipine Separately0000
Fed: Bisoprolol-Amlodipine FDC0000

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of Bisoprolol and Amlodipine

(NCT03226275)
Timeframe: Pre-dose (Baseline) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose for each treatment period

,,,
Interventionhours (Median)
BisoprololAmlodipine
Fasting: Bisoprolol and Amlodipine Separately1.006.00
Fasting: Bisoprolol-Amlodipine FDC1.006.00
Fed: Bisoprolol and Amlodipine Separately3.006.00
Fed: Bisoprolol-Amlodipine FDC3.006.00

[back to top]

Maximum Observed Plasma Concentration (Cmax) of Bisoprolol and Amlodipine

(NCT03226275)
Timeframe: Pre-dose (Baseline) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose for each treatment period

,,,
Interventionng/mL (Geometric Mean)
BisoprololAmlodipine
Fasting: Bisoprolol and Amlodipine Separately26.64.17
Fasting: Bisoprolol-Amlodipine FDC26.14.17
Fed: Bisoprolol and Amlodipine Separately21.93.19
Fed: Bisoprolol-Amlodipine FDC20.53.34

[back to top]

Apparent Terminal Elimination Rate Constant (λz) of Bisoprolol and Amlodipine

λz was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method. (NCT03226275)
Timeframe: Pre-dose (Baseline) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose for each treatment period

,,,
Intervention1 per hour (Geometric Mean)
BisoprololAmlodipine
Fasting: Bisoprolol and Amlodipine Separately0.07840.0139
Fasting: Bisoprolol-Amlodipine FDC0.07810.0134
Fed: Bisoprolol and Amlodipine Separately0.07830.0160
Fed: Bisoprolol-Amlodipine FDC0.07310.0148

[back to top]

Apparent Terminal Half-life (t1/2) of Bisoprolol and Amlodipine

Apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50 percent in the final stage of its elimination. Terminal half-life was calculated as ln(2)/λz, where λz is a terminal rate constant, which was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression on terminal data points of the curve. (NCT03226275)
Timeframe: Pre-dose (Baseline) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose for each treatment period

,,,
Interventionhours (Geometric Mean)
BisoprololAmlodipine
Fasting: Bisoprolol and Amlodipine Separately8.8449.7
Fasting: Bisoprolol-Amlodipine FDC8.8751.8
Fed: Bisoprolol and Amlodipine Separately8.8643.2
Fed: Bisoprolol-Amlodipine FDC9.4946.7

[back to top]

Apparent Total Body Clearance From Plasma (CL/f) of Bisoprolol and Amlodipine

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. (NCT03226275)
Timeframe: Pre-dose (Baseline) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose for each treatment period

,,,
Interventionliter per hour (Geometric Mean)
BisoprololAmlodipine
Fasting: Bisoprolol and Amlodipine Separately16.423.1
Fasting: Bisoprolol-Amlodipine FDC16.421.3
Fed: Bisoprolol and Amlodipine Separately17.427.4
Fed: Bisoprolol-Amlodipine FDC17.826.0

[back to top]

Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/f) of Bisoprolol and Amlodipine

Vz/f is defined as the distribution of a study drug between plasma and the rest of the body after oral dosing. (NCT03226275)
Timeframe: Pre-dose (Baseline) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose for each treatment period

,,,
Interventionliter (Geometric Mean)
BisoprololAmlodipine
Fasting: Bisoprolol and Amlodipine Separately2091660
Fasting: Bisoprolol-Amlodipine FDC2091590
Fed: Bisoprolol and Amlodipine Separately2231710
Fed: Bisoprolol-Amlodipine FDC2431750

[back to top]

Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC 0-inf) of Bisoprolol and Amlodipine

(NCT03226275)
Timeframe: Pre-dose (Baseline) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose for each treatment period

,,,
Interventionng*h/mL (Geometric Mean)
BisoprololAmlodipine
Fasting: Bisoprolol and Amlodipine Separately306216
Fasting: Bisoprolol-Amlodipine FDC306235
Fed: Bisoprolol and Amlodipine Separately287182
Fed: Bisoprolol-Amlodipine FDC281192

[back to top]

Area Under the Plasma Concentration-Time Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Bisoprolol and Amlodipine

(NCT03226275)
Timeframe: Pre-dose (Baseline) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose for each treatment period

,,,
Interventionnanogram hour per milliliter (ng*h/mL) (Geometric Mean)
BisoprololAmlodipine
Fasting: Bisoprolol and Amlodipine Separately295212
Fasting: Bisoprolol-Amlodipine FDC294205
Fed: Bisoprolol and Amlodipine Separately275167
Fed: Bisoprolol-Amlodipine FDC270174

[back to top]

Extrapolated Part of Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUCextra%) of Bisoprolol and Amlodipine

AUCextra% was calculated as area under the curve from time tlast extrapolated to infinity given as percentage of AUC 0-infinity. Here, tlast is the last sampling time at which the concentration is at or above the lower limit of quantification. (NCT03226275)
Timeframe: Pre-dose (Baseline) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose for each treatment period

,,,
Interventionpercentage of AUC0-inf (Geometric Mean)
BisoprololAmlodipine
Fasting: Bisoprolol and Amlodipine Separately3.2410.8
Fasting: Bisoprolol-Amlodipine FDC3.6010.9
Fed: Bisoprolol and Amlodipine Separately3.946.81
Fed: Bisoprolol-Amlodipine FDC3.838.58

[back to top]

Changes in the Mean Office Diastolic BP Levels (in mm Hg) in the Sitting Position

Changes in the mean office diastolic BP levels (in mm Hg) in the sitting position among the patints with HT and CAD recieving bis/perindopril FDC (NCT03730116)
Timeframe: 3 months

Interventionmm Hg (Mean)
Mean Office DBP Changes Between v3 vs Baseline15.9

[back to top]

Efficacy of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice Regarding the BP: % of Patients Achieving Target Levels

The percentage of the patients achieved the target levels of clinical BP among included patients ( SBP < 140 mm Hg and DBP < 90 mm Hg) with HT and stable CAD recieving Bisoprolol/Perindopril FDC (NCT03730116)
Timeframe: 3 month

InterventionParticipants (Count of Participants)
the Patients With HT and Concomitant Stable CAD1640

[back to top]

Efficacy of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice: # of Angina Attacks

Average decrease of the number of angina attacks in patients with HT and stable CAD who recieved the bisoprolol/perindopril FDC (NCT03730116)
Timeframe: 3 month

Interventionnumber of angina attacks per week (Mean)
the Patients With HT and Concomitant Stable CAD-3.2

[back to top]

Good and Moderate Adherence to Bisoprolol/Perindopril FDC Therapy in Patients With HT and Stable CAD in Everyday Practice

"Percentage of the patients with definite answer on question from questionnaire regarding adherence; (Compliance evaluation test - 6 questions tes; Answer No to all questions: good compliance; Answer Yes to 1-2 questions: minor compliance; Answer Yes to 3 or more questions: noncompliance)" (NCT03730116)
Timeframe: 3 month

InterventionParticipants (Count of Participants)
the Patients With HT and Concomitant Stable CAD1827

[back to top]

Impact on the Quality of Life of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice: VAS

Changes of the score in the visual analog scale (VAS) to assess the wellbeing; (minimum score 0 mm and maximum score 100 mm) among patients with HT and CAD recieving biso/perindopril FDC (NCT03730116)
Timeframe: 3 month

Interventionunits on a scale - mm (Mean)
the Patients With HT and Concomitant Stable CAD35.1

[back to top]

The Mean SBP Changes (mm Hg) at the Visit 3 vs. Baseline

Changes in the mean office systolic BP levels (in mm Hg) in the sitting position (NCT03730116)
Timeframe: 3 months

Interventionmm Hg (Mean)
Mean of SBP Changes31.5

[back to top]

Blood Loss

total intraoperative blood loss (mL) (NCT03850093)
Timeframe: at the end of surgery

InterventionmL (Median)
Gabapentin20
Bisoprolol20
Control80

[back to top]

Number of Patients Who Recieve Both IV Nitroglycerin and Propranolol During Operative Procedure

need for both IV nitroglycerine and propranolol intraoperatively (NCT03850093)
Timeframe: at the end of surgery

InterventionParticipants (Count of Participants)
Gabapentin0
Bisoprolol0
Control6

[back to top]

Number of Patients Who Recieved Intraoperative IV Nitroglycerin During Operative Procedure

need for additional intraoperative IV vasodilators (nitroglycerine (NCT03850093)
Timeframe: at the end of surgery

InterventionParticipants (Count of Participants)
Gabapentin0
Bisoprolol0
Control5

[back to top]

Time to 1st Postoperative Rescue Analgesia

time to 1st postoperative rescue analgesia (starting from administration of the studied drug) (NCT03850093)
Timeframe: on administration of 1st postoperative rescue analgesia

Interventionminutes (Median)
Gabapentin60
Bisoprolol30
Control20

[back to top]

Changes in Surgical Field Visibility

"according to change in Fromm and Boezaart surgical field category scale ranging from 0 (no bleeding) to 5 (severe bleeding) where: 0 No Bleeding.~Slight bleeding- no blood suctioning required.~Slight bleeding- occasional blood suctioning required.~Slight bleeding- frequent blood suctioning required, operative field is visible for some seconds after evacuation.~Moderate bleeding- frequent blood suctioning required, operative field is only visible immediately after evacuation.~Severe bleeding- constant blood suctioning required, bleeding appears faster than can be removed by suction .Surgery is hardly possible, and sometimes impossible." (NCT03850093)
Timeframe: scale was assessed by the surgeon every 15 minutes from the start of surgical procedure till the end

,,
Interventionscore on a scale (Median)
15 minutes30 minutes45 minutes60 minutes75 minutes90 minutes105 minutes
Bisoprolol2111100
Control4333232
Gabapentin2111111

[back to top]

Heart Rate Change

effect of intervention on the change of heart rate allover study period (NCT03850093)
Timeframe: were recorded before oral premedication (baseline), pre-induction, after induction of anesthesia, 1, 5, 10, 15 minutes after intubation and then every 15 minutes until the end of surgery

,,
Interventionbeats/ minute (Mean)
preinductionafter induction1 minute after intubation5 minutes after intubation10 minutes after intubation15 minutes after intubation30 minutes after intubation45 minutes after intubation60 minutes after intubation75 minutes after intubation90 minutes after intubation105 minutes after intubation
Bisoprolol73.167.873.370.666.366.667.767.166.36666.567.4
Control85.885.996.289.387.890.285.880.187.384.588.197
Gabapentin82.674.983.377.175.474.773.47575.375.772.775.7

[back to top]

Mean Arterial Blood Pressure Change

effect of intervention on the change of mean arterial blood pressure allover study period (NCT03850093)
Timeframe: were recorded before oral premedication (baseline), pre-induction, after induction of anesthesia, 1, 5, 10, 15 minutes after intubation and then every 15 minutes until the end of surgery

,,
Interventionmm Hg (Mean)
preinductionafter induction1 minute after intubation5 minutes after intubation10 minutes after intubation15 minutes after intubation30 minutes after intubation45 minutes after intubation60 minutes after intubation75 minutes after intubation90 minutes after intubation105 minutes after intubation
Bisoprolol86.472.376.267.267.770.266.264.766.769.466.167.2
Control92.478.292.278.676.57466.664.669.967.762.770
Gabapentin85.674.480.670.766.465.464.463.361.962.56363.1

[back to top]

Surgeon Satisfaction (Categorical)

surgeon satisfaction score where given 5 for very satisfied, 4 for satisfied, 3 for neutral, 2 for dissatisfied and 1 for very dissatisfied then number of satisfied (satisfaction score = 5) and disatisfied (satisfaction score less than 5) surgeons was compared between groups (NCT03850093)
Timeframe: at the end of surgery

,,
InterventionParticipants (Count of Participants)
surgeon satisfaction achieved (score≥ 4)surgeon satisfaction not achieved(score< 4)
Bisoprolol220
Control107
Gabapentin210

[back to top]

Visual Analogue Scale (VAS) for Postoperative Pain

postoperative visual analogue score (VAS) for pain where 0 is no pain and 10 severe intolerable pain (NCT03850093)
Timeframe: 0n full recovery, 3 and 6 hrs. after recovery

,,
Interventionscore on a scale (Median)
on full recovery3hrs. after recovery6hrs after recovery
Bisoprolol433
Control543
Gabapentin211

[back to top]

Number of Patients Who Recieved Intraoperative IV Propranolol During Operative Procedure

the need for additional beta blockers (propranolol) (NCT03850093)
Timeframe: at the end of surgery

InterventionParticipants (Count of Participants)
Gabapentin0
Bisoprolol0
Control1

[back to top]

Change in Exercise Capacity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Peak Oxygen Consumption (VO2) During Cardiopulmonary Exercise Test (CPET)

"Cardiopulmonary exercise testing (CPET) measures breath-by-breath oxygen production during symptom-limited exercise on a stationary bike. This permits the calculation of peak oxygen consumption (VO2). Percent predicted peak VO2 for body weight will also be calculated. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 6-weeks. This outcome was measured at the end of the first and second visit.

Interventionml/kg/min (Mean)
ON Beta Blockers10.0
OFF Beta Blockers11.4

[back to top]

Change in Patient-reported Quality of Life When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-29 (PROMIS-29)

"The PROMIS-29 assesses 7 domains with 4 questions with an additional pain intensity numeric rating scale. The patients' answers to the PROMIS-29 are scored from 1-5 (except for the pain numeric rating scale). The sum of the PROMIS-29 is the raw score transformed into a final T-score metric. Scores are mapped so that the values follow a normal distribution with a population mean T-score of 50 and an SD of 10. Instead of having a min or max, the PROMIS-29 raw scores have been transformed into t-scores for comparison to a reference population (the US general population) with a mean of 50 and SD of 10. Scores lower than 50 indicate worse health compared to the US general population. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker before enrollment, therefore, each subject's respective period for the OFF and ON periods could range between 3 - 6 weeks. The values measured over the time points were averaged." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, weekly, end of period and intervention visits, and during follow-up.

,
Interventionscore on a scale (Mean)
Physical Health ComponentMental Health Component
OFF Beta Blockers40.047.9
ON Beta Blockers39.846.8

[back to top]

Change in Physical Activity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Step Count on Wearable Activity Monitoring Device

"The wearable activity monitoring device measures daily step count. Due to the nature of N-of-1 trials, the duration of a subject's periods varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 and 6 weeks. We will compare average step counts over 2-week periods, which will be the final 2 weeks of each period when subjects are either on their home (ON Beta Blockers) or minimally tolerated (OFF Beta Blockers) dose. The outcome measure data is the mean collected during the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 8-weeks (last 2 weeks of each period for up to 4 periods).

InterventionCount of Steps (Mean)
ON Beta Blockers2790.5
OFF Beta Blockers3167.3

[back to top]

Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Gait Speed Portion of a Modified Version of the Short Physical Performance Battery.

"The Short Physical Performance Battery assesses gait speed, core strength when rising from a chair without using the upper extremities, and balance while standing without a cane or walker. The gait speed portion of the SPPB assesses the subject's lower extremity function. When comparing the number of seconds it takes to complete the 4-meter gait speed test, quicker speeds indicate better lower extremity function. Our research team conducted the 4-meter gait speed test according to SPPB standards, but have chosen on comparing the speed at which subjects were able to complete the test. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionseconds (Mean)
ON Beta Blockers4.3
OFF Beta Blockers4.6

[back to top]

Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Chair Rise Portion of a Modified Version of the Short Physical Performance Battery.

"The Short Physical Performance Battery assesses gait speed, core strength when rising from a chair without using the upper extremities, and balance while standing without a cane or walker. The chair rise portion of the SPPB assesses core strength. When comparing the number of seconds it takes to complete 5 chair rises, quicker speeds indicate better core strength. Our research team has chosen on comparing the speed at which subjects were able to complete the test. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionseconds (Mean)
ON Beta Blockers16
OFF Beta Blockers15.1

[back to top]

Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Balance Portion of a Modified Version of the Short Physical Performance Battery.

"The Short Physical Performance Battery assesses gait speed, core strength when rising from a chair without using the upper extremities, and balance while standing without a cane or walker. The balance test portion of the SPPB assesses the subject's ability to stand unassisted without the use of a cane or walker. Balance test scores range from 0 - 4 with higher scores indicating better ability to stand unassisted. Our research team conducted the balance test according to SPPB standards. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionscore on a scale (Mean)
ON Beta Blockers3.9
OFF Beta Blockers3.6

[back to top]

Change in Patient-reported Health When on Beta-blocker Versus When Off Beta-blocker, as Measured by the EuroQol-5D Visual Analogue System (EQ-5D VAS)

"The EuroQol-5D Visual Analogue System (EQ-5D VAS) indicates patient-perceived health on a vertical visual analogue scale. The scale ranges from 0, indicating poorest health, to 100, indicating the best health. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionscore on a scale (Mean)
ON Beta Blockers68.9
OFF Beta Blockers67.8

[back to top]

Change in Patient-reported Health Status When on Beta-blocker Versus When Off Beta-blocker, as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ-12)

"The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a heart failure-specific health status survey. Questions are ranked on 5- to 7-point Likert scales, with higher scores indicating better health status. KCCQ scores are scaled from 0 to 100 and frequently summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The max amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, bi-weekly, end of period and intervention visits, and during follow-up.

Interventionscore on a scale (Mean)
ON Beta Blockers58.7
OFF Beta Blockers66.0

[back to top]

Change in Patient-reported Cognitive Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Short Form 6a (PROMIS SF-6a)

"Patient-Reported Outcome Measurement Information System-Short Form 6a (PROMIS SF-6a) is a survey of patient-perceived cognitive deficits. Questions are ranked on a 5-point Likert scale, with higher scores indicating better cognitive function. Scores are mapped so the values follow a normal distribution with a population mean T-score of 50 and an SD of 10. Instead of having a min or max, the raw scores have been transformed into t-scores for comparison to a reference population (the US general population) with a mean of 50 and SD of 10. Scores lower than 50 indicate worse cognitive function compared to the US general population. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3-6 weeks. The outcome measure data is the mean of the data collected during the span of the measured time points." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, weekly, end of period and intervention visits, and during follow-up.

Interventionscore on a scale (Mean)
ON Beta Blockers53.8
OFF Beta Blockers52.4

[back to top]

Change in Patient-reported Sexual Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Sexual Function (PROMIS-Sexual Function)

"Patient-Reported Outcome Measurement Information System-Sexual Function (PROMIS-Sexual Function) measures self-reported sexual function and satisfaction. Questions are ranked on a 6-point Likert scale, with higher scores indicating poorer sexual function and satisfaction. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame. The score ranges from 0-10 with higher scores meaning worsened sexual function." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, end of period and intervention visits, and during follow-up.

Interventionscore on a scale (Mean)
ON Beta Blockers1.8
OFF Beta Blockers2.1

[back to top]